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Abstract 
 
A series of N3O3 triaza-tricarboxylate hexadentate ligands, based on the 6-amino-1,4-diazepine 
scaffold, has been designed and synthesised. An investigation of the suitability of these ligands 
towards application in 68Ga-PET has been conducted, with particular focus on the efficiency and 
efficacy of radiolabelling. Subsequently, selectivity for Ga(III) over other relevant cations has been 
studied, along with exploration of the kinetics of radiolabelling, stability and in vivo behaviour of the 
radiolabelled complexes in healthy rats. The four best candidates quantitatively radiolabel within 
three minutes at room temperature over the pH range 4 – 7, to give a single 68Ga-radiolabelled 
species which is sufficiently stable for in vivo application. As a result, these compounds are very 
promising candidates for use as ligands in 68Ga-PET. 
 
Decoration of the AMPED scaffold amine functionalities yielded a series of chelators, which allowed 
the 68Ga-radiolabelling properties of this family of ligands to be investigated. The ligands have a 
mixture of acyclic and cyclic properties, which facilitated rapid binding of the metal and formation of 
a stable complex. Synthetic details and 1H NMR solution state properties are described. With respect 
to radiolabelling, the best ligands were those with the least sterically demanding exocyclic amine 
substituents. However, ligands featuring a mono-alkylated exocyclic amine were prone to internal 
lactamisation under acidic conditions, which rendered these compounds ineffectual as ligands for 
68Ga.  
 
The synthesis and radiochemical evaluation of an additional series of ligands, featuring a modified 
core structure, designed to inhibit the lactamisation reaction and promote ‘pre-organisation’ of the 
ligand donors were undertaken. The synthetic methodology developed allows for selective 
functionalisation of the different amine groups of the ring. Modification of the AMPED core by 
substitution of the tertiary methyl group for a phenyl moiety increased the steric bulk close to 
exocyclic amine, which inhibited internal lactamisation. Critically, the methyl-for-phenyl substitution 
does not have a detrimental effect on the complexation properties. 
 
Finally a study was undertaken of the radiolabelled complex speciation, using NMR spectroscopy and 
X-ray crystallography. The presence of multiple radiolabelled complex species was attributed to the 
formation of kinetically trapped complexes of differing stability. The relative population of the two 
major ligand conformations is controlled by the relative steric demand of the substituents at the 
quaternary site. The exocyclic amine is subject to protonation (pKa 5.7), and therefore the relative 
population of the ligand conformers is pH dependent over the range 3 – 7. By substituting the 
methyl group for a more sterically demanding phenyl group, the population of the ligand 
conformation favouring fast and stable gallium binding was increased. 
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Chapter 1 
Background and Aims of the Project 
 
This chapter introduces medical imaging, with subsequent more detailed, focus on radionuclide imaging. 
Aspects pertaining to the application of the 
68
Ga radioisotope in positron emission tomography (PET) are 
discussed (Sections 1 -5). In section 6 the ligand system of interest is introduced and its literature history 
reviewed. The aims and specification of the project are outlined in section 7. 
 
1 Medical Imaging Techniques 
 
The effective management of diseases and conditions relies heavily on the accuracy of the 
investigation and diagnosis. Central to the diagnostic process are the physical techniques used, 
which are referred to as medical imaging techniques (or modalities). In addition to providing a 
means for diagnosis, medical imaging techniques also play an important role in the planning and 
monitoring of the treatment of a disease.1-3 
 
Medical imaging techniques are non-evasive methods that allow for the characterisation and 
measurement of biological morphology, and more recently has facilitated studies of the 
physiological and biochemical processes taking place in the body.4-6 As a result, medical imaging 
techniques can be divided into two categories. 
 
Classical (or “clinical”) imaging provides information on the morphology of the body from an internal 
perspective. Techniques which fall into this category include radiography, X-ray computed 
tomography (CT), ultrasound imaging, magnetic resonance imaging (MRI) and radioisotope imaging. 
In contrast, molecular imaging uses cellular probes which provide useful information about the 
chemical environment.7 It allows the visualization of biochemical and physiological processes taking 
place at the molecular and cellular level. Typically, a probe is selected or designed which is sensitive 
to a specific chemical analyte or process of interest, and is able to report back in a manner which can 
be detected. Some examples include radioisotope imaging (tracers) and luminescence imaging.7, 8 
 
Radiography (commonly known as ‘X-ray’) was the first medical imaging technique, and followed 
from the discovery of X-rays in 1985.9 X-ray images are produced by passing externally generated X-
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rays through a region of interest of the patient. As the X-rays pass through the body, they encounter 
electrons and particles and are consequently absorbed or scattered by the tissue. Certain tissues 
have higher density than others and will absorb and scatter more X-rays as a result. By placing a 
detector behind the patient, it is possible to distinguish the regions through which the most X-rays 
are passing, and therefore identify regions of differing density. X-ray methods also allow for 
visualization of seemingly hollow structures (intestinal tract, lungs, and vascular system) through the 
use of certain high molecular weight contrast agents. For example the intestinal tract can be 
visualized by ingesting barium sulphate.1, 9 
 
Computed tomography (CT) is essentially a more advanced form of X-ray imaging. An annular shaped 
X-ray unit is used to measure a large number of 2D X-ray slices of the patient in the plane of the 
annulus. Specialised software is then used to process the data into a 3D image showing the internal 
morphology of the patient.9 
 
Ultrasound imaging uses high frequency sound waves directed towards the body to image regions of 
soft tissue. The sound waves are reflected when they come into contact with micro-bubbles in the 
tissue, with the tissue density being related to the magnitude of the reflected wave. From the 
reflected signal, it is possible to determine the different distances at which reflections took place 
and the relative density of the tissue, allowing an image to be constructed incorporating the tissue 
densities and relative positioning.7 
 
Magnetic resonance imaging (MRI) effectively determines the distribution of water protons inside 
the patient. The resonant frequency of the water protons depends on their exact location within an 
applied magnetic field. Thus, by applying a gradient magnetic field over a specific region, it is 
possible to acquire spatial information about the water relaxation rates within that region. Different 
tissues have characteristic water relaxation rates, and thus it is possible to construct an image which 
shows the relative positions of different tissues. Enhanced MRI, which provides better images in a 
shorter time, can be achieved through the use of paramagnetic contrast agents, which enhance the 
relaxation rate of the water protons close to the contrast agent. Enhanced relaxation rates result in 
better contrast between regions, and hence better images.2, 3, 9 
 
Radioisotopes, both metals and non-metals, are elements with an unstable nucleus due to an 
unfavourable ratio of protons and neutrons. In order to obtain a more stable configuration the 
isotopes undergo radioactive decay, whereby the excess energy is released either as a particle of the 
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nucleus or one of its electrons.9, 10 The energy emitted is either in the form of particles (α- or β-
particles or Auger electrons) or as electromagnetic radiation (X-rays and/or γ-rays). By detecting 
these emissions it is possible to determine the location of the radiolabel (administered 
radioisotope). Photon emitting radionuclides are detected directly by single photon emission 
computed tomography (SPECT), whereas particle emitters are detected indirectly by positron 
emission tomography (PET).1, 9, 10 Radionuclide imaging is only useful when the radiolabel has a  bio-
distribution profile of interest. Although certain radioisotopes naturally accumulate in specific 
tissues, the radioisotope is usually attached to some form of targeting agent which determines its 
fate. For example, iodide has a natural affinity for thyroid tissue, and therefore 123I can be used for 
imaging of the thyroid gland.11 The radioisotope 82Sr, on the other hand, tends to accumulate in the 
bones and liver.12 Radionuclide imaging can also be used to follow certain physiological process and 
reactions.  
 
 
 
Figure 1.1 Radionuclide scans (with 
18
F-FDG, 
111
In-OctreoScan
TM 
and 
68
Ga-DOTATOC) of a patient with 
metastases (chest area) and a neuroendocrine tumour (top of the brain), showing the greater affinity of 
68
Ga-
DOTATOC than 
111
In-OctreoScan
TM
. Localisation of 
18
F-FDG occurs in areas of high metabolic activity, and is far 
less useful for the imaging of neuroendocrine tumours. Picture taken from.
13
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For example, 2-[18F]fluoro-2-deoxy-d-glucose (FDG) is an analogue of glucose which can be used to 
assess metabolic activity. FDG is taken up by cells which exhibit high metabolic rates (and therefore 
have a high rate of glucose consumption) such as the brain, kidneys and certain cancer tumours. 
Once inside a cell, the glucose molecule is phosphorylated which prevents it from leaving, and 
therefore facilitates PET imaging of the region.8 A commercially used PET agent, 111In-OctreoScanTM, 
has a peptide fragment which mimics somatostatin (SST), and has affinity for certain SST receptors 
which are over-expressed by primary neuroendocrine tumours and metastases.14  However, 
OctreoScanTM is currently in competition with the more efficient SST PET imaging agent 
68Ga-DOTATOC (Figure 1.1).14 
 
Whilst all the techniques listed above can provide very useful highly resolved anatomical 
information, they are limited by the fact that their resolution is insufficient to investigate cellular 
conditions and function.3 
 
Molecular imaging techniques, such as luminescence and nuclear magnetic resonance spectroscopic 
imaging, are quickly emerging as techniques which can provide useful information on cellular and 
molecular processes or conditions. The information is derived from the luminescence or magnetic 
resonance properties of an administered chemical entity. These information providing entities are 
commonly described as molecular probes, as opposed to imaging agents. The premise is that these 
molecular probes should report on some process or analyte of interest.  
 
As shown in the preceding discussion, there is a wide range of imaging modalities available. It is 
important to note that each has advantages and disadvantages in terms of the resolution, 
measurement time, applicability, costs and additional requirements (i.e. equipment, tracers to make 
imaging possible). A summary of the different imaging modalities and their characteristics is shown 
in Table 1.1. 
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Table 1.1 Comparison of the key characteristics of different imaging modalities.
3, 7, 9
 
 
Imaging modality Tissue penetration Resolution Time required for 
measurement 
ultrasound deep 300 μm s 
Fluorescence microscopy shallow  500 nm s 
SPECT deep 2-3 mm min - h 
PET deep 1-2 mm min - h 
MRI deep 200 μm min - h 
CT deep 400 μm min 
 
Furthermore, some of the techniques are inherently susceptible to outside conditions which may 
vary. For instance, magnetic resonance imaging (MRI) is temperature sensitive, whereas the signal 
detected from a radionuclide in PET/SPECT is not. For these reasons, it can be advantageous to apply 
more than a single imaging modality to a particular study. This has led to a relatively new approach, 
referred to as multimodal imaging.7 The basic premise is that for imaging techniques which utilise an 
imaging agent (to provide a detectable signal or increased contrast), it is possible to incorporate 
properties required by more than one imaging technique into this single entity. This has obvious 
benefits in terms of costs and time (licensing of the imaging agents, clinical trials, running costs), and 
minimizes the effect on the patient. Furthermore, multimodal imaging agents also ensure identical 
localization of the previously separate tracers.7, 15 There are a number of obstacles to the synthesis 
of multi-modal imaging agents, but this is beyond the scope of this discussion.  
 
2 Radionuclide Imaging 
  
2.1 General  
 
The concept of a tracer was first introduced by George de Hevesy (1923), and was defined as a 
chemical substance, which when introduced into a system can be followed through the course of a 
process of interest.16 The tracer should; not influence or disturb the system, and be able to provide 
information on processes taking place of distribution of a chemical substance.16 Radiotracers, are 
widely applied in medicine and research for the study of in vivo pharmacokinetics, physiological 
processes, imaging (diagnosis) and radiotherapy. Often confused, a radioligand and radiotracer have 
an essential difference in the ‘biological’ mechanism which makes the imaging targeted. A 
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radioligand is a radiolabelled molecule that can bind/interact with another molecule in a predictable 
fashion, thereby allowing the target to be imaged. This differs from a radiotracer which is able to 
follow/trace the in vivo behaviour of naturally occurring molecule by virtue of its chemical similarity, 
thereby providing information on a biological process. 
 
The two most prevalent fields of radionuclide research are radio-imaging and radiotherapy. In 
radiotherapy, the primary objective is to induce cell death by directing radiation at a specific target 
within the body. Parasitic or infected cells can be dosed with ‘lethal’ radiation from nuclei which 
emit α-particles, β+/--particles or Auger electrons. For a given radionuclide, the interaction of the 
emitted radiation with the target tissue should be maximised, and therefore efficient targeting is 
crucial.3, 9 
 
Diagnostic radionuclide imaging (radio-imaging) also relies on the radiolabel being concentrated in 
or isolated in certain parts or systems of the body. The photons resulting from the radioactive decay 
are detected by external cameras and the data processed to provide information about the location 
and shape of the region where the radiolabel has accumulated. This is quite different to X-ray 
imaging, where external radiation is directed at the patient and regions of differing density 
determined by the amount of radiation absorbed. 
 
2.2 Advantages and Disadvantages of Radionuclide Imaging 
 
 In addition to being independent of the external environment, the very high sensitivity of radio-
imaging is a significant advantage over imaging techniques such as MRI and structure-depicting 
imaging techniques. In a recent study using a 13C-labelled drug, the administered dose required for 
MRI and radionuclide detection in vivo was determined. The study was conducted on a rat, and 
extrapolated for a 70 kg man.17 Detection by MRI and radionuclide imaging required 10 g and 1 μg 
doses of the drug respectively.17 The high sensitivity of radionuclide imaging arises from the fact that 
there is no significant background signal.18 A further benefit of radionuclide imaging is that through 
appropriate design, and chemical modification of the radiolabelled probe, the radionuclide can be 
targeted to specific tissues or receptors, thus allowing the disease to be diagnosed more directly 
than techniques which rely only on anatomy. In addition, it may be possible to investigate 
biochemical and physiological processes in the body using this technique.3, 19-21 
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In other areas of molecular imaging (luminescence and MRI) there is considerable effort directed 
towards the development of responsive imaging agents.22-25 Such imaging agents have the inherent 
ability to respond to the presence of a chemical substance or stimulus in a manner which can be 
easily detected. It is not possible to alter the emission properties of a radionuclide, and as a result 
responsive probes based on radionuclides are not possible.  However, attempts are being made to 
incorporate radionuclides into responsive systems in which they may carry out a tracer function.7 
 
2.3 Types of Radionuclide Imaging 
 
Radiolabels which emit γ-rays (electromagnetic radiation) pass through human tissue relatively 
easily, and can be detected directly using an externally-located Anger camera, by means of single 
photon emission computed tomography (SPECT). The γ-rays emitted must be sufficiently energetic 
to penetrate the human tissues and be detected by an externally positioned detector, but not 
outside the detectable energy range of the detector. The images produced by SPECT, map the 
radionuclide distribution in one plane, thus producing a two-dimensional map of the radionuclide 
population distribution.3, 9, 10 
 
In contrast, emitted particles (β+: positrons emitted from neutron deficient radionuclides) only travel 
a short distance (~ 4 mm) before they encounter an electron.3, 9, 10 During the collision the masses of 
the positron and electron are converted into pure energy. The emitted energy is called annihilation 
radiation, and is characterised by collinear photos (γ-rays of 511 keV each) moving in opposite 
directions (Figure 1.2).9, 26 The collinear photons produced by positron emitting radionuclides can be 
detected simultaneously using two externally located detectors by a technique called positron 
emission tomography (PET).9, 26, 27 If two photons are detected along a line at the same time, then 
the origin of the photons (positron-electron collision) must lie somewhere along that line. The exact 
location can be determined by the intersection of two such lines, and if a large number of these lines 
are recorded then a 3D image mapping the radionuclide distribution can be produced (Figure 1.2).26 
The positron only travels a short distance in tissue before it is annihilated, which gives PET images a 
resolution of approximately 1 - 2 mm. PET has been employed to follow therapeutic response28,  
tumour imaging29, neurotransmission30 and the measurement of blood flow.14, 19, 31-33 
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Figure 1.2 Diagram illustrating β
+
-particle emission and annihilation (when it collides with an electron) 
producing co-linear γ-rays. Detection of coincident emitted γ-rays allows a three-dimensional image of the 
radiotracer distribution to be constructed. Figure reproduced with the permission of Benedikt Sandhöfer. 
 
Recently a new ‘field’ of research, called ‘THERANOSTICS’, has developed which is effectively a 
cooperation of radionuclide THERApy and diagNOSTIC imaging. The premise is that, 
radiopharmaceuticals which prove effective in diagnostic imaging could be utilized in radionuclide 
therapy by simply changing the identity of the radionuclide that is incorporated.  Such an approach is 
particularly feasible when the radionuclide used has isotopes which are suitable for use in diagnostic 
and therapeutic applications.15, 20 
 
2.4 Choice of radioisotope 
 
The choice of radionuclide is of vital importance, not only in terms of choosing a radionuclide with 
the appropriate radioactive decay properties, but also in terms of the intended imaging application 
(i.e., whether the intended application is imaging by SPECT or PET) and radiolabel precursor. For 
example, different metals have different coordination geometries and preferred coordination sphere 
sizes; if the intended ligand-radionuclide pair is an unsuitable match, the complex is likely to be 
unstable and the rate of radiolabelling slow. Dissociation of the metal complex is likely to result in 
loss of the intended biodistribution, therefore care should be taken to ensure that the chelator and 
metal ion will give rise to a stable complex in vivo. Similarly for non-metal radionuclides, the choice 
of radionuclide should take into account the intended application (specifically the duration) as well 
as the radiolabelling protocol.14, 34 
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Of particular interest to this project are targeted radioligands, and therefore some form of targeting 
vector is essential. A number of biological peptides and antibodies have been shown to be effective 
in the targeting of certain conditions. These biomolecules are often large, and as a result have very 
slow pharmacokinetics relating to accumulation (days). Consequently their application requires a 
radionuclide with a suitably long half-life such as 89Zr (78.4 h) and 124I (100.2 h). The disadvantage of 
using these radionuclides is the large radiation dose to the patient. Smaller engineered biological 
‘fragments’ have been identified which can serve a similar targeting function has the larger peptides. 
These fragments are often cheaper and easier to produce, and considerably easier to work with. The 
faster pharmacokinetics means that a radionuclide with a shorter half-life can be used, thereby 
decreasing the patient radiation dose, and imaging experiments are considerably shorter. In this 
regard, the ideal radionuclide for use as an imaging agent possesses the following set of properties:3, 
19, 26, 35-37 
 
 A high abundance of electromagnetic radiation to be detected. This is also known as the 
radiative yield, and is important since a radionuclide with a high yield can be administered in 
smaller amount than one which has a low yield. 
 The electromagnetic radiation should have sufficient energy to penetrate the body, yet be 
sufficiently low to be easily detected.  
 In the case of particle emitters, a lower energy particle is preferred. The energy of the 
emitted particle determines the distance the particle will travel, and is therefore inversely 
related to the image resolution. 
 A low abundance of particulate radiations (α, β) to minimize the harmful radiation dose to 
the patient.  
 A short half-life such that any particulate radiation dose is minimized, but still long enough 
to permit sufficient time for radiolabelling, administration and detection of the imaging 
agent. Furthermore, the half-life of the radionuclide should be well suited to the 
pharmacokinetics of the targeting vector that will be used.  
 A decay product which is a stable isotope, will not compromise the stability of the ‘active’ 
imaging agent and is non-toxic. 
 It should be affordable and readily available. 
 Carrier-free and of high chemical purity so that there is no competition from stable isotopes 
of the same element or others. 
 Easy and fast to complex or react (significantly shorter than the half-life of the decaying 
radioisotope) in a way which renders them useful as imaging agents. 
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2.5 Metal and non-metal radionuclides for PET 
 
PET employs mainly relatively short lived positron emitting radionuclides.32 Table 1.2 shows a 
summary and comparison of the important properties of metal and non-metal radionuclides which 
could be used in PET. Also included are a three γ-emitting radionuclides (SPECT application) of 
commercial importance. Properties which are particularly advantageous for PET/SPECT are 
highlighted in green, while those considered undesirable are in red.  
 
Table 1.2 Comparison of radionuclides with properties suitable for use in PET and SPECT.
10, 26, 32, 37-39
 
 
Radionuclide Half-life Emax (keV) Radiation type production 
11
C
 
20.3 min 961 β
+
 (100 %) cyclotron 
13
N
 
9.97 min 1190 β
+
 (100 %) cyclotron 
15
O
 
2.1 min 1732 β
+
 (100 %) cyclotron 
18
F
 
109.8 min 634 β
+
 (97 %) cyclotron 
66
Ga
 
9.5 h 4153 β
+
 (56 %) cyclotron 
52
Fe 8.2 h 800 β
+
 (57 %) cyclotron 
68
Ga
 
67.6 min 1899 (511) β
+
 (89 %) generator 
64
Cu
 
12.8 h 656 β
+
 (19 %) cyclotron 
55
Co
 
17.5 h 1513, 1037 β
+
 (77 %) generator 
86
Y
 
14.7 h 2335, 2019, 1603, 1248 β
+
 (33 %) cyclotron 
89
Zr
 
78.4 h 897 β
+
 (23 %) cyclotron 
99m
Tc
 
6.0 h 141 γ (89 %) generator 
111
In
 
67.9 h 245, 172 γ cyclotron 
67
Ga
 
78.26 h 91, 93, 185, 296, 388 γ cyclotron 
 
Besides the relevance of the biological application and suitability of the radionuclide the choice of 
radionuclide depends on a number of other considerations, among which are the cost and 
convenience of production.  Besides substantial cost savings, there are a number of advantages of 
generator produced radionuclides over cyclotron produced alternatives:3, 20, 34-36, 40-42 
 
 The use of cyclotron produced radionuclides requires that there be a cyclotron in the nearby 
vicinity to allow for synthesis of the radiolabel and subsequent application whilst the 
radionuclide is still viable. 
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 Generator produced radionuclides are available almost ‘on-demand’, whilst cyclotron 
radionuclides are typically delivered once a day (in the absence of an on-site cyclotron). 
 Generator produced radionuclides consist of a long-lived parent nuclide which decays to give 
the desired, short lived, daughter radionuclide. The daughter radionuclide is easily isolated 
by solvent extraction or ion exchange. 
 
In some cases short lived radionuclides are desirable. For instance the short half-life of 13N (t½ = 9.97 
min) allows it to be re-administered in short time frames, or be followed closely with longer lived 
radionuclides to obtain additional information.32 PET applications generally prefer longer lifetimes, 
such that the radiopharmaceutical can be administered, localise and imaged. Radionuclides such as 
18F and 68Ga are considered to have suitable decay half-lives for the large majority of biological 
targeting vectors.32 
 
Another important consideration is the radiolabelling method required. Non-metal radionuclides 
such as 18F and 15N require fast organochemical reactions, which are in some cases not the final step 
in the synthetic pathway.32 This can result in significant decay of the radionuclide, and radioactivity 
exposure. The advantage of this method is that often, the radiolabelled tracer and precursor are 
chemically similar32 Metal radionuclides are radiolabelled using chelation chemistry, which requires 
an appropriate chelating moiety. This may have a negative impact on the biological properties of the 
targeting vectors present, but has the benefit of radiolabelling being the final step and being 
conducted in aqueous media (advantageous for large peptides).32, 36, 42 
 
3 The 68-Gallium radioisotope and its application 
 
3.1 General 
 
The synthetic benefits of metal radionuclides make them attractive alternatives to non-metal 
radionuclides such as 18F, 123I and 15O in PET/SPECT. Metal radionuclides which have found 
application in radionuclide imaging include 67Ga, 111In and 99mTc. The 99mTc radionuclide was first used 
as a radioimaging agent in 1964 and has become the workhorse of radionuclide based diagnostic 
imaging. This is primarily a result of its favourable nuclear properties (in particular the low 
particulate emission and t½) and generator production.
20, 35, 40 The 99mTc radionuclide is obtained by 
decay of the 99Mo radionuclide, which has a half-life of 2.7 days. As a result, the 99Mo/99mTc-
generator therefore has a short shelf life (~ 1 week). This short shelf-life, coupled with recent 
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shortages of 99Mo and the benefits of PET over SPECT imaging have necessitated the need for 
application of other radionuclides.19, 20, 33, 35, 43 As outlined previously, the important factors to 
consider when evaluating the suitability of a radionuclide are the half-life, mode of decay, cost and 
its availability.  
 
Gallium has three radioisotopes, with properties that are conducive to their use as imaging agents in 
nuclear medicine and research. 67Ga is a γ-ray emitter whose energy (184.6 keV), absence of 
particulate emission and relatively long half-life (78.27 h) make it ideal for use in SPECT (gamma 
scintigraphy).40 However, it is disadvantaged by the fact that its production requires a cyclotron. 67Ga 
radiolabels have been used for nearly 60 years (with the first production for human use being in 
1953) for the imaging of inflammation, infection and, to a lesser extent tumour imaging.44 It has 
been administered as gallium citrate, which is quickly dissociated in vivo through ligand exchange to 
the iron binding protein transferrin.40 Some tumours have receptors for apo-transferrin, thus 
providing a means for non-specific tumour imaging. The mechanism for retention in these tumours 
is unknown, but it is accompanied by accumulation in the liver, lungs, spleen and bones. 67Ga-
transferrin also clears slowly from the blood. The gallium is bound within the iron-binding sites of 
transferrin.19, 36 Radioisotopes, 66Ga and 68Ga are both positron emitters and therefore suitable for 
PET applications. The radioactive properties of the three isotopes are listed in Table 1.3. 
 
Table 1.3 Radioisotopes of gallium and their nuclear properties.
21, 35, 40, 41
 
 
Radioisotope t½ (hrs) β
+
 abundance (%) β
+
max (keV) γ abundance (%) Eγ (keV) 
67
Ga 78.27 - - 37 184.6 
66
Ga 9.49 56 4153 44 1039, 2572 
68
Ga 1.13 89 1899 11 (511)* 
* two collinear photons produced by positron-electron collision  
 
66Ga is suitable for radio-imaging due to its relatively long half-life, which allows for measurements 
over a long time and extended synthetic pathways to the radiolabel. However it is compromised by 
its low positron abundance and cyclotron source. The 68Ga radionuclide, on the other hand, can be 
easily obtained from an on-site 68Ge/68Ga generator, has high positron abundance (89%) and 
intermediate positron maximum energy.  With a half-life (1.13 h) which lies between the half-lives of 
the frequently used 11C (0.33 h) and 18F (1.82 h), it has excellent radioactive decay characteristics. 
Generator-produced radionuclides are favoured because they are cheaper (with respect to the initial 
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cost), more convenient and place fewer restrictions on synthetic techniques. The 68Ge parent 
radionuclide has a long half-life, which gives a generator with a long shelf-life. Furthermore, 
methods have been developed which allow the 68Ga to be eluted in a high chemical and radioisotope 
purity.19, 32, 37, 45-49  
 
An interesting, and very attractive, advantage of gallium over other radionuclide stems from the 
variety of gallium isotopes available. The isotopes 66Ga, 67Ga, 68Ga and 71Ga can be used in 
therapeutic, SPECT, PET and even NMR applications respectively. Thus, once a ligand system has 
been devised which is able to target a region of interest, it is possible to image or trace (by SPECT, 
PET and NMR) and subsequently treat the condition simply by changing the isotope used 
(THERANOSTICS). 
 
The advantages of the 68Ga radionuclide over other radioisotopes are:19, 32, 34-38, 40, 41, 50, 51 
 
 The high positron abundance of 68Ga means that acquisition times are considerably reduced 
in comparison to 66Ga 
 The short half-life reduces the particulate dose to the patient, and is between the half-lives 
of 11C and 18F – the two most commonly used PET radionuclides. It is also well suited to the 
pharmacokinetics of many biological targeting vectors.  
  Availability from a 68Ge/68Ga generator, rendering it cheap and readily available compared 
to other radioisotopes. Its application allows for PET imaging at facilities without a nearby 
cyclotron.  
 The images obtained from PET (with 68Ga) are more resolved and informative than those 
obtained from SPECT (with 67Ga). 
 It has an intermediate maximum positron energy 
 The incorporation of the metal into the ligand is often the last synthetic step, which makes 
synthesis of the radiolabel potentially faster, safer and easier. 
 
Despite these advantages of 68Ga, the interest in targeted 68Ga radiolabels is relatively recent. 
Administration of free gallium (as gallium citrate) does allow for some useful imaging.40, 41 However, 
it is necessary to influence the biodistribution of the radionuclide by stabilising it as a coordination 
complex. Furthermore, for the biodistribution of a complex to be driven by its physiochemical 
properties (size, charge, lipo- / hydro-philicity), it must be kinetically and thermodynamically stable 
with respect to dissociation under in vivo conditions.19, 34, 40 
Chapter 1: Background and Aims of the Project 
 
 
 
Page 14 
 
  
 
The pre-requisites of a complex suitable for 68Ga PET in vivo are as follows: 
 
 It should be stable with respect to hydrolysis (formation of hydroxide complexes) and acid-
/cation- promoted complex dissociation in the pH range 2-8. If not sufficiently stable 
precipitation of gallium hydroxide (above pH 3.6) or formation of gallium-transferrin may 
occur.40 
 Kinetic inertness to ligand exchange by coordinating proteins such as transferrin. This ligand 
exchange process is favoured by the high concentration of these ligands in vivo and the high 
stability constants of their complexes (Ga-transferrin: log K = 20.3).52 
 
3.2 Elution, preparation and purification of 68Ga 
 
The majority of β+/--emitting radionuclides are produced using expensive cyclotrons, which require 
professional operators. A far more convenient method of radionuclide production is the generator 
system, which consists of a long lived parent radionuclide which decays to give the daughter 
(desired) radionuclide.10, 26 The daughter radionuclide can then be post-processed to remove any 
unwanted radioactive and non-radioactive metals. 
 
Such a system is very desirable due to the cost effectiveness, almost on demand availability of the 
radionuclide, ease of use, carrier free nature of the radionuclide and high generator yield.26, 39, 41, 46, 53 
The value of this radionuclide source is evident when it is considered that 80% of SPECT medical 
examinations make use of 99mTc, despite the fact that the 99Mo/99mTc-generator has a shelf life of just 
over one week.20, 35 
 
The long lived parent radionuclide, 68Ge (t½ = 270.6 days), gives the 68Ge/68Ga-generator a shelf life 
of 2-3 years. This, coupled with the suitability of 68Ga for radiopharmaceuticals, makes it a 
radionuclide which many consider to have a bright future.19, 41, 42, 51, 53 Commercial application of this 
generator has been somewhat hindered by the:10, 36, 54 
 
• Chemical form of 68Ga upon elution 
• Presence of toxic and competing metal ions  
• Low concentration of 68Ga in the generator eluate (high volume) 
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The 68Ge/68Ga-generators consist of the parent radionuclide immobilised on a column made of 
inorganic oxides (such as aluminium, tin and titanium) and even in some cases even organic resins.10, 
19, 45, 54 Due to the long half-life of 68Ge it is very important that its removal from eluate is efficient. A 
considerable amount of work has been done regarding the development of generators and 
accompanying elution methods that provide carrier free 68Ga in high radiochemical and chemical 
purity. A detailed discussion of the evolution of 68Ge/68Ga generator design and accompanying 
elution techniques is beyond the scope of this discussion. For more information the reader is 
referred to a review by Maecke et al.19 
 
The generator widely utilised currently is titanium(IV)dioxide (Cyclotron Co. Obninsk, Russia), which 
is eluted using 8 mL of 0.1 M hydrochloric acid.19 The generator is thought to have desirable 68Ga 
generator yield and 68Ge breakthrough, however also has a number of disadvantages. The eluate 
volume (8 mL) is relatively high and the eluate itself is strongly acidic, contains measurable amounts 
of 68Ge activity and metal impurities.  Metal impurities include zinc(II) (from 68Ga decay), titanium(IV) 
(residual column material) and iron(III) (in the column eluate).19 Removal of metal impurities is of the 
upmost importance because the majority of radiolabelled precursors have poor metal ion selectivity, 
and even small amounts of impurities may compete for the precursors because the concentration of 
68Ga in the eluate stream is very small (nM).19, 49 
 
It is common for groups to develop/adopt automated strategies or protocols for the post-
purification and pre-concentration of the generator eluate, which can be categorised into two 
general techniques.19  
 
The first of these is fractionation of the generator eluate directly, which allows the 68Ga to be 
identified in a smaller volume (pre-concentration) and the presence of any impurities, resulting from 
generator elution, to be reduced.55, 56 The more widely applied and reliable protocol is to make use 
of an ion exchange resin to ‘hold’ the 68Ga, whilst the impurities are removed.19 Subsequent removal 
of the 68Ga from the resin using a smaller solvent volume allows for effective pre-concentration. 
Velikyan et al have developed an efficient method, based on an anion exchange resin, which has 
been fully automated and gives a final volume of 200 μL (unknown acidity).48, 54 Another efficient 
method described by Zhernosekov et al makes use of a cation exchange resin.49 The benefit of this 
method is that the 68Ga is obtained in 400 μL of 98% acetone-0.05 M hydrochloric acid, ready for 
radiolabelling. The entire process from generator elution to ‘ready for radiolabelling’ is illustrated in 
Figure 1.3. 
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Figure 1.3 Diagram representing a typical setup for the elution and pre-concentration and purification of 
68
Ga 
from a 
68
Ge/
68
Ga generator. Figure reproduced with the permission of Benedikt Sandhöfer. 
 
3.3 Radiolabelling with 68Ga 
 
Incorporation of the radionuclide (radiolabelling) is the key step in the synthesis of a 
radiopharmaceutical, and considerable effort has focused on minimising the time taken to do so, i.e. 
increasing the rate of radiolabelling. It is important to minimize the radiolabelling duration mainly 
due to the short 68Ga half-life, but radiation exposure of the person carrying out the synthesis is also 
a consideration. It is usually accepted that synthesis, purification and application of the 
radiopharmaceutical should not exceed 3.5 half-lives (~2.5 h). Even in instances where the 
application duration is very short, there are obvious advantages to a radiopharmaceutical which has 
decayed less.  
 
In the case of metal ion radionuclides, radiolabelling is invariably the final step, and thus the 
synthesis is considered complete when the maximum possible amount of 68Ga is incorporated into 
the tracer. This yield (experimentally measured radiolabelling yield) does not take into account 
decay of the radionuclide, and is considered as a compromise between radionuclide decay and 
actual chemical yield.10, 46 
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3.4 Radiolabelling optimisation 
 
The ideal radiopharmaceutical precursor is one which quantitatively radiolabels at room 
temperature in less than 10 minutes, and possess a relatively wide pH window of radiolabelling.32, 46  
Such a precursor could be incorporated into a kit-like strategy in which the precursor and any 
additional chemical substances required (buffers, stabilisers etc.) are lyophilised together in a vial.19, 
48 Radiolabelling protocol would then consist of adding the post-processed generator eluate, shaking 
the vial and application of the radiopharmaceutical. Radiolabelling is primarily optimised through 
variations in concentration, temperature and pH.46 The limiting requirement is that radionuclide 
incorporation should reach greater than 90% in less than 10 minutes at 90 °C.35, 39, 46 
 
Due to the stringent time factors involved, the concentration of the radiolabel precursor (μM) 
greatly exceeds that of the radionuclide 68Ga (nM). These conditions are used to ensure 
radiolabelling occurs quickly and completely, i.e. all the available 68Ga is complexed. With such a 
large excess of the precursor (10000 – 100000 equivalents), the effect of increasing concentration on 
radiolabelling yield is limited. Typically, groups focus more on determining the concentration of the 
precursor which can be used without having a negative impact on radiolabelling yield.39, 46 
 
Temperature is usually the first consideration, when optimising the rate of radiolabelling yield. As 
would be expected there is normally an increase in the rate with increasing temperature. Microwave 
irradiation has also been shown to have significant effect on the radiolabelling yield. In fact, greater 
yields have been reported for microwave irradiation than those achieved by conventional heating at 
the same temperature.46, 57, 58  
 
The effect of pH on the radiolabelling yield is also well documented.46, 48 From a ligand design 
perspective this is not a surprising result. Ligand donor groups have lone electron pairs, which are 
subject to de/protonation at characteristic pH’s. Protonation of a ligand donor groups hinders 
complexation of the radionuclide, because the energy barrier for removal of the proton has to be 
overcome. The ideal radiolabelling pH is one at which all the donor groups are deprotonated, and 
thus primed for complexation of the radionuclide. However, the speciation of the 68Ga radionuclide 
should also be taken into consideration. Increasing the pH is complicated by the formation of 
insoluble gallium hydroxide above pH 3.6.32, 40, 46, 59 If higher pH’s are required, a chemical substance 
capable of weakly binding the 68Ga radionuclide, preventing formation of the hydroxide, but still 
allowing formation of the desired radiolabel is needed.46 Buffer anions, such as HEPES, acetate, 
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glutarate and citrate, have been shown to be effective in this respect.59 Careful choice of the buffer 
used allows it to perform a dual function in radiolabelling, i.e. to adjust the pH of the generator 
eluate and to prevent hydroxide formation.  
 
Many biomolecules are sensitive to pH and temperature, and can be irreversibly damaged 
(denatured in the case of peptide based biomolecules) if the temperature is too high or the pH too 
acidic.20, 32, 43 When the radiopharmaceutical precursor includes some form of biomolecule, which is 
often the case for bifunctional chelators and macromolecules, the optimisation needs to be carried 
out within the boundaries set by the biomolecule being used.10, 32 
 
4 Biodistribution of the 68Ga Radionuclide 
 
The biodistribution of a 68Ga-radiolabelled species is determined by it chemical form, and falls into 
one of three categories: 
 
1. The free ion, or the ion weakly bound to labile donors, such that dissociation of the complex 
occurs in vivo). 
2. Coordination complexes of Ga(III), where the overall lipophilicity, size and charge 
determines the biodistribution. 
3. Gallium complexes with a tethered targeting moiety, which directs the radiolabel to a 
specific region, tissue or receptor. 
 
Administration of the free ion results in the formation of 68Ga-transferrin (the natural chelator of 
Ga(III) in vivo) which primarily accumulates at sites of infection, inflammation, bones and, to a lesser 
extent, tumours.10, 34, 41 
 
When a 68Ga coordination complex is administered to a patient, its biodistribution is controlled by 
the physiological properties of the complex. A relatively large number of 68Ga complexes could be 
used for imaging of the renal, biliary and reticuloendotheial systems, since these are often the 
clearance pathways for the complexes.3, 19 However, probes based on 99mTc and 123I are currently 
given preference for such applications.20, 35, 40 
 
The PLEB and HBED (Figure 1.4) complexes of 68Ga clear via the renal and biliary system, thus 
allowing for PET imaging of the liver and kidneys.60 More lipophilic complexes, such as NOTPR (Figure 
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1.4), clear via the endogenous biliary route, thereby enabling PET imaging of the respective 
systems.61 Lipophilic cationic 68Ga complexes such as TX-TACNH3
62 (Figure 1.6) fall in the same 
category as heart perfusion agents 99mTc-MyoviewTM,63 and 99mTc-CardoliteTM,63, which are believed to 
target mitochondrial uptake.34 99mTc-Cardolite® became clinically available in 2008, and is routinely 
used in clinical practice. 
  
 
 
Figure 1.4 Structures of 
68
Ga ligands HBED
60
, PLEB
60
, TX-TACNH3
62
 and NOTPR
61
. Also shown are, 
99m
Tc heart 
perfusion agents, Myoview
TM
 and Cardolite
TM
.
63
 
 
Recently, two lipophilic cationic 68Ga complexes based on the DEDPA framework have been reported 
(Figure 1.5).33 The complexes show improved blood, lung and kidney clearance, coupled with 
persistent heart uptake (compared to the parent DEDPA ligand), displaying myocardial retention (1% 
initial dose per gram) comparable to 99mTc-CardoliteTM.33 Another example of an untargeted 
biodistribution is the 68Ga complex of the tripodal tetrahedral complex of the ligand NS3, which 
shows remarkable stability in vivo despite being coordinatively unsaturated (Figure 1.5).30 The 
complex crosses the blood-brain-barrier and shows high heart-to-blood ratio; believed to be a result 
of the complex being neutral, of low molecular weight and lipophilic.19, 30 
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Figure 1.5 Structures ligands NS3
30
 and H2DEDPA
33
 derivatives, whose 
68
Ga complexes shown myocardial 
uptake. [
68
Ga.NS3] also crosses the blood-brain-barrier.  
 
Whilst partially effective at accumulating radiolabels within specific regions or systems, these 
complexes are not targeted radiolabels in the strictest sense. Instead, the biodistribution within the 
body is “controlled” by modifying the physiochemical properties of the complexes so that they 
prefer clearance via one pathway over another, or have greater affinity or slower rates of clearance 
for certain tissues over others. 
 
A more directed approach to modification of the bio-distribution is to use bifunctional chelators.20, 38, 
41, 60, 64-66 A significant amount of work has been done in this field. Bifunctional chelators bind the 
68Ga nuclide, and provide a point of attachment for a targeting moiety. Typically, a receptor is 
identified that is unique or over-expressed with a condition of interest, and then the receptor 
conjugate is attached to the 68Ga complex.20, 43, 66-68 The premise of this methodology is that the 
radiolabel will have a higher affinity for regions where the receptors are found, than for normal 
tissue.14, 21, 34, 69 However, targeted radiolabel distribution is not always simply a case of adding a 
known receptor to a stable complex. For example, hypoxic cells have a tendency (compared to 
normal healthy tissue) to accumulate charge-neutral electron-poor nitroimidazole, although a NOTA 
nitroimidazoles derivative showed poorer tumour accumulation than the parent NOTA complex in a 
hypoxic tumour model.70 
 
In both therapeutic and imaging applications of radioisotopes, the in vivo stability of the radiolabel is 
of vital importance. If the radionuclide becomes disconnected, the intended biodistribution will be 
lost and as a result the signal to background signal ratio will decrease.19, 20 Furthermore, the 
radionuclide is potentially harmful to the patient. Thus, the success of a radiolabel depends primarily 
on the stability of the parent complex in vivo. The fate of a released radionuclide depends on its 
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chemical form. If a metal complex becomes disconnected from its targeting moiety, then the intact 
complex will be cleared from the body. However, if the metal cation becomes detached from the 
ligand it will accumulate in the bones and liver, where it will release potentially harmful radiation.32, 
43 
 
5 Coordination Chemistry of Gallium  
 
5.1 The Ga(III) ion 
 
A detailed knowledge of the coordination chemistry of gallium is crucial to the synthesis of suitable 
ligands. In aqueous solution, the only stable oxidation state of gallium is +3, and is only present as 
the Ga(III) aqua ion under strongly acidic conditions. In the pH range 3 – 7, hydrolysis to the 
insoluble Ga(OH)3 occurs in the absence of suitable stabilizing agents, such as citrate, HEPES, acetate 
or oxalate.20, 35 At physiological pH and the gallium concentrations used for radiopharmaceuticals, 
exclusive formation of the soluble [Ga(OH)4]
- prevents formation of the insoluble Ga(OH)3.
19, 35 
Despite this, the formation of [Ga(OH)4]
- is equally undesirable in terms of radiolabelling.  
 
The Ga(III) cation has a high charge density and a relatively small ionic radius (0.62 Å) and is classified 
as a hard Lewis acid.34, 40 It forms strong dative bonds to highly ionic, non-polarizable hard Lewis 
bases such as nitrogen and anionic oxygen. Therefore, ligands featuring carboxylate, phosphonate, 
phosphinate, hydroxamate and amine functional groups are likely to give rise to thermodynamically 
stable complexes with Ga(III).34, 35, 38 There are also ligands with softer donor groups like phenolates 
and thiolates, which give rise to stable complexes.20, 34, 35, 38 Tetra- and penta-dentate ligands 
complexes have been reported, but the vacant coordination sites and ability to hold extra donors 
make them vulnerable to nucleophilic attack (hydrolysis) and ligand exchange.34 The more 
characteristic coordination sphere is a distorted octahedron (due to the small size of the ion), which 
together with the d10 configuration of the Ga(III) ion  affords excellent stability – provided that 
suitable ligands are used.19, 40 
 
The Ga(III) ion has a unique selectivity issue resulting from its chemical properties. The coordination 
chemistry (as a result of the ionization potential, ionic radii, electronic configuration and 
coordination geometry) of the ion are remarkably similar to that of high-spin Fe(III). Transferrin is a 
plasma protein which has two iron binding sites, and as a consequence a high affinity for Ga(III). 
Chapter 1: Background and Aims of the Project 
 
 
 
Page 22 
 
  
Ligand exchange in vivo involving transferrin is a common threat to gallium complexes, and is 
evident by considering the relative affinities: log K (Ga3+) = 20.3 and log K (Fe3+) = 22.8.41, 52 
 
5.2 Ligands for chelating Ga3+ 
 
The 68Ga radionuclide has desirable radiochemical properties for use in PET which, coupled with the 
reliability, convenience and low cost of the 68Ge/68Ga generator, make it a radionuclide with 
exceptionally high potential to make PET more widely available. However, in order to realise this 
potential suitable ligands are required.  A suitable ligand should ideally meet the following criteria: 
 
 The ligand should form complexes with high thermodynamic stability and, more importantly, 
is kinetically inert to prevent transchelation of the metal. Gallium complexes need to be 
stable to hydrolysis and more stable than the Ga-transferrin complex.40 
 Radiolabelling of the ligand should ideally occur rapidly under mild conditions with a low 
excess of the ligand.58 
 In order be useful in imaging, the ligand should provide a point of conjugation for targeting 
vectors. Also useful in this regard is versatility, such that the pharmacokinetics can be 
adjusted (by changing the overall polarity). Furthermore, conjugation of a biological vector 
should not cause a significant debilitating effect on the radiolabelling.57 
 The ligand should be selective for Ga over other metals present. Especially Fe3+ (0.05 nM in 
the hydrochloric acid used to elute the generator), Ca2+ (2 mM in serum), Mg2+ (1 mM in 
serum) and Zn2+ (68Ga decay).58, 71 Ideally the synthesis of the ligand should be simple, fast 
and cost effective.20, 35 
 
In order to make 68Ga complexes useful and effective in a variety of 68Ga-PET applications it is widely 
considered/accepted that conjugation to a suitable targeting vector is necessary using a bifunctional 
complexing or chelating (BFC) agent.20, 38, 48, 66 The topic of BFC’s for 68Ga is covered in a number of 
publications, and will not be covered in detail here. For detailed reviews on this topic the reader is referred to: 
(a) H. R. Maecke et al, J. Nucl. Med. 2005, 46, 172S; (b) M. D. Bartholoma, Inorg. Chim. Acta. 2012, 389, 36; (c) M. J. Welch 
et al, Chem. Rev. 1999, 99, 2219; (d) H. R. Maecke, Contrast Media Mol. I. 2008, 3, 53. 
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Thus, in order to realise the potential of the 68Ge/68Ga generator, the primary challenges for 
synthetic chemists are to design ligands which stabilise the Ga(III) ion in vivo, radiolabel rapidly 
under mild conditions and provide a point of attachment for a targeting vector.20, 35  
 
What follows is a brief overview of reported ligands suitable for 68Ga PET. This project is primarily 
concerned with laying the ground work for novel ligands suitable for 68Ga-PET. In this regard, rapid 
radiolabelling under mild conditions to give complexes with high in vivo stability is of the upmost 
importance. Modification to yield bifunctional ligands is an important consideration, will however 
form the basis of work subsequent to this study. Thus the discussion which follows focuses on the 
radiolabelling properties and stability of the subsequent complexes, as these are pre-requisites for 
their application. The discussion which follows is only a brief overview of some of the most promising and prevalent 
ligands for 
68
Ga-PET. For a more comprehensive overview which predates the more modern ligands discussed here, the 
reader is referred to: (a) M. D. Bartholoma et al., Chem. Rev., 2010, 110, 2903; (b) M. J. Welch et al, Chem. Rev. 1999, 99, 
2219; (c) H. R. Maecke, Contrast Media Mol. I. 2008, 3, 53; (d) H. R. Maecke et al, J. Nucl. Med. 2005, 46, 172S. 
 
The efficient and stable complexation of the 68Ga radionuclide has been studied for 4 decades.36, 72 
Early work was dominated by the focused efforts of Martell and Welch, and later succeeded by 
Maecke and co-workers with the DOTA ligand.73-75 The current so-called ‘gold standard’ of 68Ga 
ligands is the aminocarboxylate ligand DOTA (Figure 1.6). The most well-known 68Ga complex 
featuring this core is the bioconjugate 68Ga-DOTATOC, which was reported in 2001 by Henze and co-
workers (Figure 1.1).76 It is currently used in clinical practice for the PET-imaging of neuroendocrine 
tumours and metastases.43 
 
 
 
Figure 1.6 Structure of ligands NOTA and DOTA which have dominated the chelation 
68
Ga in clinical practice 
(for 
68
Ga-PET) and research. 
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The ‘popularity’ of DOTA for 68Ga-PET arises from two features in particular. Firstly, the gallium-
DOTA complexes have exceptionally high stability in vivo, with 67Ga-DOTA reported to be stable in 
serum (in vitro) for 1250 h.77 The stability in vivo is largely a result of the macrocyclic effect resulting 
in a high kinetically stability, whilst the thermodynamic stability (log K = 21.33) is comparable with 
Ga-transferrin (log K 20.3).52, 78 The second feature which makes DOTA attractive is the potential for 
bio-conjugation. DOTA has an N4O4 donor system and is more commonly used for chelation of large 
metal ions, such as the lanthanides, which require octadentate ligands.79 Crystal structures of 
[Ga.DOTA] reveal that the ligand binds using an N4O2 donor set, with two flailing carboxylate arms.
80 
These ‘superfluous’ functional groups have been exploited by many groups to provide the 
attachment of targeting vectors yielding BFC’s.19, 20, 66, 79, 80  
 
Despite these advantages, DOTA has several drawbacks. Optimal radiolabelling with 68Ga is 
inherently slow (30 min), requires high temperatures (90 °C), high ligand concentrations and rather 
acidic media (pH 4.6). The long radiolabelling times allow significant radioactive decay, whilst the 
harsh conditions are unsuitable for many biological targeting vectors. A basic knowledge of 
coordination chemistry is required to understand why these harsh conditions are required. The 
DOTA ligand is designed to hold larger metal ions with the N4 ring of cyclen primed to offer an anti-
prismatic square base not ideally suited to the Ga(III) ion. The 12-N4 ring has pKa values of 12 and 11 
with two bifurcated hydrogen bonds stabilising and rigidifying the ring conformation.78 
Deprotonation of the ligand is the rate limiting step in the metal ion binding, as it is associated with a 
high energy barrier to the conformational change that allows it to occur. Furthermore, DOTA and its 
derivatives are difficult and expensive to synthesise, with many groups purchasing BFC precursors 
from commercial suppliers at a high cost.79, 81 In fact, the dominance of DOTA derivatives in 68Ga-PET 
is believed to be related to the commercial availability of DOTA-3tBu; a useful precursor for the 
synthesis of BFCs based on DOTA.20 The drawbacks of DOTA highlighted the need for ligands which 
radiolabel more quickly and under milder conditions.  
 
Gallium complexes of the macrocycle NOTA (and its derivatives) were first reported in the late 
1980’s by Parker and co-workers82, and were subsequently elaborated on by Maecke and co-
workers75 towards the end 1990’s. Since then, considerable effort has been expended towards the 
synthesis of BFC’s based on NOTA and its derivatives.75, 83-85 The ligand benefits from rapid 
radiolabelling (10 min) at room temperature at pH 3 – 5.5.48 NOTA has a smaller binding cavity than 
DOTA and supports octahedral metal ion geometries, which is a better match for the Ga(III) ion. As a 
result the selectivity for Ga is better, and the complex has high thermodynamic (log K = 31)64 and 
Chapter 1: Background and Aims of the Project 
 
 
 
Page 25 
 
  
excellent kinetic stability in vivo.58 One of its derivatives featuring a conjugation facility, NODAGA, 
has been linked to proteins at pH 4.1 in 7 min.86 The major drawback of NOTA is that optimal 
radiolabelling apparently requires acidic conditions, which narrows the window of possible biological 
vectors. Although a number of NOTA derivatives featuring functionalities for conjugation have been 
reported, these too are synthetically challenging and can be expensive to prepare.75, 85, 87 
 
Structural analogues of NOTA which have shown excellent potential are the phosphinic acid 
derivatives (Figure 1.7). Despite gallium complexes of these related ligands first being reported back 
in 1994 by Parker and co-workers61 for 67Ga complexation, their potential as 68Ga-PET BFCs has only 
been exploited in the last 2 years by Notni and co-workers.57, 58, 71, 88 NOTA derivatives featuring 
phosphinic acids allegedly radiolabel at 95°C in less 5 minutes over the pH range 1 – 5.57, 58 
Radiolabelling at room temperature occurs at lower ligand concentrations than NOTA (at pH 3.3), 
but the difference is not considerable. The unique feature of these complexes is their ability to label 
under strongly acidic conditions (pH 1), and at much lower ligand concentrations (1 μM), albeit at 
high temperature (95°C). This is made possible through the use of the phosphinic acid groups as the 
primary donor. Their lower pKa (~ 1) than carboxylates (~ 3.5) means they are protonated at much 
lower pH, and hence able to bind Ga at much lower pH’s.58 However, the same is not true for the 
nitrogen donors of the 9-N3 ring. In this case the energy barrier to deprotonation (at pH 1) is very 
high. Under these conditions it is highly unlikely that the N3 donor set will be involved in metal 
binding. A more likely scenario is that, under acidic conditions, the gallium ion is being bound weakly 
by the three anionic phosphinate groups in an ‘out-of-cage’ manner. Radiolabelling may be 
observed, but not to give the intended N3O3 species. It is possible that a subsequent increase in pH 
may deprotonate the 9N3 scaffold, alllowing the Ga ion to ‘drop’ into the cavity and be bound as a 
stable N3O3 complex. Realistically, the radiolabelling of ligands with polyaza rings at pH < 2 to give a 
stable complex is not feasible. Furthermore, it lacks any real practical relevance. The original benefit 
was thought to be the ability to label the strongly acidic generator eluate directly, thus reducing the 
overall radioactive decay. However, the eluate volume is too large for practical labelling and requires 
pre-concentration anyway. Furthermore, radiolabelling and storage of BFCs featuring biological 
vectors under strongly acidic conditions is not feasible.58 Complexation of 68Ga using TRAP-type 
ligands which possess carboxyethyl substituents at phosphorus (TRAP-Pr), is further complicated by 
the tendency to form less stable ‘out-of-cage’ complexes.88 Notwithstanding these drawbacks, TRAP 
ligands are well-suited for 68Ga-PET, and BFCs derivatives have shown promise during in vivo 
evaluation. Although too acidic for most applications, the radiolabelling pH range makes 
radiolabelling procedures more robust.58 The real value of these ligands is their ability to label faster 
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at lower ligand concentration than NOTA, rather than the labelling pH range. However, this value is 
only realised at very high temperature. Furthermore, labelling at room temperature is not practical 
because this requires high ligand concentrations (100 μM) and long labelling times (20 min). 
 
 
 
Figure 1.7 Structure of the TRAP ligand, and two derivatives, which label rapidly at room temperature. By virtue 
of the phosphinate donors these TRAP radiolabels more quickly, and with a lower ligand concentration, than 
NOTA.
57, 58, 88
 
 
The ‘renaissance’ of the 68Ge/68Ga generator37 and dominance of NOTA and DOTA (Figure 1.6) in 
68Ga-PET, is evident in the number of promising chelators that have been reported in the last 5 years 
alone.10, 19, 20, 35 It is interesting to note that, with few exceptions, trends have seen a deviation away 
from rigid cyclic chelators towards more flexible acyclic ligands.19, 20 Acyclic chelators are typically 
synthetically less challenging and tend to radiolabel rapidly, but the absence of the macrocyclic 
effect can render them less kinetically stable and less metal-ion selective.20, 34, 35 
 
The acyclic ligand HBED (Figure 1.8), which is based on an EDTA-type framework, forms very stable 
68Ga complexes (log K = 39).86, 89 The ligand shows ~ 95 % radiolabelling at pH 4.6 in 10 minutes at 
room temperature with a ligand concentration of 10 μM.86 More recently, the ligand has been 
modified (HBED-CC: Figure 1.8) to give a BFC with conjugated proteins that have shown quantitative 
radiolabelling at pH 4.1 and room temperature in 4 min in some cases.90 However, in most BFC’s of 
HBED-CC radiolabelling yields of ~ 85 % at 40°C are reported.86, 91 Whilst a good result, the drawback 
of non-quantitative radiolabelling is that the radiolabelled BFC will have to undergo a more complex 
purification prior to application. This adds to the radioactive decay, and can be challenging when 
biological vectors are present.  
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Another acyclic ligand with promise is H2DEDPA
81 (Figure 1.8), which radiolabels quantitatively at 
room temperature and pH 4.5 in less than 10 min. The complex has relatively high thermodynamic 
stability (log K = 28) and is sufficiently stable in vivo.81 The H2DEDPA ligand also has the highest 
reported specific activity (9.8 ± 0.1 mCi.mol-1) of any ligand which does not require purification.33 
Certain conjugated derivatives of H2DEDPA have shown similar properties, although a greater ligand 
concentration (100 μM) is required to maintain the favourable radiolabelling behaviour.67 Two more 
lipophilic derivatives (Figure 1.5), which also have favourable radiolabelling properties and stability 
profiles, show persistent heart uptake (> 1 % ID.g-1 over 2 h) in mice.33 
 
 
 
Figure 1.8 Structures of ligands HBED
89
 (and HBED-CC
91
 its derivative for biomolecule conjugation) and 
H2DEDPA.
81
 Each of these ligands displays favourable radiolabelling behaviour, and form radiolabelled 
complexes of sufficient stability. Furthermore, each has been elaborated to yield BFC’s with similar 
radiolabelling and stability profiles. 
 
One drawback shared by all of the ligands described is the fairly acidic pH required for radiolabelling. 
A larger radiolabelling pH window would allow for greater diversity in the biological vectors 
investigated. Blower and co-workers43 recently presented the acyclic ligand, CP256 (Figure 1.9), 
which makes use of defriprone functional groups use in the sequestration of Fe(III).92 The ligand 
consists of three Defriprone moieties which bind in an O,O-bidentate fashion to give a neutral 
complex with Ga(III).43, 92 The parent ligand radiolabels in less than 5 min at room temperature over 
the pH range 5.5 – 6.5 in less than 5 min, with a ligand concentration of 10 μM, to give a 
radiolabelled complex which is stable to decomplexation and transchelation in human serum the 
presence of apo-transferrin. The ligand CP256 radiolabels 68Ga quantitatively, more quickly and 
under milder conditions than any of the ligands reported to date. Given that the CP256 is structurally 
based on donor groups used in the treatment of Fe(III) overload, an area of possible concern is the 
high affinity of the ligand for Fe(III). The authors have not reported any Fe(III) challenge experiments, 
and the possibility of transchelation should not be ruled out. A BFC derivative has been reported, 
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YM103-C2Ac (Figure 1.9), and shows very similar radiolabelling behaviour and complex stability.43 A 
PET imaging study of the BFC derivative was carried out in a normal mouse. The radiolabelled 
complex had accumulated almost exclusively in the kidneys, with a small amount of excretion to the 
bladder at 90 min post-injection.43 Accumulation of the radiolabelled complex in the kidneys may be 
a further area of concern, especially when the iron sequestration properties of the ligand are taken 
into account. In some instances, in vivo kidney uptake is an indication that the BFC has been 
degraded.65 
 
 
 
Figure 1.9 Structure of ligands CP256 and its BFC derivative, YM103-C2Ac. Both ligands display favourable 
radiolabelling behaviour, and form a 
68
Ga radiolabelled complex which is stable in vitro.
43
 
 
6 Ligands based on the AAZ scaffold 
 
6.1 Introduction to AAZ 
 
A review of the literature surrounding the 6-amino-1,4-diazapine (DAZA) reveals that it was first 
reported in 2004, in its capacity as a ligand.93 The core was used as a scaffold for aminocarboxlate 
groups to give heptadentate ligands which continue to show promise as ligands for Gd-MRI imaging 
agents.68, 94-100 It is interesting to note that prior to this, Rossignoli101 (1997) and  Hegetschweiler102 
(2000) had suggested that this tridentate ligand would be suitable for the coordination of octahedral 
metal ions. Hegetschweiler went on to publish a comprehensive report on the coordination 
chemistry of DAZA and its 6-methylperhydro derivative (AMPED: Figure 1.10).103, 104 This followed 
work by Neves and co-workers that investigated the use of AMPED as a mimic of triazacyclononane 
(9-N3) in terms of it metal chelating ability.
105 The AMPED ligand consists of three amines, two of 
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which are endocyclic incorporated within the seven membered ring, the third nitrogen exists as an 
exocyclic primary amine at the 6-position (Figure 1.10).  
 
 
 
Figure 1.10 structures of relevant tridentate ligands 6-amino-1,4-diazepine (DAZA), 6-amino-6-methylperhydro-
1,4-diazepine (AMPED) and 1,4,7-triazacyclononane (9-N3). 
 
As a result of the early endeavours of Aime and co-workers, interest in the tridentate ligand scaffold 
was sparked on three fronts: 
 
 Coordination of metal ions requiring octahedral ligand fields. 103-107 
 As an ancillary ligand in catalysis using rare earth metals.108-111 
 As a ligand for metal enhanced MRI applications.68, 98, 100, 112, 113 
 
What follows is a brief review of the literature surrounding the use of DAZA and its derivatives as 
metal chelators, covering the applications relevant to this project 
 
6.2  DAZA as a chelator for metals requiring a hexadentate ligand field 
 
Nitrogen based facial tridentate (fac-N3) ligand moieties such as 9-N3 (Figure 1.10) have seen wide 
applications in coordination chemistry including modeling of the active sites of metallo-enzymes, 
stabilization of catalytically active metal centres and transition metal complexes.103, 114, 115 
 
Cyclic chelators like those based on 9-N3 are attractive because they possess restricted and well 
defined modes of coordination which allow for the easy design of a desired coordination sphere. In 
many cases, the coordination geometry enforced is distorted from a regular configuration, a feature 
which often gives rise to very interesting properties. 99-103, 112 Furthermore, the amine groups can be 
elaborated or decorated to multidentate ligands.103-107, 116  
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The major disadvantages of these chelators is that their synthesis, modification and extension 
(functionalisation) is both time consuming and expensive.105 Thus, chelators mimic the structural 
characteristics, of 9-N3 in particular, are of considerable interest.
103, 105 Neves concluded that, based 
on the structural and physiochemical properties of DAZA and TACN complexes, that the DAZA ligand 
was a ligand that could potentially mimic the important properties of 9-N3.
105 It is interesting to note 
that this statement was made despite their report that Ni(9-N3)2 was approximately five orders of 
magnitude more thermodynamically stable than Ni(DAZA)2.
105 The inherent advantages of DAZA are 
a two-step facile synthesis from readily available starting materials, and a synthetic route that 
enables selective functionalisation of the primary amine.93 
 
Hegetschweiler and co-workers compiled a comprehensive report on the coordination chemistry of 
a series of complexes of divalent first row transition metal complexes [Ni(II), Cu(II), Zn(II), Cd(II), 
Co(II)] of the form [M(DAZA)]2+ and [M(DAZA)2]
2+, making direct comparisons to analogous fac-N3 
complexes. There are two interesting features of DAZA and its derivatives when the crystal structure 
of the free ligand is compared to that of the bound ligand. Firstly, it is apparent that there is a 
degree of flexibility in the position adopted by the exocyclic amine (Nexo) relative to the ring.
103 In the 
free ligand it takes up an equatorial orientation, but adopts an axial orientation when bound to a 
metal ion (Figure 1.11). This change in orientation is a reflection of the inherently flexibility of seven 
membered rings, which typically have a large number of low energy conformations.103 The Nexo 
functional group is more sterically demanding than a proton, therefore in free DAZA, the lowest 
energy conformation/s are invariably those in which the amine adopts the less sterically demanding 
equatorial position.  However, tridenate binding of DAZA necessitates that the Nexo adopt an axial 
position. Secondly, when acting as a tridentate ligand, DAZA  almost always adopts a chair 
conformation.103 This conformation is under considerable torsional strain, as evidenced by the 
eclipsed conformation of the N-CH2-CH2-N ring fragment.
103 
 
In a later publication, Hegetschweiler hypothesised that it may be possible to improve the ligating 
properties of DAZA by addition of a methyl group at the 6-position. This ligand is commonly known 
as AMPED (Figure 1.10).104 Similar modification had been found to be beneficial with the ligand TACH 
(Figure 1.12), where the addition of methyl groups onto the ring (Me3TACH) promoted axial 
orientation of the nitrogen donors thus improving the ligand kinetics and complex stability (Figure 
1.9).117-119 However, only a weak gain in stability was observed for the DAZA-AMPED modification. In 
contrast to the findings of Neves, Hegetschweiler went on to state that DAZA is only a mimic of 
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TACN insofar as the manner in which they bind metals.103, 104 Both can form complexes with large 
metal ions (such as lanthanides), because the 5 remembered chelate rings they form are well suited 
to such metals.97, 103, 104 In terms of metal binding ability, TACN and Me3TACH are very efficient, 
whereas AMPED (and even more so DAZA) is not.104 The complexes [M(DAZA)]2+ and [M(AMPED)]2+ 
were found to have among the lowest stability constants (log K1) when compared with similar cyclic 
tri-amine complexes. This was thought to be largely due to the torsional strain resulting from the 
unfavourable ring conformation.  
 
 
 
Figure 1.12 Structures, and abbreviated names, of ligands to which reference is made in the text. 
 
Aime and co-workers have reported the stability constant for a variety of metal complexes with the 
tetra-acetate derivative of AMPED (AAZTA: Figure 1.12). For Mg(II), Ca(II), Sr(II) and Mn(II) the log 
KML values were between 8.3 and 15.4, whereas with larger Cu(II), Zn(II), Pb(II) and Cd(II) ions 
complexes have considerably lower values (18 – 21).97 With the larger lanthanide ions, values were 
between 18 and 22, i.e. slightly higher than most of the non-lanthanide metal ions. The increasing 
log KML with size of the metal ion, indicates that the binding pocket of AAZTA is better suited towards 
smaller metal ions.97 It is interesting to note that, compared to the more flexible DPTA ligand (Figure 
1.12), the lanthanide complexes of AAZTA are less stable whereas the non-lanthanide complexes are 
slightly more stable.97 This indicates that AAZTA has a ‘blend’ of cyclic (due to the ethylene diamine 
diacetate fragment) and acyclic (due to the iminoadicetate group) properties.97, 100, 103, 104 The acyclic 
properties afford the ligand rapid ligation kinetics characteristic of aminopolycarboxylates. The 
acyclic portion contributes to the complexes being thermodynamically stable and kinetically inert 
which is characteristic macrocyclic polyazacarboxylates.95, 100 As a result, the coordination cage of 
AAZTA is more rigid than DTPA, but more flexible than the likes of NOTA.95, 97 
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Despite being found to be largely unsuitable as a tridentate ligand, a number of researchers 
recognised potential in the AAZTA ligand. 
 
6.3 Imaging related applications of AMPED based ligands 
 
In this section metal complexes incorporating the DAZA ligand are discussed. Complexes with 
potential use as imaging agents are of particular interest, because some of the desirable ligand 
properties are in-line with those of this project.  For an imaging agent to be considered ‘promising’, 
the primary concern is stability in vivo. The ability to conjugate the ligand to a moiety which provides 
some form of optimization is of interest in most imaging applications, and of relevance to this work.  
 
Aime et al reported the synthesis, characterization and relaxometric properties of a Gd diaqua ligand 
complex, which uses an AMPED core decorated with 4 acetate groups from the three nitrogen atoms 
to give AAZTA (Figure 1.12).93 The synthesis of AAZTA follows a simple, high yielding route which 
uses cheap and readily available starting materials. Furthermore, the extension and modification is 
relatively simple in comparison to other ligand systems used in the past.112 This feature of AAZTA has 
subsequently been exploited by numerous groups.68, 94, 96, 99, 112 
 
The [Gd(AAZTA)(H2O)]ˉ complex  has a stability constant (log K) of 19.3 which is comparable with 
that of [Gd.DPTA] – a commercially used MRI contrast agent.93 Furthermore, [Gd(AAZTA)(H2O)]ˉ 
shows no signs of transmetallation and is virtually unaffected by the presence of endogenous anions. 
[Gd(AAZTA)(H2O)]ˉ displayed a relaxivity of 7.1 mM
-1s-1 at 20MHz and 298 K over the pH range 2-11, 
which is better than the relaxivities of most commercially used MRI CA’s (4-5 mM-1s-1).93 Interest in 
AAZTA, and its derivatives, for use in Gd-enhanced MRI was sparked by this complex, which 
displayed good magnetic properties coupled with high thermodynamic and kinetic stability.93 In fact, 
all reported gadolinium complexes (for MRI applications) based on the DAZA scaffold feature the 
same N3O4 7-membered core, first reported in 2004. 
 
The crystal structure of the free ligand reveals two nearly identical crystallographic independent 
molecules, which differ slightly in the conformation of the ring (Figure 1.13). The structure was 
described as chair-like with the exocyclic nitrogen in an axial position.95 This is not strictly true, with 
the conformation more accurately described as a twisted-chair conformation in which the exocyclic-
nitrogen takes up a pseudo-axial orientation. The C-O bond distances reveal that only two of the 
Chapter 1: Background and Aims of the Project 
 
 
 
Page 33 
 
  
acetate groups are deprotonated, with the charge being balanced by protonation of their respective 
amines, to give a zwitterion.95 
 
 
 
Figure 1.13 Various views of the crystal structures of the the [Gd(AAZTA)(H2O)]ˉ complex (top), and AAZTA free 
ligand (bottom). Hydrogen atoms and water molecules have been excluded for clarity. Note: the regular chair 
conformation adopted by the AMPED scaffold, eclipsed nature of the ethylene diamine bridge, and how the 
Gd(III) ion “stands out” of the AAZTA binding cavity in the Gd(AAZTA)
-
 complex. In contrast the free ligand is 
considerably more twisted, with Nexo adopting a pseudo-axial orientation. In the case of the metal complex, 
only one half of the dimer is shown.
95
 
 
The [Gd(AAZTA)(H2O)]ˉ anion crystallizes as a dimer in the form M2L2, consisting of two ligands in 
similar conformations. It has been suggested that formation of the dimeric species is favoured by the 
exposed Gd core (a result of the restricted coordination sphere of AAZTA) which is presented to the 
acetate groups of another complex.100 The structure reveals interesting details about the 
conformation of the AMPED core. As expected, it adopts a near perfect regular chair conformation 
(the N-CH2-CH2-N fragment has a deviation 3.0 ° from perfectly eclipsed), with its seven donor 
groups encompassing just over half the coordination sphere of the metal centre (Figure 1.13). The 
coordination geometry is labelled as a distorted bicapped pentagon, with 3 nitrogen donors, 4 
oxygen (acetate) donors and 2 bridging oxygen donors – shared between two adjacent Gd centres.95 
A single water molecule is included to make each Gd centre formally decacoordinate.95 The Gd-Nexo 
distance (2.599 Å) is slightly shorter than the Gd-Nendo distance (2.778 and 2.681 Å), which is not 
entirely surprising given the inherent flexibility of the exocyclic amine and the presence of two 
attached acetate groups.95, 100 This is a consistent feature for metal complexes featuring tridenate 
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DAZA ligand derivatives.103, 104 These distances are significantly longer than those reported for 
cobalt(II), copper(II), nickel(II) and zinc(II) complexes (M-N: 1.946-2.108 Å) with DAZA, as should be 
expected based on the relative ionic radii.  
 
The conformation adopted by the DAZA core (equivalent atoms of the ring are eclipsed: Figure 1.13) 
and the exposed metal ion hardly seem conducive to formation of a stable complex. The author 
attributes the high stability of [Gd(AAZTA)(H2O)]ˉ to three structural features: 
 
1. The four anionic acetate groups form a shallow convex surface through the Gd centre, which 
contributes to the stability of the compound with respect to anion approach and binding. 
2. The lack of strain within the complex. 
3. The flexibility of the four acetate arms. 
 
This is in contrast to the findings of Hegetschweiler, who attributed the observed low stability of the 
metal complexes to the torsional strain within the bound ligand.103, 104 It is likely that, the anionic 
oxygen donors enhance the stability of the complexes formed, relative to the unfunctionalised DAZA 
based complexes. However, this does not detract from the fact that there is inherent structural 
strain in the bound ligand. In fact, a crystal structure of a very similar europium complex (only 
modified by the addition of a hydroxyl group onto the tertiary methyl) reveals a pseudo-twisted-
chair conformation of the ring, a conformation which is expected to have less inherent structural 
strain than the [Gd(AAZTA)(H2O)]ˉ complex (Figure 1.13).
100 It is noteworthy that whilst there is a 
bridging of two Gd centres in the solid state structure, in solution the anion almost certainly exists as 
the monomeric species with two bound water molecules – as suggested by 17O NMR studies.95 
 
The sufficient stability, facile synthesis and good relaxometric properties of [Gd(AAZTA)(H2O)]ˉ has 
fostered considerable interest in the use of AAZTA as a chelator for Gd MRI contrast agents. Wiener 
et al have illustrated the synthetic flexibility and modification potential of the AMPED core for use as 
a bifunctional MRI probe.100 Provision for the attachment of a targeting moiety was made by 
replacing the exocyclic methyl with an oxyethyl substituent.100 Vitally, this new binding site does not 
result in any unwanted side reactions, and does not become involved in complexation.100 A large 
number of ligands, with a variety of conjugation functionalities, have been reported.68, 94, 96, 99, 120 The 
vast majority use the tertiary ring carbon of AAZTA as a point of attachment. These examples are not 
discussed in detail here, but some examples are illustrated in Figure 1.14.  
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Figure 1.14 Examples of DAZA based heptadentate ligands used for complexation of Gd(III), which feature 
functionalisation at the quaternary carbon of the ring.
94, 96, 100, 112
 
 
From the preceding literature survey, it is evident that other research groups have focused on 
modification at the exocyclic methyl position to induce higher relaxivities (through reduced 
molecular rotation primarily) and seek a targeted bio-distribution.  
 
The approach at Durham has been somewhat different, in that we have sought to take advantage of 
the different amine groups of the AMPED ring to synthesise complexes where the substituents at the 
endocyclic nitrogen’s are varied, whilst the Nexo acetate groups are maintained. This approach was 
for the most part chosen because this chemistry had not been explored.  
 
The mono- and di-glutarate derivatives of AAZTA (Figure 1.15) were synthesised, with the premise 
that the glutarate groups could alter the water exchange dynamics, and provide a means for the 
addition of hydrophilic groups. A range of optically pure di- and mono-glutarated Gd(AAZTA) 
derivatives have been synthesised, each of which contained two coordinated water molecules. It 
was thought that the glutarate derivatives influence the second hydration sphere in a manner 
conducive to increasing relaxivity.98 The complexes only showed small improvements compared to 
the relaxivity of the parent complex. The author suggested that overcrowding at the metal centre, 
inhibits the approach of water molecules, thereby slowing the water exchange.98 As a result, the 
relaxivities of the glutarate derivatives are not very different from the parent complexes. 
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Figure 1.15 Modification of the AAZTA at the endocyclic amines. The diglutarate
98
 (left) and di-azaxanthone
121
 
(right) derivatives of AAZTA.
 
Conformations of the two chiral centres in the di-glutarate can be the same [(R,R) 
or (S,S)] or different [(S,R)]. 
 
Directly following this work the suitability of the scaffold was evaluated in other fluorescence 
imaging applications aimed at anion sensing. This was facilitated by the substitution of the  
endocyclic acetate groups for azaxanthone moieties, which acted as sensitizing chromophores and 
provided the necessary donor groups (pyridyl nitrogens: Figure 1.15).121 In a screening protocol the 
overall stability was lower than a DOTA equivalent, and thus only of use in vivo under controlled 
conditions.121 Interestingly, these are the only two modified AAZTA ligands in which functionalisation 
has occurred at a position other than the tertiary carbon of the ring.  
 
During the course of this research two publications appeared which correspond closely to work 
carried out in this project. In 2011 Botta et al reported a series of manganese complexes featuring 
hexadentate AAZTA-like ligands (Figure 1.16).113 The complexes were evaluated in terms of their 
thermodynamic and relaxometric properties as potential MRI contrast agents. In comparison to the 
[Mn.AAZTA] complex (log K = 14) the hexadentate complexes were three orders of magnitude less 
stable, and thus are not sufficiently stable for use in vivo. Manganese(II) has coordination numbers 
of six or seven, which led the author to believe that the difference was attributed to the glycine 
moiety of the hexadentate ligands being a weaker coordinating group than the iminodiacetate of 
AAZTA.113 Given the apparent wealth of octahedral manganese(II) complexes in the literature, this 
may not be the only contributing factor. Inherent strain within the ligand, and different donor sets 
may also play a role.  
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Figure 1.16 AAZTA and hexadentate ‘AAZTA-like’ ligands synthesised by Botta et al (2011) as potential ligands 
for Mn(II) MRI contrast agents.
113
 
 
In 2012 Manzoni et al68 published the first example of a gallium complex featuring the DAZA scaffold. 
Specifically they used the parent AAZTA ligand tethered to an RGB peptidomimetic via the 6-carbon 
of the ring (Figure 1.17). The peptide used has been shown to have high affinity for αvβ3 receptors, 
which are overexpressed in a variety of cancers. The gallium complex was not investigated in detail, 
but rather used as a proof of principle for the gadolinium equivalents.  
 
 The resulting radiolabelled complex was stated to be more stable than the DTPA equivalent, and 
sufficiently stable for in vivo testing.68 Radiolabelling of AAZTA and the conjugate was carried out at 
pH 3.8 (no further detail was provided), and injected into rats bearing a glioblastoma tumour model. 
The untargeted radiolabel, [68Ga.AAZTA], was eliminated rapidly from the blood and accumulated in 
the bladder. The radiolabel was visible in the tumour at 20 min post injection, and undetectable at 
50 min. Consistent with the larger size of the radiolabelled complex, [68Ga.AAZTA]-DB58, the kinetics 
of clearance were slower. Tumour accumulation was highlighted at 40 min, largely due to reduced 
background signal, and was still visible at 70 min.68 
 
 
 
Figure 1.17 The AAZTA ligand BFC derivative, AAZTA-DB58, used in 
68
Ga-radiolabelling and subsequent in vivo 
glioblastoma tumour model trails. Picture from 
68
. 
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Prior to the 68Ga-study, evaluations of the relative affinity of the free DB58, [Gd.DPTA-DB58] and 
[Gd.AAZTA-DB58] were carried out. It was found that the DTPA analogue produced chelates with 
satisfactory αvβ3 receptor affinity, whereas the AAZTA analogue did not. Subsequent efforts to 
transfer these findings from Gd complexes to 68Ga complexes for PET studies, found that only the 
[68Ga.AAZTA-DB58] was sufficiently stable in vivo to warrant further testing.68 The stability of the 
[68Ga.AAZTA] complex is favourable; however, for in vivo application the detrimental effect of the 
AAZTA ligand on the binding affinity of DK58 to the αvβ3 receptor is undesirable. It is evident that 
modifications to the AAZTA ligand are required, in order for the ligand to be useful.68 
 
The choice of AAZTA in this regard is interesting. In addition to having a detrimental effect on the 
binding affinity, AAZTA also is not ideally suited to the chelation of gallium(III). The heptadentate 
ligand has one too many donor groups, which could result in coordinative promiscuity within the 
ligand complex. This could result in speciation problems, which may influence the pharmacokinetics 
of the radiolabel. On the other hand, if unused, the additional acid group could be seen as beneficial 
in terms of the pharmacokinetic properties of the complex. 
 
6.4 Summary: DAZA as a potential ligand for 68Ga-PET 
 
It is apparent from the discussion that, as a ligand, DAZA and its derivatives have had mixed 
fortunes. Besides its potential application in Gd-enhanced MRI as the AMPED scaffold with four 
acetate donors, the ligand has found little use. In its simplistic triamine form, a series of 
comprehensive publications by Hegetschweiler103, 104, not only found the ligand to be a poor mimic 
for 9-N3, but in general a poor chelator of metals requiring an octahedral coordination geometry.  
Furthermore, subsequent efforts to improve its binding properties through modification of the core 
(to give AMPED), have proven largely unsuccessful.104 The DAZA core was evaluated as an ancillary 
ligand in rare earth metal catalysis108-110, however interest in the tetra- and penta-dentate 
derivatives subsided.   Hexadentate AAZTA-like ligand derivatives were evaluated for potential 
application as manganese MRI contrast agents, but the complexes are not sufficiently stable for in 
vivo application.113 
 
Although interest in these ligands in Gd MRI applications continues, it could be argued that even 
here the ligand is not particularly well suited.  Reported stabilities are not better than DTPA 
equivalents, which probably isn’t good enough for clinical application in spite of the favourable 
Chapter 1: Background and Aims of the Project 
 
 
 
Page 39 
 
  
magnetic properties. Structural data suggests that the favourable magnetic properties observed, 
partly arise from the fact that AAZTA is not a suitable ligand for Gd. The gadolinium ion is too big for 
the cavity of AAZTA, and as a result the metal ion is significantly exposed. This makes the Gd centre 
accessible to coordinating water molecules, and gives rise to the favourable relaxation properties.  
The exposed metal ion, coupled with the inherent strain in the coordinated ligand, means complexes 
like these are likely to be on the border of what is acceptable in terms of stability.  
 
Tumour binding affinity studies indicate that the AAZTA ligand has a detrimental effect on 
receptor-vector binding affinity. In order to overcome this problem, the AAZTA ligand requires 
modification to alter its pharmacokinetics.68 Doing so could be problematic considering the cramped 
nature of the ligand, especially at the iminodiacetate. Furthermore, there is evidence that 
modification of the endocyclic amines effects stability and magnetic properties.98, 121 
 
At the outset of this research, there were no reports of gallium complexes which incorporate the 
AMPED core structure. In terms of coordination geometry, ‘AAZTA-like’ ligands should be well suited 
to octahedral coordination geometry requirements of 68Ga(III). Crystal structural data of DAZA and 9-
N3 based complexes show that the core fac-N3 structures are very similar.
103-105 This suggests that 
hexadentate derivatives of DAZA (similar in form to NOTA) should give rise to sufficiently stable 
complexes for use in vivo, provided that the metal ion is of suitable size and nature. Furthermore, it 
has already been shown that the AMPED ring has considerable conformational flexibility, giving the 
ligand a mixture of cyclic (stability) and acyclic (flexibility).95, 97 These features may promote fast 68Ga 
radiolabelling. Ln-AAZTA crystal structures show that the chelator takes up approximately half of the 
coordination sphere of the metal. However, it should be noted that the Gd(III) ion is significantly 
larger than Ga(III). Therefore, it is expected that Ga(III) would fit better for the binding site of AAZTA 
(or its derivatives). Despite some complications, the ligand has been shown to be extremely versatile 
in terms of conjugation, it is easy and cheap to synthesize and gives complexes that are sufficiently 
stable for in vivo application.93, 112 In addition, the lower ligand denticity required by gallium(III) may 
permit greater ligand modification. This may become important in terms of optimising the 
pharmacokinetics of the gallium complexes.  
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7 Aims and specification 
 
The objective of this project is to evaluate the suitability of hexadentate ligands based on AMPED for 
68Ga-PET. Specifically, the aim is to design, synthesise and characterise a series of novel hexadentate 
ligands based on the AMPED scaffold for radiochemical evaluation with 68Ga. Initial evaluation would 
take the form of radiolabelling and stability studies, with subsequent in vivo evaluations of suitable 
candidates. Further work would look to improve upon these ligands.  
 
Radionuclide imaging with 68Ga, both in research and clinical practice, is dominated by the use of the 
ligand derivatives of NOTA and DOTA. The high temperatures required for radiolabelling of DOTA, 
are largely addressed with NOTA without detriment to the stability of the resulting complex. 
However, its application is hindered by the acidic pH required for radiolabelling, cost and difficult 
syntheses. Whilst they serve the purpose, improvements to increase efficiency, suitability, 
application and costs are required to realise the potential of the favourable 68Ga-radionuclide. 
Specific areas of improvement include quantitative radiolabelling at milder pH and room 
temperature, whilst maintaining sufficient in vivo stability. 
 
The specification for a ligand ideal for application in 68Ga-PET is as follows:10, 19, 20, 35, 39, 41 
 
1. A derived gallium(III) complex which is sufficiently kinetically inert and 
thermodynamically stable in vivo over a period of 2 hours. 
2. Quantitatively radiolabels with 68Ga within 10 minutes at room temperature over a 
wide pH range, which includes mildly acidic environments. 
3. Follows a synthetic procedure which is cheap, fast and simple. 
4. Provides a point of attachment for biological vectors. Synthetic flexibility to adjust 
the pharmacokinetics of the complex is also favourable. 
5. The ligand should display selectively for gallium, over other metal ions it may 
experience in vivo and during radiolabelling. 
6. Synthesis of the ligand should be conducted in a manner such that the radiolabel 
precursor meets all quality control requirements. Specifically, the final product 
should have known composition and be of very high purity.  
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Chapter 2  
AMPED Based Ligands for 68Ga(III) 
 
This chapter discusses the synthesis and solution NMR behaviour of a series of hexa- and hepta-dentate aza-
carboxylate ligands (Section 1 and 2), followed by an assessment of their suitability for application in 
68
Ga-
PET (Section 3). 
 
1 Synthetic Aspects 
 
Three main methods have been described for the synthesis of 6-amino-1,4-diazepines for use as 
ligands in metal complexes.1-3 This fac-N3 7-membered ring features a single exo- and two endocyclic 
amines, which can be functionalised to increase the ligand denticity. In particular, interest in this tri-
amine has focused on its use in complexes of transition3-7 (titanium, scandium, manganese) and 
lanthanide2, 8-15 (gadolinium, europium) metal ions. 
 
The ligand AAZTA, which has been shown to produce stable complexes with lanthanide metal ions, 
features the tribasic core modified by the addition of a methyl group at the 6-position to yield 6-
amino-6-methylperhydro-1,4-diazepine (AMPED; see Scheme 2.1). Synthesis of this core is both 
cheap and synthetically facile, with modification to alter the characteristics of the ring for bio-
conjugation seemingly straightforward.2, 13, 14 Gugliotta was the first to show how 6-hydroxylalkyl 
derivatives can be used to form a range of 6-substituted AMPED scaffolds.13 Following the success 
obtained with the stable coordination of lanthanide ions and the relatively facile ligand synthesis, 
this published synthetic protocol2 seemed a sensible starting point for the synthesis of ligands 
suitable for the formation of stable gallium complexes.  Furthermore, the other syntheses described 
require a greater number of steps and are potentially hazardous.3, 6  Each ligand discussed in this 
section features the AMPED scaffold, with modifications to the structure being made exclusively 
through functionalisation of the amines. This approach was chosen as it would allow assessment of 
the suitability and potential of the triamine core, whilst making relatively simple structural changes. 
The intention was to optimise the N-substituents in the first instance (Chapter 2), and subsequently 
consider modifications to the core structure (Chapter 3) which could further improve the ligands 
ability to bind Ga(III) rapidly, yet form kinetically stable complexes.   
 
Chapter 2: AMPED Based Ligands for 68Ga(III) 
 
 
 
 
Page 46 
 
  
A series of six ligands were initially identified as synthetic targets (Figure 2.1). In spite of the fact that 
the ligand AAZTA (L1) is likely to be unsuitable, given that it is heptadentate, it was evaluated as the 
parent ligand of the series. Thought to be better suited for the complexation of gallium(III), the 
remaining targets present N3O3 hexadentate donor systems. An important consideration of potential 
ligands for PET is the lipophilicity of the radiolabelled complex. To explore the effect of varying 
lipophilicity on the complexation bahaviour of the ligands, the ligands have been elaborated with 
methyl groups at various positions (L2-4). The potential of the system for the development of bi-
functional chelators was also investigated through Nexo-substitution with a masked benzylamine (L
5). 
 
 
 
Figure 2.1 Synthetic targets featuring the AMPED core. 
 
In this section, an overview and discussion of the synthetic techniques used to make these ligands 
will be given. The discussion will initially focus on the synthesis of AMPED which is central to every 
target, and will be followed by a discussion of its functionalisation to yield the desired ligands. 
 
During the course of this research ligands (specifically AAZ3A, L2 and the (RRR) enantiomer of L3) 
have been published elsewhere, for the complexation of manganese(II) with aim of developing MRI 
imaging agents.7 
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1.1 Synthesis of the AMPED Core 
 
The synthesis of AMPED is a well-established and high yielding two-step procedure that uses 
relatively cheap and readily available starting materials, allowing per gram-scale batches being to be 
prepared in an overall yield of 71 % (Scheme 2.1).2 Numerous research groups have made use of this 
synthetic strategy, or ones adapted from it, for the synthesis of ligands suitable for the complexation 
of metal ions – most often heptadenate ligands for lanthanide metal ions.2 
 
 
 
Scheme 2.1 Synthesis of the AMPED core, with intermediates shown. Method adopted from Aime and co-
workers.
2
 
 
Other methods for the synthesis of very similar rings have been described. However, they require a 
greater number of steps, give poorer yields and in some cases are potentially hazardous.3, 5, 6 A 
further benefit of the method of Aime and co-workers, is that functionalisation of the quaternary 
carbon is possible through small modification to the reactants used in the first step. This 
modification has been exploited by numerous groups for the synthesis of derivatives suitable for bio-
conjugation.14-18 
 
The key step is the formation of the seven-membered ring, which is accomplished by a nitro-
Mannich type co-condensation reaction (Scheme 2.1). Initial reaction between paraformaldehyde 
and the bis-benzyl protected ethylenediamine affords a di-iminium intermediate, which in turn 
reacts with nitroethane to form the seven-membered ring. The choice of benzyl groups is convenient 
(and necessary, as became apparent later) since catalytic hydrogenation (using Pd(OH)2/C) of 1,4-
dibenzyl-6-methyl-6-nitroperhydro-1,4-diazepine (1) results in concomitant reduction of the nitro 
group and bis-N-debenzylation, leading to formation of AMPED. Whilst convenient, this synthetic 
strategy does have its shortcomings. As noted by Parker8 and Botta16, differential N-substitution of 
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the Nexo and Nendo amines is possible, but the procedure is non-trivial and inefficient. Taking into 
consideration the nature of the synthetic targets this is not of concern at this stage, however when 
differential N-substitution is required, selective deprotection would be more versatile. The synthesis 
of modified derivatives of these ligands tailored towards bio-conjugation would benefit significantly 
from a more flexible synthetic strategy.  
   
The product of the hydrogenolysis reaction, AMPED (2), following filtration through Celite® and 
removal of solvent under reduced pressure, is a golden yellow oil which forms an oily white solid 
upon standing in an inert environment. If left open to the atmosphere, the oil/solid gradually 
changes form and darkens over the course of a week. The triamine, 2, is strongly basic, which 
suggests that the compound reacts with carbon dioxide to yield a carbamate. In support of this, 
Hegtschweiler et al have shown that bubbling carbon dioxide through a solution of AMPED results in 
formation of its dicarbamate.19 
 
It is possible to reverse this reaction by stirring the carbamate in concentrated hydrochloric acid (7 
M) to give the protonated chloride salt of AMPED. This chloride salt is stable in air, and can be 
converted back to the free amine as required. Despite the benefits of producing the protonated  
chloride salt, praparing fresh AMPED as required was found to be more time efficient and reliable. A 
further difficulty experienced with handling and synthesis of AMPED is that the free triamine is 
relatively volatile, and evaporates under the reduced pressure of a high vacuum line.   
 
1.2 Functionalisation of the AMPED Scaffold 
 
Synthesis of Ligand L1 
The synthesis of ligand L1 was achieved using the method described by Aime and co-workers 
(Scheme 2.2).2 This entailed the per-N-alkylation of the endo- and exo-cyclic amines using an excess 
of t-butyl bromo-acetate and potassium carbonate, in acetonitrile at 368 K. Hydrolysis of the t-butyl 
esters using trifluoroacetic acid gave the final product (L1), as the protonated bis-trifluoroacetate 
salt, in a good yield.  
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Scheme 2.2 Synthesis of L
1
 (AAZTA) as described by Aime and co-workers.
2
 
 
Attempted Synthesis of AAZ3A 
Synthesis of the remaining targets revealed some interesting characteristics relating to the reactivity 
and accessibility of the endocyclic amine of AMPED. The attempted synthesis of AAZ3A is a good 
example of some of these characteristics. Initial attempts directed towards the synthesis of the 
intermediate tris-N-substituted t-butyl acetate ester, 5, used three equivalents of t-butyl bromo-
acetate and potassium carbonate at 368 K.  Under these conditions only a small amount of 5 was 
obtained (~ 10 %) with a considerably larger portion of the tetra-alkylated product, 3 (~ 30 %). In our 
experience, it was not possible to exclusively produce 5 in an acceptable yield. The optimal yield was 
obtained when the reaction was carried out with 2.5 equivalents of t-butyl bromo-acetate, 2.5 
equivalents of potassium carbonate in acetonitrile at room temperature.  
 
Subsequent hydrolysis of the t-butyl esters using trifluoroacetic acid to give the final product also 
proved problematic. Whilst the 1H NMR spectrum could be interpreted in a manner consistent with 
the structure, HR MS-ES+ revealed that the compound had a molecular ion peak approximately 18 
mass units smaller than that of the theoretical mass. LC ESMS data revealed that during the course 
of the experiment there was rapid conversion of the desired tri-acid into the isolated product, 6. We 
believed that this conversion corresponded to an internal lactamisation reaction involving the 
exocyclic amine and Nendo-acetate substituent (Scheme 2.3). Such a reaction is consistent with the 
observed change in mass, and during 2011 was reported by other research groups for the same 
compound.7 The formation of this lactam ring is essentially irreversible. The reaction is acid 
catalysed, and therefore it is possible to suppress its formation through the use of base-labile esters. 
Indeed, Botta and co-workers have shown that by replacing the t-butyl esters with methyl esters it is 
possible to isolate AAZ3A.7 Taking into consideration that the radiolabelling experiments would all 
be conducted at pH < 7 and the apparent ease with which the lactam formed, it is evident that 
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AAZ3A would not be sufficiently stable for use as a ligand under radiolabelling conditions. The 
attempted synthesis of AAZ3A did bring to light two interesting features of the exocyclic amine; it is 
very reactive and easily accessible to incoming nucleophiles.  
 
 
 
Scheme 2.3 Attempted synthesis of AAZ3A resulting in lactamisation to give 6. The free triacid, AAZ3A, is 
shown as an intermediate, but was not isolated. 
 
Synthesis of Ligand L2 
Fortuitously, a target chelator structurally very similar to that of the AAZ3A, which will not undergo 
lactamisation had already been identified.  The N-methylated triacid, L2, only differs from AAZ3A by 
the presence of an N-methyl substituent. The N-methyl group, prevents formation of the lactam 
ring. The logical procedure for the synthesis of L2 was to methylate the already synthesised tri-ester 
(5), with acid hydrolysis of the subsequent ligand precursor no longer viewed as problematic in the 
absence of the N-H functional group. Due to the accessibility and reactivity of the terminal amine, 
direct alkylation was avoided initially, thinking that this could result in formation of a quaternary 
ammonium salt resulting from over-methylation. The Eschweiler-Clarke reaction uses excess formic 
acid and formaldehyde to methylate the nitrogen of primary or secondary amines, and has been 
used with considerable success for the methylation of cyclen endocyclic amines. The main benefit of 
this method is that methylation occurs via reductive amination, which cannot result in the formation 
of quaternary salts. This is because the intermediate product is an iminium salt, which cannot form 
at a tertiary amine site. This method is also attractive because it would enable simultaneous N-
methylation and ester hydrolysis, due to the presence of formic acid. The desired product was 
observed by ES-MS along with that of the un-methylated lactamised product seen previously. This 
result is perhaps not surprising given the propensity for lactamisation of 5 under acidic conditions, 
and indicates that the rate of methylation and rate of ester hydrolysis (followed by lactamisation) 
are comparable. Reaction workup and separation of these compounds proved exceedingly difficult, 
so it was decided to explore alternative methods.  
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Attempts at direct methylation of 5 were tentative, given the likelihood for formation of a 
quaternary ammonium salt, due to the high reactivity of methyl iodide and the exocyclic amine of 5. 
Indeed, even with one equivalent of methyl iodide and 0.5 equivalents of potassium carbonate at 
room temperature in acetonitrile a significant amount of the di-methylated ammonium salt was 
obtained. Separation of the di- and mono-methylated products was difficult, and instead a milder 
method was sought which suppresses formation of the ammonium salt. This was achieved with a 
yield of 41 % using a single equivalent of methyl iodide and potassium carbonate in the less polar 
solvent dichloromethane (Scheme 2.4). Subsequent ester hydrolysis of 7 was carried out using 
dichloromethane : trifluroacetic acid (1 : 1) to afford L2 as the protonated bis-trifluoroacetate salt. 
During the course of this research Botta et al have published a different method for the synthesis of 
the L2. The triester 5 is also utilized, however methylation to produce 7 is carried out by reductive 
amination with formaldehyde and H2 over Pd/C.
7 
 
 
 
Scheme 2.4 Conditions used for methylation, and subsequent ester hydrolysis to yield L2. 
 
Synthesis of Ligand L3 
The tri-propionic acid derivative, L3, features a ‘vacant’ exocyclic amine position and is therefore at 
risk of internal lactamisation under acidic conditions. It was thought that the steric bulk afforded by 
the α-methyl groups of the propionate N-substituents might prevent lactamisation through both 
hindrance of the reaction at the exocyclic amine, and the preferred adoption of a solution conformer 
that does not favour the ring closure reaction.   
 
Formation of the ligand precursor, 9, was relatively simple with N-substitution with the ethyl 
propionate esters, using an excess of the enantiomerically pure (R)-trifluoromethyl-sulphonate, 
producing the tri-N-substituted (SSS)-product (9) exclusively (Scheme 2.5).  
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Scheme 2.5 Synthesis of ligand (SSS)-L3 from AMPED. 
 
Presumably, the absence of the tetra-N-substituted derivative is associated with an increase in the 
extra steric bulk about the exocyclic amine imparted by the α-methyl groups of the incoming 
nucleophile. Hydrolysis of the esters was an area of concern, because there are undesirable side 
reactions which need to be avoided. Taking into account the potential for internal lactamisation 
under acidic conditions, base hydrolysis of the esters was considered to be a more sensible approach 
as opposed to acid catalysed hydrolysis. However, it is possible that under basic conditions the chiral 
propionate arms could form enolates leading to racemisation at each chiral centre. Provided that the 
rate of ester hydrolysis was much greater than the rate of enolate formation, this side reaction 
would not be a problem. 
 
The acid catalysed hydrolysis was assessed by refluxing 9 in hydrochloric acid overnight. Analysis of 
MS-ES data revealed that lactam formation was occurring, although it was evident that there was a 
significant decrease in the rate this reaction. Whilst not useful synthetically, this result did suggest 
that the tri-propionic acid (if isolated) would probably be sufficiently stable for use in radiolabelling 
evaluations. This reduced tendency towards lactamisation as compared to AAZ3A has subsequently 
also been noted by Botta and co-workers.7 Base catalysed ester hydrolysis of 9 was achieved by 
stirring with 3.1 equivalents of sodium hydroxide in THF : water (1 : 1) for  17 hours. There was no 
evidence of racemisation at the α-carbon position, as deduced by analysis of 1H and 13C NMR 
spectra. 
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Synthesis of Ligand L4 
The N-methylated (SSS)-propionic ligand, L4, was synthesised from 9 in a manner akin to that for the 
synthesis of the acetate analogue L3. The N-methylation reaction was less efficient, which is probably 
a result of the increased steric demand of the propionate substituent, hindering alkylation under the 
very mild conditions. Efforts to improve the yield by increasing the solvent polarity resulted in the 
formation of the quaternary ammonium salt. Ester hydrolysis of 11 was carried out under basic 
(sodium hydroxide) conditions, following the success already obtained with this approach (Scheme 
2.7). In theory, acid catalysed hydrolysis is also feasible for this ligand. 
 
 
Scheme 2.7 Conditions used for methylation, and subsequent ester hydrolysis to synthesise ligand L4. 
 
Synthesis of Ligand L5 
The synthesis of ligand L5 was relatively straightforward and made use of the tri-ester 5. A series of 
functional group transformations on a commercially available reagent yielded the para-acetamide 
benzylic bromide derivative (16), which was inserted at the exocyclic amine of 5. This reaction 
required harsher conditions (353 K, two equivalents caesium carbonate, acetonitrile) than those 
needed for the formation of 7 and 11. This was followed by ester hydrolysis using trifluoroacetic acid 
to give ligand L5 (Scheme 2.8), as the protonated bis-trifluroacetate salt. 
 
 
Scheme 2.8 Conditions used for alkylation, and subsequent ester hydrolysis to synthesise ligand L5.  
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2 pH Potentiometric 1H NMR Analysis of Ligand L2 
 
There is considerable interest in optimising the conditions and procedures used to create a more 
efficient radiolabelling protocol. Optimisation of the radiolabelling conditions is often ligand specific, 
whereas improvements to the procedure are universally applicable.20 The efficiency of a 
radiolabelling protocol is not only determined by the quantitative measurements of yield and rate. 
Qualitatively, the way in which the radiolabelled complexes are prepared and how these affect 
further use of the radiolabelled complex also needs to be taken into account. For example, if the 
radiolabelled complexes are intended for in vivo use, it is considerably more ‘efficient’ if the 
radiolabelling is done at a pH and temperature close to physiological conditions. Therefore, although 
there is expected to be an increase in the rate of radiolabelling with temperature, increasing the 
temperature to the maximum allowed (363 K in water) is not always the most practicable.  
 
As already stated a key consideration is the pH at which the radiolabelling is carried out. Ligands, like 
those described in the previous section, have donor groups which can be protonated and 
deprotonated depending on the prevalent pH. The protonated nature of these groups has a 
significant effect on the rate of complexation. Therefore determining and understanding the pKa 
values of the ligands is very helpful in defining the best conditions for complexation.  
 
In many cases, changes to the protonation state of the donor groups are signalled by changes in the 
chemical shift of ligand protons. By following the changes in proton shift with pH, it is possible to 
estimate certain ligand pKa values within the pH range of interest.  
 
It is appropriate at this point to introduce a labelling system for the differently protonated species of 
the ligand. It is difficult to state unequivocally what the optimal protonation state of the ligand 
should be, because the exact speciation of the metal ion under the radiolabelling conditions is not 
known and this will influence how the ligand and metal interact on approach. Envisioned as being 
the ideal state for complexation, the triply negative tribasic state is designated L3-, with protonation 
of the amines being formulated in the label as a salt species, i.e. [HL3-]2- is the singly N-protonated 
species.  
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Figure 2.2 
1
H NMR spectra (298.1 K, D2O, 700 MHz) of ligand L
2
 at pH 12.0 (blue), 7.2 (green) and 2.0 (red). The 
structure shown is intended solely to illustrate the atom labelling scheme, and does not reflect the protonation 
state or conformation of the ligand. 
t
BuOH was added as reference, δH =1.10 ppm.  
 
The 1H NMR spectrum of L2 has a number of resonances, which were assigned with the help of 2D 
NMR spectroscopy (COSY, HSQC and HMBC). The spectrum of L2 at pH 12.0, 7.2 and 2.0 (Figure 2.2) 
has the signals of interest assigned. The diastereotopic methylene protons H4 and H5 gives rise to 
two multiplets which form an AAᶦBBᶦ-multiplet. Diastereotopic methylene protons of H2 and H7 form 
an AAᶦBBᶦ-doublet, due to the absence of neighbouring C-H groups. An AB-doublet is generated for 
the diastereotopic acetate CH2 protons (of H
8
 and H
10). For each isolated ring CH2 proton of the 7-
membered ring (H2 and H7) the signal which resonates to higher frequency was determined to be the 
proton adopting a pseudo-equatorial site in the major conformer. A more detailed account of this 
orientation assignment is provided in Chapter 4 Section 2.2.1. The quaternary methyl (H1ᶦ), 
remaining acetate (H12) and N-methyl (H14) substituents all appear as singlets (Figure 2.2).  
 
The protonation constants of L2 were determined in the pH range 2 – 13 by measuring the pH 
dependent 1H NMR shifts of the non-exchangeable protons. A solution of L2 in D2O, containing t-
butyl-alcohol as a reference, was prepared and the 1H NMR spectrum recorded at 700 MHz at 295.2 
± 0.2 K. The pH of the sample was then increased (and recorded) by the addition of deuterated 
sodium hydroxide, and the 1H NMR spectrum recorded under the same conditions. Once a pH of ~ 
12.5 had been reached, deuterated hydrochloric acid was used to reduce the pH of the solution, and 
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further 1H NMR spectra were recorded to confirm the accuracy of the previously recorded data. A 
pH dependent shift variation was observed for H2&7, H4&5, H1ᶦ, acetate protons (H8&10 and H12) and the 
N-Me substituent, H14 (Figure 2.2). The chemical shift (ppm) for each of these resonances was 
plotted against pH (Figure 2.3). For the spin-coupled proton signals of H8&10, H4&5 and H2&7, the mean 
chemical shift was compared as a function of pH. 
 
 
 
Figure 2.3 Variation in chemical shift for ligand L
1
 as a function of pH (meter reading), at 700 MHz and 295 K in 
D2O. See Figure 2.2 for proton labelling scheme. Protonation constants shown are determined using the pH 
meter reading, and thus require correction to give the pKas. The plots have been fitted using standard iterative 
least squares minimisation methods, and the errors quoted relate to the fitting only. 
 
All the 1H NMR titration curves (Figure 2.3) display distinctive changes over well-defined pH values, 
related to the stepwise N-protonation of the ligand. The protonation/deprotonation steps which 
take place, occur rapidly on the NMR timescale, such that the observed chemical shifts are a 
weighted average of the chemical shifts of the two species involved in that protonation step. In 
assessing these changes, the following equation has been used: pD = pH (meter reading) + 0.41.21 
The mean protonation constant in D2O (pKa) is 5.70 (± 0.1) for the equilibrium shown and 11.7 (± 
0.15) for the first pKa value, in each case adjusted for the pD/pH change. The experimentally 
determined pKa values are listed in Table 2.1, along with values for other relevant compounds.  
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Table 2.1 Comparison of the experimentally determined pKa values (298 K) for L
2
 with representative ligands of 
similar structure. 
 
 L
2 a
 H3DAZA
b,1
 H3AMPED
c,22
  L
1
 
d,12
 L
2
 
d,7
 
pKa,1 11.7 (0.15) 9.2  9.54 9.97 (0.03) 10.90 (0.04) 
pKa,2 5.70 (0.1) 6.5  6.70 6.42 (0.05) 5.14 (0.05) 
pKa,3 < 3 3.2  1.91 3.75 (0.05) 3.71 (0.06) 
pKa,4 - - - 1.94 (0.05) 2.17 (0.08) 
a
Determined by NMR (D2O, 700MHz, 295 K). 
b
Determined by pH-metric titration (298 K, 0.1 M KCl).
c
Determined by NMR 
titration (D2O, 298 K, no inert electrolyte, no errors published).
d
Determined by potentiometric analysis (298 K, I = 0.15 M 
NaCl). 
 
As the pH was decreased, a shift for each signal was observed to higher frequency, as expected with 
the increased level of protonation. Starting from basic pH, the addition of acid produces a downfield 
shift of the methylene protons with an inflection point at pH ~ 11.3. This is assigned to the 
protonation of an amine consistent with the observed shift to higher frequency of the chemical 
shifts associated with to the ring protons. Within the range pH 7 – 10 there is no apparent change in 
the ligand protonation state, with the mono-protonated form dominant, [HL3-]2-. A second inflection 
was observed at pH ~ 5.3. This is also assigned to the protonation of an amine, and was 
characterised by a further shift to higher frequency of the ring proton resonances. A third incipient 
inflection was observed at ca. pH 3.0, which probably corresponds to protonation of one of the 
carboxylic acids. The di-protonated species [H2L
3-]-, is the dominant species over the range pH 3.5 – 
5.  
 
The protonation sequence can be assigned tentatively on the basis of the pH dependence of 1H NMR 
chemical shifts and the pKa values of related literature compounds. It is well known that protons 
close to a basic site shift to higher frequency (become deshielded) following protonation.23, 24 This 
effect is greater with decreasing number of bonds (distance) between the protonation site and the 
proton, allowing the site to be assigned by considering the relative shift of the proton resonances. 
However, due to the conformational flexibility of 7-membered rings, assigning the protonation 
sequence based on chemical shifts can be problematic because protonation can induce significant 
conformational changes that may influence the chemical shifts of even more remote ligand 
protons.25, 26 
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Botta et al have assigned the protonation sequence of L2, based on the hypothesis that “the first 
protonation step in part occurs at the nitrogen atom of the ring and in part at the exocyclic primary 
amine. Following the second protonation step, the first proton is then transferred to the exocyclic 
nitrogen.”7 Zsolt et al12 made the same assignment for the most basic pKa of L
1 (AAZTA), as did 
Hegetschweiler and co-workers for 6-amino-1,4-diazepine.1 No explanation was offered for this 
assignment that implies a non-specific distribution of the added proton atom over the three amino 
groups. This protonation sequence in which the exocyclic amine protonates before a endocyclic 
amine is ‘universally’ applied to ligands featuring the DAZA core, and was first proposed by 
Hegetschweiler and co-workers.1 The assignment was based on a model which takes into account 
suitable de-shielding constants, and can be used to identify the different tautomeric forms of the 
partially protonated species.25, 26 The protonation sequences of L1 and L2, by Botta et al, were 
assessed based on the pH dependence of the 1H NMR chemical shifts.7 None of these examples have 
taken into account possible protonation induced conformation changes to the 7-membered ring, 
and the possible de-/shielding effects that these changes may have. 22, 25, 26 
 
The importance of such effects can be assessed by considering the possible effect of protonation on 
ring conformation. For heterocyclic ligands such as 9-N3 (Figure 2.4), amine protonation is not 
expected to have a significant effect on the ring conformation, due to the rigidity of the ring. 
However, protonation of an endocyclic amine of L2 (in its L3- state) is likely to give rise to a bifurcated 
hydrogen bond (similar to that observed for 9-N3) distributed over each endocyclic amine.
27 Such a 
protonation is expected to have a significant effect on the preferred ring conformation, relative to 
the deprotonated species. Protonation at the exocyclic amine could also have a significant effect on 
the ring conformation, because of the competition between the tertiary carbon substituents for the 
sterically less demanding equatorial position. Protonation of the exocyclic nitrogen increases its 
effective steric bulk in aqueous media, enhancing the preference of the protonated N-substituent to 
take up an equatorial position.22 Thus prior to N-protonation the methyl group may adopt this 
position, but switch to an axial site following Nexo protonation, modifying the structure of the 
preferred conformer. Indeed, discontinuities in conformational analysis (based on NMR shielding 
effects) have been attributed to conformational changes that result from amine protonation for 
similar cycloheptane structures.25, 26 
 
The structure of L2 could be viewed as a combination of DACHDA28 (H2DACHDA = 1,4-diaza-
cycloheptane-1,4-diacetic acid) and dmGly29 (N,N-dimethylglycine) (Figure 2.4). However, the first 
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pKa values for these ligands are 9.83 and 9.94 (298 K) respectively, which is not particularly helpful in 
discerning the protonation sequence of L2. The first protonations of DACHDA and dmGly are very 
similar. The fact that this is not the case for the first two protonation steps of DAZA based ligands, 
can be understood in terms of the simple electrostatic interactions between the positive charges 
located at the amino-groups which hinders the second protonation event.30  
 
 
 
Figure 2.4 Structures of DAZA
1
, DACHDA
28
 and dmGly
29
 which are structural ‘components’ of L
2
. The triamine 
ligand 9-N3 is also shown, to which reference is made in the text.  
 
Which amine protonates first – starting from basic pH – is debatable. Indeed there is inconclusive 
data as to the location of the proton, with some proposing that the protonation occurs partially at all 
three amines.1, 7, 12, 22 The fact that there are shifts to higher frequency experienced for all the rings 
protons as well as H8 and H9 at the first and second protonation steps, makes it difficult to assign the 
two steps to particular nitrogen atoms.  
 
We propose that the first protonation occurs at the endocyclic amines, generating a bifurcated 
hydrogen bond similar to that observed in the first protonation step of 9-N3 based systems.
27 It is 
likely that the bifurcated proton will be better stabilised and accommodated in this case. 
Furthermore, the presence of the negatively charge carboxylate groups will serve to reduce the local 
overall charge. The second protonation step is accompanied by shifts of H1ᶦ, H12 and H14 to higher 
frequencies, which are consistent with protonation of the exocyclic amine. The other protons also 
shift to higher frequencies, which could be related to conformational changes, resulting from 
protonation of the exocyclic amine.22, 25 
 
The pH-chemical shift plots of L2 (Figure 2.3) reveal some important information. In the pH range 5 – 
11, the ligand exists exclusively as a single species which is the single protonated ammonium species 
[HL3-]2-, with the proton probably ‘spread’ across endocyclic amines as a bifurcated hydrogen bond. 
Between pH 4 and 7, ligand L2 exists as a mixture of the mono- and di-protonated species, [H2L
3-]-. 
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The latter becomes the exclusive species between pH 3 and 4. Although less favourable for 
radiolabelling, it should be noted that there is still a significant portion of [HL3-]2- at pH 5. 
Radiolabelling with 68Ga(III) was to be examined inside the range pH 2 – 7, in which case a large 
portion of which will have the mono-protonated form of L2, [HL3-]2-, as a dominant species. The 
fastest rates of radiolabelling are expected to occur with this species. 
 
3 Radiochemical Evaluations 
 
In this section the suitability of ligands L1-5 for chelation of 68Ga(III), primarily in terms of the 
radiolabelling efficiency and kinetic stability of the complexes, is evaluated. In the first instance the 
optimal labelling conditions for the ligands are identified (Section 3.1), with subsequent stability 
evaluation of the systems deemed suitable based on the radiolabelling results (Section 3.2). Further 
radiochemical evaluation studies (concentration dependent kinetics and competition experiments) 
on ligands displaying satisfactory stability are presented in Section 3.3. 
 
3.1 Radiolabelling Studies with Ligands L1-5 
 
Gallium-68 has a relatively short half-life (68 minutes), which means it is useful in imaging 
applications for approximately 2 hours after generator elution. Taking into account the number of 
steps required from generator elution to in vivo injection (i.e. elution, eluate purification, 
radiolabelling, radiolabel purification, pH adjustment, Injection), an efficient and rapid radiolabelling 
protocol is of the upmost importance. Typically, radio-labelling is carried out for a maximum of ten 
minutes, to ensure that there is sufficient time for the remaining procedures to be conducted.   
 
As a result, there is considerable focus on the development of ligands which are able to bind 68Ga(III) 
rapidly and form a complex with high kinetic stability. Ideally, a chelator is sought which binds 
68Ga(III) quantitatively in less than 10 minutes at room temperature. Quantitative radiolabelling 
eliminates the need for complex purification of the radiolabel prior to in vivo administration. In 
theory, such a labelling protocol would allow for the development of easy to use ‘kits’ in clinical 
practice.31-33 The idea with the kit is that the ligand, and any other chemical substances required 
(such as buffer), are lyophilised into a suitable vial. Radiolabelling would then be carried out by 
simply adding the 68Ga container eluate, and mixing the contents at room temperature.32, 33 Low 
temperatures are also preferred in the sense that useful ligands may be conjugated to temperature 
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sensitive biomolecules. Radiolabelling efficiency also shows a dependency on pH, and most chelators 
operate best within a given pH window. As is the case with temperature, pH should be chosen 
keeping in mind the sensitivity of biomolecules that may be used. For example, quantitative labelling 
of DOTA with 68Ga, whilst producing radiolabelled complexes of exceptionally high kinetic stability, 
requires heating at 368 K for 30 min at pH 4.6.34 The long radiolabelling time allows for considerable 
radioactive decay of the radiolabel, whilst the high temperature and low pH are unsuitable for many 
biomolecules of interest in imaging. Despite these drawbacks, DOTA is still the ‘industry standard’ 
for 68Ga-PET. Whilst it is the most applied ligand in clinical PET imaging practice, it does not possess 
characteristics which make it ideal for radiolabelling with 68Ga. A basic understanding of the 
coordination chemistry of DOTA and 68Ga is required to understand why they are a somewhat 
unsuitable pairing in some regards. The reader is referred to Chapter 1 Section 5.2 for a more 
detailed discussion of this ‘mis-match’.  In practice, a ligand which radiolabels with a > 90 % yield at 
368 K in less than 10 minutes (to give a stable radiolabelled complex) is still potentially useful.20 
 
In order to evaluate the suitability of the synthesised ligands, the dependence of radiolabelling on 
ligand concentration, temperature and pH was determined. Typically, the concentration of the 
chelator greatly exceeds that of the 68Ga(III), and therefore concentration kinetics is less important. 
This aspect was therefore assessed once both the pH and temperature had been optimised, for 
ligands deemed suitable for 68Ga-PET. The ligands (L1-5) evaluated in this work are shown below 
(Figure 2.5). 
 
 
 
Figure 2.5 First generation ligands synthesised for evaluation as potential 
68
Ga-PET imaging agents. 
 
The generator eluate contains 68GaCl3 which exists as freely available 
68Ga(III) for pH < 3.6. However, 
when the pH exceeds ~ 3.6 the water insoluble hydroxide, 68Ga(OH)3, begins to form. In order to 
prevent this from occurring a suitable anion can be added, which weakly binds the 68Ga(III), thereby 
slowing the formation of the hydroxide but still allowing the radiolabel to form.  Popular choices 
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include acetate, succinate, glutamate, lactate, oxalate and tartrate as well as the anions present in 
TRIS and HEPES buffer solutions.35 These anions can be formulated as buffers to give a desired pH, 
thereby serving a dual purpose. The radiolabelling results section has been divided into two parts. 
The first, deals with radio-labelling at pH < 3.6 with no buffer present, and the second, considers the 
radio-labelling at pH > 3.6 in the presence of a suitable buffer. 
 
The radiolabelling yield is defined here as the percentage of the total radioactivity (68Ga) associated 
with the ligand, and was measured using a TLC radio-imager. This is different to the radiochemical 
yield (decay corrected) which also takes into account the decay of the 68Ga(III) radio-isotope. The 
background radiochemical noise, determined in a series of control experiments, is typically ~ 4% of 
the total measureable radioactivity on a radio-imaged TLC plate. For this reason radiolabelling yields 
measured to >96 % are assumed to have reached completion unless there is clear evidence that this 
is not the case, i.e. a noticeable peak on the radioactivity population distribution map.  
 
3.1.1 Radiolabelling at pH < 3.6 
 
There are obvious benefits to labelling of the generator eluate directly; most notably fewer steps 
permitting less radioactive decay. However, the strongly acidic conditions of the eluate (pH ~ 1.0) 
are not conducive to complex formation. Indeed, when tested, no radiolabelling was observed under 
these conditions for any of the ligands, even at 368 K. This can be attributed to the protonated 
nature of the ligand under these conditions, which hinders electrostatic encounter with the charged 
metal ion species and suppresses formation of the Ga-ligand bonds. 
 
Ad hoc adjustment of the cation-exchanger eluate pH using a suitable base was time consuming, and 
a protocol involving addition of a predetermined amount of base proved inefficient because the 
resulting pH was not reproducible. The pH can also be increased by suitable dilution. However, there 
is a careful balance to be struck between the final volume and radioactivity content. For a given 
amount of generator eluate, the final volume needs to be small enough to make further studies 
(stability and in vivo assays) feasible, but sufficient to provide the necessary increase in pH. A 12.5 
fold dilution of the cation-exchanger eluate with Milli-Q ultrapure water produced a labelling 
solution with a pH ~ 2.3, and sufficient radioactivity to make further evaluations possible.  
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The results of the radiolabelling experiments at pH ~2.3 for each ligand at 298, 323 and 368 K are 
shown below (Figure 2.6).  
 
 
 
Figure 2.6 Temperature dependent radiolabelling kinetics of ligands L
1-5
 at pH 2.3, shown as the percentage of 
the radioactivity which is associated with the radiolabelled complexes at 1, 3, 5 and 10 minute time intervals. 
Activity ~ 100 MBq 
68
Ga(III) at t = 0 minutes. [
68
Ga] = 0.18 nM. [L
n
] = 10 µM. Vtot =5 mL. 
 
As expected, increasing the temperature improves the radiolabelling yield.  The most efficient 
radiolabelling is observed for L1, which produces a quantitative yield within 3 minutes at 298 K. The 
other ligands require 323 K and 10 min to produce the same result, with the exception of L4 which 
labels quantitatively at 363 K. The superior radio-labelling efficiency of L1 is likely due to having a 
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greater number of carboxylic acids which foster more efficient 68Ga complexation. Differences in the 
labelling kinetics of the other 4 ligands are small, which is unsurprising considering their structures 
all feature three carboxylic acids and a tri-basic core. Slower labelling rates associated with L4 and L5 
may be related to increased steric bulk about the exocyclic amine, hindering arrangement of the 
donor groups for metal-complexation. 
 
To further assess the influence of pH in absence of a buffer we considered a larger dilution. A 100 
fold dilution of the cation-exchanger eluate with Milli-Q ultrapure water produced a labelling 
solution with a pH ~ 3.3. Although this larger dilution meant resulting radiolabelled solutions had a 
low radioactivity to volume ratio (insufficient for stability studies and in vivo assays), the results still 
provided useful insight into the influence of pH on radiolabelling kinetics. 
 
The results of the radiolabelling experiments at pH ~ 3.3 for L2, L3 and L5 at 298, 323 and 368 K are 
shown in Figure 2.7. The radiolabelling data for L1 and L4 is not shown, because no significant change 
was measured. 
 
 
Figure 2.7 Temperature dependent radiolabelling kinetics of ligands L
2
, L
3
 and L
5
 at pH 3.3, shown as the 
percentage of the radioactivity associated with the radiolabelled complexes at 1, 3, 5 and 10 minute time 
intervals. Activity ~ 12 MBq 
68
Ga(III) at t = 0 minutes. [
68
Ga] = 0.02 nM. [L
n
] = 50 µM. Vtot =5 mL. 
 
Again, an increase in the labelling efficiency is observed with increasing temperature. Also evident is 
a significant increase in the radiolabelling efficiency with the increased labelling pH. This is most 
noticeable for L2 and L3 at room temperature where the labelling yield approximately tripled in 
value. This increase can be understood in terms of the reduced degree of protonation of the donor 
groups at higher pH, which facilitates complexation more readily. 
 
The labelling protocols discussed so far were, at face value, very successful. In all but one instance (L4 
– which radiolabelled quantitatively at 298 K) > 99 % radiolabelling could be achieved within 10 
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minutes at 323 K. This is a very good result taking into account the strongly acidic conditions. 
However, there is an inherent problem of stability and speciation for some of the ligands complexes.  
 
Firstly, the radiolabelled complexes of L4 and L5 were unstable in Phosphate Buffered Saline (PBS) at 
physiological pH (7.4). Complete de-complexation was observed within 10 minutes after placing the 
radiolabelled complex in the buffer solution at room temperature. Radiolabelled L1 (AAZTA) was 
more stable under the same conditions, with 80 % of the radiolabelled species intact after 2 hours at 
physiological pH and 310 K. Stability at physiological pH is essential and, as a result, the complexes of 
L1, L4 and L5 synthesised under these conditions are unsuitable. Secondly, radiolabelling of L1 and L2 
produced multiple radiolabelled species (Figure 2.8). In the context of radio-labelling the formation 
of multiple species is also undesirable. In the case of L2 one of the species accounts for ~ 90 % of the 
chelated 68Ga, and as a result this system is still of interest (Figure 2.8). However, radiolabelling of L1 
results in the formation of three species, two in nearly equivalent amounts and a third minor species 
(i.e., a ratio of 2 : 2 : 1). This ligand is therefore also not suitable for 68Ga-PET, when radiolabelled 
under these conditions. The origins and nature of these multiple radiolabelled species are discussed 
in more detail in Chapter 4 Section 1. No instability was observed for the radiolabelled complexes of 
L2 and L3, formed at pH 2.3, at physiological pH and temperature. 
 
 
 
Figure 2.8 Selected radio-imaged TLC plates from the radiolabelling of ligands L
1
 and L
2
 with 
68
Ga. Region (1) is 
the radio-imaged TLC plate orientated horizontally, with the baseline (denoted by ‘O’) on the left. Region (2) 
shows the radioactivity population distribution curves. In each case there is no unchelated 
68
Ga, and all peaks 
originate from radiolabelled complexes of the respective ligand. Radiolabelling was carried out at 368 K and pH 
2.3 for 10 min, using the standard protocol for this pH. TLC plates were eluted using the indicated solutions. The 
two ‘L
1
’ plates are of the same radiolabelling experiment, spotted on different TLC plates and eluted with 
different solutions. These were required to discern the three radiolabelled species present. 
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3.2.2 Radiolabelling at pH > 3.6 
 
From consultation of the 1H NMR pH titration curve of L2 (Chapter 2, Section 2, Figure 2.3), the N,Nˈ-
diprotonated species is dominant at pH < 3.5. The equilibrium with the N-monoprotonated ligand 
(pKa 5.7 (±0.1)) most probably involves a significant ligand conformational change. Given that we had 
already observed an increase in the radiolabelling efficiency with a relatively small increase in pH, 
there is good reason to believe that a further increase in pH might encourage a higher labelling yield. 
Furthermore, the presence of this conformational equilibrium may also play a role in explaining the 
formation of the radiolabelled species observed previously. By increasing the pH further, insight into 
the nature of these species might be gained.  
 
A disadvantage of the protocols described in Section 3.2.1, is the large ‘end-volume’ of the radiolabel 
(i.e. 5 mL). The radioactivity : volume ratio is appropriate for further evaluations. However, it is not 
economical as a large portion of the radioactivity goes to waste (only 200 µL is used per stability 
evaluation, and 800 µL per an in vivo study). An advantage of making use of a buffer system is the 
potential to alter the pH in much smaller volumes.  
 
Numerous buffer systems at varying concentrations and pH were considered for their ability to 
produce the desired pH and inhibit formation of the colloidal hydroxide, 68Ga(OH)3. The HEPES and 
acetate buffers where chosen because they had the desired effect, and can be used to cover the pH 
range 4.0 – 6.5. These are popular choices because: 
 The acetate buffer has FDA approval for use in humans, a useful buffering range and is 
effective in preventing formation of gallium hydroxide.35 
 The HEPES buffer, whilst not yet approved for use in humans, has been used commercially 
for the synthesis of 111In radiopharmaceuticals (where the HEPES is removed before the 
radiolabel is administered), and can produce radiolabelled complexes with very high specific 
activity.35 
 
Radiolabelling was evaluated for L1-5 at pH 4.0 and 5.3 (using an appropriately prepared 0.2 M 
CH3COOH/NaCH3COO buffer) and pH 7.0 (using an appropriately prepared 1.0 M NaHEPES solution). 
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Radiolabelling experiments were carried out for each ligand at 298, 323 and 368 K and at pH 4.0, 5.3 
and 7.0. The results for the radiolabelling at 298 K for L1-5 are shown below (Table 2.2), as the time 
taken to reach the maximum yield. 
 
Table 2.2 Maximum radio-labelling yield (%) achieved and the time taken (minutes) at 295 K for L
1-5
 at pH 4.0, 
5.3 and 7.0. Activity ~ 100 MBq, [
68
Ga] ~ 0.66 nM (t = 0), [L
n
] = 10 µM, Vtot = 1.4 mL. 
 
 
 
pH 
Maximum radiolabelling yield (%) at 295 K
 
Time taken to achieve maximum yield (min) 
 
L
1 
 
L
2
 L
3
 L
4
 L
5
 
4.0 97* 
1 
98* 
1 
99 
3 
95* 
10 
92* 
10 
5.3 96* 
1 
97* 
1 
98 
3 
95* 
10 
90* 
10 
7.0 96* 
3 
97* 
1 
98 
3 
92* 
10 
89* 
10 
*
indicates the presence of more than on radiolabelled species 
 
Control experiments were conducted to confirm that the weak associations between 68Ga and the 
buffer anions did not result in ‘bound-68Ga’ spots on the radio-imaged TLC plates. Indeed, there were 
no observable differences between the control experiments performed in the absence (pH < 3.6) 
and presence of the buffer (pH > 3.6). The increase in pH had a significant effect on the 
radiolabelling efficiency and in the cases of L4 and L5 changed the relative proportion of the 
radiolabelled species. 
 
There was a noticeable perturbation to the ratio of observed radiolabelled complex speciation for L1 
(9 : 9 : 1) and L2 (18 : 1) in comparison to that observed for labelling at pH ~ 2.3. Radio-labelling of L4 
and L5 produced two radiolabelled species in ratios of 11 : 8 and 5 : 4 respectively, whereas at pH 2.3 
and 3.3 only a single species was observed. These changes suggest that pH plays a key role in 
determining the constitution and speciation of the radiolabeled complexes. Ligand L3 maintained 
formation of a single radiolabelled complex, and showed no change in the Rf value of the complex on 
the TLC plate. The major species of L4 and L5 were unstable at physiological pH and temperature, 
whilst all other radiolabelled complexes were stable (under the same conditions). 
 
Ligands L1 and L2 showed quantitative radiolabelling in less than one minute at room temperature. 
Labelling of ligand L3 was only slightly slower, reaching completion in 3 minutes. The radio-labelling 
of L4 and L5 was considerably slower, and elevated temperatures (303 K for 10 minutes) were 
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required to produce > 95 % radiolabelling. Nearly quantitative labelling at 303 K is a good result; 
however, investigation of both of these ligands (and L1) was discontinued due to the inherent 
speciation problems associated with formation of the radiolabelled complex.  
 
3.3 Stability of Radiolabelled Complexes [68Ga.L2] and [68Ga.L3] 
 
A labelling system is used where the italicised subscript after the radiolabelled complex indicates the pH at 
which it was formed. For example, [
68
Ga.L
1
]2.5, indicates that the 
68
Ga-radiolabelled complex incorporating 
ligand L
1
 was formed at pH 2.5. 
 
In order to fully evaluate the usefulness of these ligands for 68Ga-radiolabelling, it is vital to assess 
the stability of the resulting radiolabelled complexes. Stability evaluations were performed at 
physiological pH (1.0 M PBS) and temperature (310 K) in the presence of DTPA, Fe(III), apo-
transferrin and newborn calf serum. The stability of the radiolabels was assessed at 10, 20, 30, 60 
and 120 min using the radio-imaged TLC method to determine the amount of radiolabelled product 
intact. Approximately 5 MBq of the radiolabelled solution was used for each experiment which 
translates to a 68Ga concentration of 0.16 nM. The DTPA and Fe(III) were both prepared to give a 
final concentration of  0.8 µM during the challenge experiments, which is a 5000-fold excess with 
respect to the radiolabelled complex. The apo-transferrin used had a 0.005 % iron and a final 
concentration of 0.8 mg/mL which, taking into account the presence of two gallium biding sites, 
equates to a 130-fold excess with respect to the radiolabelled complex.  
 
Based on observations and the results of the radiolabelling studies in the previous section, ligands L1, 
L4 and L5 had been deemed unsuitable, and were not evaluated further. Radiolabelling of ligand L2 
also produced two species, however the minor species was only present as 2 - 10 % of the total 
chelated 68Ga (depending on the radiolabelling pH), and was therefore still of interest. Ligand L3 is of 
particular interest because only a single radiolabelled species, which was stable under physiological 
pH and temperature, was observed. 
 
The stability of the radiolabelled complexes produced at pH 2.3, 4.0, 5.3 and 7.0 was determined for 
ligands L2 and L3; Table 2.3 shows the stability of each complex with respect to the apo-transferrin 
experiment. No instability was observed for the radiolabelled complexes during the Fe(III) (0.8 µM), 
newborn calf serum and DTPA (0.8 µM) challenge experiments.  
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Table 2.3 Stability of the investigated ligands at 120 minutes in a competition experiment in the presence of 
130-fold excess apo-transferrin. Challenge experiment conducted at physiological pH and temperature. 
 
pH at which radiolabelled 
complex was synthesised 
Percentage of Radiolabel/s intact after 120 min (%) 
 
[
68
Ga.L
2
] [
68
Ga.L
3
] 
2.3 10 8 
4.0 95 97 
5.3 95 99 
7.0 93 98 
 
It was evident from the time interval radio-TLC data of [68Ga.L2]4.0-7.0, that any observed instability 
was due to decomplexation of the minor species. Careful examination of interval data suggested 
that the major species remained intact throughout. In contrast, a very poor stability profile for the 
radiolabelled complexes was observed following formation at pH 2.3. 
 
No observable evidence (i.e. there was no noticeable evidence of 68Ga signal greater than 
background activity, other than that of the complex) of complex instability was found for the 
radiolabelled complex [68Ga.L3]4.0-7.0 over 2 hours in all of the stability challenge experiments. In 
contrast, a very low stability profile for the radiolabelled complex was observed following formation 
at pH 2.3.  
 
Of the first generation series of ligands, it is evident that L3 is the most suitable ligand for 68Ga-PET. 
In terms of radiolabelling and stability (of the radiolabelled complex) it possesses the ideal 
characteristics and compares favourably with the best ligands in the literature. What sets this ligand 
apart from reported systems is its ability to undergo efficient radiolabelling over the pH range 4.0 – 
7.0 at room temperature. Quantitative radiolabelling at lower pH (pH 2.3) is possible with elevated 
temperatures (10 min at 323 K); however the formed radiolabelled complexes are not sufficiently 
stable. Ligand L2 displays very similar radiolabelling characteristics and as a result is also a potential 
candidate, despite its radiolabelled complex speciation problem. 
 
The radiolabelling efficiency displayed by L2 and L3 is considerably better than that of DOTA (a 
reference standard for 68Ga radiolabelling) and comparable with the most promising chelators 
published (Figure 2.9). The macrocyclic ligand NOTA (Figure 2.9), has been quantitatively 
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radiolabelled at room temperature in the pH range 3.5 – 5.36, 37 The phosphinic acid derivative, TRAP, 
also radiolabelled at room temperature but requires a lower ligand concentration than NOTA.32, 33, 38 
The acyclic ligand H2DEDPA
39 (Figure 2.9), quantitatively labels within 10 minutes at room 
temperature and pH 4.5 (earlier time intervals have not been reported). Other promising acyclic 
chelates are CP25640 which quantitatively radiolabels within 5 minutes at room temperature and pH 
6.5, and HBED-CC41 which displays acceptable radiolabelling when conjugated to an antibody (Figure 
2.9). Of particular value is the fact that, unlike any of the ligands above, L3 can be radiolabelled over 
the pH range 4.0 – 7.0 at room temperature. Note: all radiolabelling data and conditions quoted 
above are the optimum conditions, and give rise to radiolabelled complexes which are sufficiently 
stable for 68Ga-PET. 
 
 
 
Figure 2.9 Ligands NOTA, H2DEDPA, TRAP, HBED-CC and CP256 which display favourable properties for 
68
Ga-
radiolabelling.  
 
3.4 Speciation of the 68Ga-Radiolabelled Complexes 
 
Accurate quantification of the relative amounts of the minor/major radiollabelled species was not 
always possible, due to the poor separation of the species on the TLC plate. However, it was possible 
to make some observations regarding the variation of their ratio with the labelling pH.  
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The heptadentate ligand L1 has more than the required number of donor groups to bind the Ga(III) 
ion, which is coordinatively saturated by a hexadentate ligand. This suggests that the multiple 
speciation may arise from the formation of constitutional isomers (Figure 2.10). More specifically, 
two radiolabelled species with L1 could arise from N3O3 and N2O4 binding modes of the ligand. Three 
species were observed for the radiolabelling of L1 at pH 2.3 with the two major species occurring in a 
1 : 1 ratio. A third species accounted for 10 % of the observed species. When the pH is increased to 
4.0 and 5.3 the presence of the minor species halved. It is proposed that the major species are 
constitutional isomers, because no change in their relative proportion was observed with change in 
pH or temperature.  
 
 
 
Figure 2.10 Constitutional isomers that may arise from radiolabelling of L
1
; these two isomers are tentatively 
assigned to the two major species observed. 
 
Ligands L2-5 are hexadentate donors and thus this explanation is not applicable. Closer examination 
of the speciation profile and structures of these ligands leads to some interesting observations. The 
radiolabelled complex of ligand L3 is stable over the pH range 4.0 – 7.0 and only a single species is 
observed. Radiolabelled L2, may be considered slightly less suitable than L3 due to the presence of an 
unstable minor species (10 % of radiolabelled L2). Radiolabelling of L4 and L5 at pH 2.3 produces a 
single observable species each. However, the stability of their radiolabelled complexes is very poor 
at pH 7.4. It appears that as the steric bulk around the exocyclic nitrogen increases so the stability of 
the resulting radiolabel (produced at pH 2.3) decreases.  
 
Considering the radiolabelling at higher pH, it was found that the relative speciation of L2 improved 
slightly, with the predominant species accounting for 96 % of the radiolabelled ligand. Radiolabelling 
of L4 and L5 at pH ≥ 4.0 resulted in the formation of multiple radiolabelled species, with ratios of 11 : 
8 and 5: 4 respectively. In each case, the minor species is stable at physiological pH and temperature, 
whilst the other is not. 
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The possible origin and nature of these multiple radiolabelled species are discussed in more detail in 
Chapter 4 Section 1, but may be tentatively explained as follows. It is presumed, based on crystal 
structures of ligands with an AAZ core (See chapter 1 section 6 figure 1.13 for an example), that each 
ligand will try to assume a chair-like conformation in formation of a stable metal complex.1, 3-5, 10, 14, 22 
The most stable/prevalent conformation will be determined, in part, by the nature of the ring 
substituents. Radiolabelling at pH 2.3 produces more of the stable radiolabelled complex species 
when the steric bulk at the endocyclic amine is lower, suggesting that ‘overloading’ this amine 
disfavours formation of the chair-like conformation required to form a stable metal complex.  It is 
tentatively proposed that as the steric bulk at the exocyclic amine increases, so the degree of ligand 
pre-organisation toward the favoured chair-like conformation is reduced, with the exocyclic amine 
functionality preferring instead an equatorial orientation. This is illustrated for ligands L2 and L5 
(Figure 2.11). These structures represent possible binding conformations of the ligands, and not 
conformations of the protonated ligands. When the exocyclic amine is equatorial, the N3O3 donor set 
is not arranged for efficient metal complexation; but rather some form of relatively weak association 
with the 68Ga consistent with the observed lower stabilities. Thus, we propose that the multiple 
radiolabelled species observed are also constitutional isomers featuring different ligand binding 
modes; loosely, such systems have been termed coordination isomers or linkage isomers. 
 
 
 
Figure 2.11 Representation of the different possible binding conformations of ligands in [Ga.L
1
] and [Ga.L
5
]. 
Gallium metal has been excluded for clarity. The different species are shown to be in equilibrium, but in reality 
no exchange was observed with time. The equilibrium illustrates the potential of a given ligand to favour one 
conformation over the other, which may be determined by the relative steric demand of the quaternary carbon 
substituents.  
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In Section 2 of this chapter the 1H NMR pH titration curve of L2 was shown. It depicted a pKas of 
approximately 11.7 and 5.70, associated with protonation of the endocyclic amines (bifurcated) and 
endocyclic amine respectively. When the exocyclic amine is protonated, it possesses greater steric 
bulk, and as a result the equilibria shown above will be shifted further to the right, since this is a 
conformation preferred by the free ligand. It could be argued that below pH 5.7, forces of repulsion 
between the two positive charges resulting from protonation of the exocyclic and endocyclic (shared 
bifurcated proton) amines, further favours an equatorial position of the exocyclic amine group and 
hence formation of the less stable radiolabelled isomer. Consistent with this postulate, it was found 
that for [Ga.L2-5] there is an increase in the amount of the stable radiolabelled complex as the 
radiolabelling pH is increased beyond the endocyclic amine pKa. 
 
It is interesting to note that [Ga.L4]2.5 and [Ga.L
5]2.5 appear to lie predominantly on the disfavoured 
side of the equilibrium, with the favoured (stable) radiolabelled complex being produced in greater 
amounts when the radiolabelling pH exceeds 4. Only a small perturbation of the radiolabelled 
complex speciation was observed for [Ga.L2] with increasing radiolabelling pH, but there was 
nonetheless a considerable increase in the proportion of the stable isomer. A single radiolabelled 
complex species was observed for [Ga.L3] over the entire pH radiolabelling range evaluated. 
However, only [Ga.L3]4.0-7.0 were stable. This suggests that the different radiolabelled species of L
2 
and L3 are not fully distinguishable on TLC.  
 
These observations, regarding changes in overall stability with changes in changes in radiolabelling 
pH, are consistent with the reduced steric bulk at the exocyclic amine favouring formation of the 
stable radiolabelled complex. In agreement with this, the proportion of the third radiolabelled 
species (< 10 %) of L1 diminished as the radiolabelling pH increased.  
 
A further series of experiments was conducted to establish whether it was possible to alter the 
relative speciation of the radiolabel through induced conformational changes of the bound ligand. 
The radiolabelled complex was synthesised at pH 2.5, and then the pH of the solution was increased 
to 5. Buffer was not used to increase the pH, as this could possibly allow for re-complexation of 
‘released’ 68Ga(III). The relative ratio of the radiolabelled isomeric species was unaltered, indicating 
that the pH change was unable to induce a rearrangement to the more stable isomer. Thus the 
species formed were kinetically slow to undergo any dissociation/re-complexation process and 
conformational changes of the bound ligand are seemingly not possible, under these experimental 
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conditions. This is consistent with the formation of ‘kinetically trapped’, constitutionally isomeric 
complexes (Figure 2.10). 
 
3.5 Further Radiochemical Evaluation of L2 and L3: Competition and Concentration Studies 
 
The following evaluations were conducted by radiolabelling at pH 4.0 using a 0.2 M acetate buffer at 
room temperature. 
 
3.5.1 NOTA Competition 
 
Equimolar amounts (20 µM) of NOTA and the ligand of interest (L2 or L3) were premixed in 1 mL of 
0.2 M acetate buffer (pH 4), and radiolabelled with ~ 100 MBq 68Ga (0.66 nM). The relative ratio of 
[Ga.NOTA] and [Ga.Ln] determined at 1, 3, 5, 10 and 120 min time intervals. Within 1 minute of the 
being added, all of the available 68Ga was complexed. The relative proportions of the [Ga.NOTA] and 
[Ga.Ln] formed are a rough indication of the relative rate of radiolabelling of the ligands. The 
radiolabelled complexes formed were left at 298 K for two hours, and the relative proportions of the 
radiolabelled complexes re-measured. This gives an indication of the relative stability of the two 
radiolabelled complexes. The conditions (pH and ligand concentration) used were those optimised 
for NOTA, and thus offers an accurate evaluation of L2 and L3. 
 
For ligand L2; 65 % of the available 68Ga was complexed as [Ga.L2], with [Ga.NOTA] making up the 
difference. For ligand L3: slightly less radiolabelled L3 formed, with 56 % of the available 68Ga 
complexed as [Ga.L3] and the remainder as [Ga.NOTA]. This indicates that NOTA, L2 and L3 have 
comparable radiolabelling kinetics under these conditions. No changes in the relative proportions of 
the complexes were detected over 2 hours in either case. Indicating that no trans-chelation had 
taken place, and the complexes were kinetically stable (under these conditions). 
 
3.5.2 Metal Ion Competition 
 
The radiolabelling efficiency of L2 and L3 was evaluated in the presence of increasing concentrations 
of calcium(II), iron(III) and copper(II) as their chloride salts. The standard labelling protocol at pH 4 
was applied, i.e. [Ln] = 10 µM, [68Ga] = 0.66 nM ~ 100 MBq, Vtot = 1.4 mL. 
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Calcium(II) is a biologically significant ion in typical extracellular concentrations of 2 mM.42 Iron(III) is 
often a contaminant present in the generator eluate due to ‘generator breakthrough’ and the use of 
hydrochloric acid, and can be present in the generator stream at concentrations of 0.05 nM. Iron(III) 
in the generator eluate originates from the hydrochloric acid used. Copper(II) was also tested due to 
its exceptionally high affinity for tri-basic nitrogen ligands (Irving-Williams series). Along with the 
iron(III) studies, this competition provides some insight into the affinity of the ligands for gallium 
compared to these metal ions. In particular, the tolerance was determined, defined as the maximum 
amount of added metal ion which still allows quantitative labelling (at 298 K and within 10 minutes). 
 
The presence of Ca(II) had very little effect on radiolabelling, with concentrations of 8.0 M being 
tolerated by L2 and L3. Radiolabelling in the presence of iron(III) was affected more with L2 and L3 
tolerating 3.5 and 4.0 equivalents with respect to the amount of ligand present. The extent of 
radiolabelling decreased to ~ 75 % with the number of equivalents of iron(III) was increased to 5.0 
and 10 equivalents, for L2 and L3 respectively. As expected, the presence of copper was the least 
tolerated, with L2 and L3 tolerating 1.25 and 1.2 equivalents with respect to the amount of ligand 
present. Taking into account the large excess of the metal ions (at least µM concentrations) in 
relation to the amount of 68Ga(III) used (0.66 nM), L2 and L3 display a relatively high affinity for 
gallium over both calcium, copper and iron. 
 
As an indication of the relative amount of 68Ga present; the ligand is in a ~ 1.5x104 fold excess 
(assuming 68Ga : Ln is 1 : 1 in the complex). 
 
3.5.3 Dependence of Radiolabeling Yield on Ligand Concentration 
 
The minimum ligand concentration required to provide quantitative labelling with ~ 100 MBq 68Ga (~ 
0.66 nM), within 10 minutes at 298 K and pH 4, was determined for L2 and L3. Both L2 and L3 
radiolabelled quantitatively at a concentration of 5.0 µM, but the yield was reduced to 32 and 23 % 
respectively at a ligand concentration of 1 µM. This compares favourably with the acyclic chelators 
CP25640 (10 µM, 298 K, pH 6.5) and HBED41 (10 µM, 298 K, pH 4.6). This is also significantly better 
than macrocyclic chelators NOTA32, 36 (100 µM, 298 K, pH 3.6), and the industry standard DOTA32, 34 
(10 µM, 368 K, pH 4.4). The tri-phosphinic acid ligand TRAP32, 33, 38 is also comparable with 
quantitative labelling at a concentration of 100 µM, and an 80 % yield at a 3 µM (368 K, pH 3.3). 
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Note: All literature ligands are reported in their respective optimised conditions. Optimised labelling 
pH was not determined for L2 and L3. 
 
4 Summary 
 
The results indicate that functionalisation of the exocyclic nitrogen plays a key role in determining 
the suitability of the ligand (in terms of radiolabelling efficiency and radiolabelled complex stability) 
for 68Ga-PET, and that further synthetic effort should take this into account. The tri-propioniate 
ligand, L3, displayed quantitative radiolabelling at 298 K in less than 5 min over the pH range 4.0 – 
7.0, with the formation of a single stable radiolabelled species. Similar radiolabelling efficiency was 
observed for L2, but formation of the stable radiolabelled complex is accompanied by the presence 
of a minor (< 10 %) unstable radiolabelled complex. Metal competition studies indicate a high 
relative affinity of both ligands for gallium over calcium(II), iron(III) and to a lesser extent copper(II). 
The acetate derivative of L3 would also have been a interesting candidate, had its usefulness not 
been compromised by its tendency to undergo lactamisation in acidic aqueous media. 
 
The protocol developed for radiolabelling at pH ≥ 4 is highly efficient and is simple to conduct. A 
significant benefit of ligand L3 and the radiolabelling protocol used is that purification of the 
radiolabelled ligand is not necessary, because the acetate anion is approved for use in vivo and the 
radiolabelling yield quantitative. Therefore, for L3, it is possible to produce the radiolabelled 
complex, including generator elution and 68Ga post-purification using the cation-exchanger method, 
within 10 minutes. This short time frame of preparation coupled with the small radiolabelling 
volume gives rise to high specific activities.  
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Chapter 3  
Second Generation AMPED Based Ligands for 68Ga(III) 
 
This chapter discusses the synthesis of a series of hexadentate aza-carboxylate ligands based on a modified 
AMPED scaffold (Section 1 and 2), followed by an assessment of their suitability for application in 
68
Ga-PET 
(Section 3). In section 4, the behaviour of a ligand candidate from each series is assessed in vivo. 
 
1 Introduction and Objective  
 
The results obtained on the first generation chelators indicated that increasing steric bulk at the 
exocyclic amine hinders radio-labelling, favours the formation of multiple radiolabelled species and, 
consequently, reduces the stability of the resulting radiolabeled complex. It is believed that reducing 
the steric demand at the exocyclic amine facilitates formation of the more stable radiolabelled 
complex species. However, the extent to which steric bulk at the exocyclic amine could be reduced, 
has already been explored (Chapter 2). 
 
In order to promote the ligand conformation that is most pre-organised for gallium binding, it was 
necessary to increase the steric bulk of the other substituent at the tertiary carbon (Figure 3.1). In 
the most extreme case, in which the exocyclic amine is protonated, the A-value for this substituent is 
expected to be between 6 and 10 kJ.mol-1, depending on the number and size of the amino 
substituents.1 This provided a reference point as to the nature of 1ᶦ.  A phenyl and t-butyl group, 
with A-values of 12 and 20 kJ.mol-1 respectively, are both significantly larger than an exocyclic amine, 
and would therefore both serve the purpose. Despite the fact that t-butyl is expected to have a more 
profound effect, there were a few reasons why we opted to make use of the phenyl moiety. These 
include: 
 There was some concern over what effect a very large increase in the steric bulk would have 
on reaction at the quaternary site (C1), required for the formation of the 7-membered ring. 
(Chapter 2 Scheme 2.1). A smaller change in steric bulk would still provide the necessary 
shift in steric balance. 
 The phenyl group would facilitate the use of experiments and analyses involving UV-visible 
spectroscopy (such as HPLC) to a much greater extent than the t-butyl group. 
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 The phenyl group provides scope for modification leading to bioconjugation (bifunctional 
chelators), by making use of the phenyl group as part of a spacer or linker moiety.  
 
 
 
Figure 3.1 Core structure numbering system for chelators based on 6-amino-1,4-diazepine. The N-substituents 
do not form part of the core structure. AMPED (1
ᶦ
 = Me) and APPED (1
ᶦ
 = Ph) 
 
Thus, the objective was to synthesise a series of chelators which would provide information on the 
effect of the modified scaffold (APPED: Figure 3.1), in comparison to chelators based on the AMPED 
core. The comparison can be made using NMR spectroscopic experiments and single crystal X-ray 
data. In addition, radiochemical experiments would provide information on the suitability of the 
chelators in terms of the rate of complexation and formation of the desired single species. 
Specifically, the synthesis of chelators akin to those which showed promise in Chapter 2 was 
undertaken (Figure 3.2). Therefore, the APPED analogues of ligands L4 and L5 were not considered. 
Although it had already been shown that the tetra-acid derivative of AMPED (AAZTA: L1) was 
unsuitable for complexation of 68Ga(III), it forms part of this series because its precursor is expected 
to form as a by-product.  
 
 
 
Figure 3.2 Ligand targets (based on the APPED triamine) to evaluate the effect of introducing a phenyl moiety. 
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2 Synthetic Aspects 
 
There are a few examples in the literature of cyclic polydentate chelators featuring a modified 
AMPED core. A number of groups have ventured to use the quaternary site as a position from which 
targeting vectors could be attached (Figure 3.3(a)).2-6 However, to date, there are no examples of 
alterations made to significantly increase the steric bulk at this site. There is a patent containing a 
bicyclic system (Figure 3.3(b)) which bridges the ethylene carbons C4 and C5.7 However, the influence 
of this alteration on the ring conformation is unclear, and has not been discussed.  
 
 
 
Figure 3.3 General structures of polydenate chelators featuring a modified AMPED core.
7, 8
 
 
An identical modification has been made to the ethylene diamine bridge of DTPA, in an attempt to 
increase the rigidity of the ligand ‘backbone’. 68Ga-radiolabelled complexes, consisting of this 
modified DTPA, showed improved stability and radiolabelling with respect to the unmodified ligand.9 
The authors had perhaps hoped that this modification would have a similar effect on their AAZTA-
system.   
 
2.1 Proposed Syntheses of APPED 
 
At first glance, the logical synthetic route would be to simply replace the nitroethane in the synthesis 
of the original AMPED system (Scheme 2.1 Chapter 2) with phenylnitromethane. Consultation with 
colleagues in the field who have attempted this synthesis previously and from our own experience 
suggested that this was not going to be straightforward. Reduction of the nitro group and 
deprotection of the benzyl protecting groups is carried out by hydrogenation in the presence of Pd/C 
(or Pd(OH)2/C). Under these conditions, the 7-membered APPED ring is unstable, presumably due to 
hydrogenolysis of the endocyclic N–C bond. As a result, a new synthetic approach was required. It 
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seemed evident that deprotection to yield the free triamine (APPED) was going to be the key step 
and needed to be addressed as a priority, whilst N-functionalisation to yield the desired chelators 
should be less difficult.  
 
Two possible routes to the APPED core were proposed: the first focused on making minimal changes 
to the established method, and relied upon modifying the nature of the deprotection step. The 
second route required a completely new strategy to avoid this deprotection step. 
 
Whilst working with the AMPED system, it was established that it was possible to reduce the nitro 
functionality selectively using tin(II) chloride and 6M hydrochloric acid. This provided an alternative 
method for deprotection of the nitro group. However, concomitant cleavage of the benzyl 
substituents on the endocyclic nitrogens also needed to be undertaken. These benzyl groups are 
important to the efficiency of the ring formation reaction, and thus any changes should ideally 
maintain their aromatic nature. The use of methoxy substituted benzyl groups for amine protection 
has been demonstrated, and they can be easily deprotected in the presence of acid.10 Therefore, by 
substituting the benzyl protecting groups with methoxy-functionalised benzyl groups, the exocyclic 
amine deprotection could be undertaken at the same time as the nitro-reduction (Scheme 3.1).  
More specifically, 2,4-dimethoxy benzyls where chosen, because the additional stabilization effect of 
the ortho- and para- methoxy groups on the positively charged benzylic intermediate should 
enhance the rate of the deprotection step. 
 
 
Scheme 3.1 Proposed synthesis of APPED, using a modified protocol to that used for the synthesis of AMPED.  
 
The second option was to consider an entirely new approach, one more akin to the synthesis of 
polyaza macrocycles.11, 12 The precursor 2-nitro-2-phenylpropane-1,3-diol, which owing to the 
presence of the di-hydroxyl groups may allow formation of the 7-membered ring by cyclisation with 
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an appropriate di-tosylamide (Scheme 3.2). The benefit of this method is that there is no need for 
the nitro and benzyl protecting groups. The route proposed is similar to that used for the synthesis 
of triazacyclononane. However, this did not guarantee success in this system, and the steric bulk 
close to the tosylate leaving group was considered problematic. 
 
 
Scheme 3.2 Proposed synthesis of APPED using a Tosyl cyclisation approach. Synthesis of starting materials is 
not shown. 
 
Faster progress was made with the method outlined in Scheme 3.1, and as a consequence the 
alternative route other was not continued further. 
 
2.2 Synthesis of PAPED Based Ligands 
 
The syntheses of phenylnitromethane (21) and the protected diamine (20) were undertaken using 
known functional group transformations. The former, by nitration of benzybromide using an 
aqueous suspension of silver nitrite.13 For the latter, ethylenediamine was reacted with the 
synthesised 2,4-dimethoxy-benzylaldehyde to yield a di-imine, which was subsequently reduced to 
give the diamine (20) using sodium borohydride in a ‘2-step-1-pot’ procedure (Scheme 3.3). 
 
 
 
Scheme 3.3 Synthesis of the modified protected ethylene diamine (20) *the diimine is an intermediate, but was 
not characterised. 
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2.2.1 Synthesis of the Protected Triamine 
 
The conditions first attempted for the nitro-Mannich type reaction to construct the 7 membered 
APPED ring were akin to those used for the AMPED system (Scheme 2.1).  A product was isolated in a 
relatively poor yield of 22 %, following silica gel column chromatography. The 1D and 2D NMR 
spectra were consistent with the desired compound at first inspection. However the [M+H]+ peak 
was found at one mass unit too low. Infra-red spectra revealed that the nitro symmetric and 
asymmetric stretching frequencies (1350 - 1530 cm-1) were absent. Moreover, a broad band at ~ 
3250 cm-1 suggested the presence of a hydroxyl functional group. Substitution of the nitro group by 
a hydroxyl group was consistent with the infra-red, mass spec and NMR data. Indeed, Crozet et al. 
have reported an example of rarely observed nitro-hydroxyl exchange in a tertiary nitroalkane.14 It is 
believed that the nitro adduct is formed, followed by a fast SN1 solvolysis reaction, in which the nitro 
group is substituted by a hydroxyl group in a two-step process (Scheme 3.4). Such a reaction 
requires the intermediary of a carbocation, which is stabilized under the polar protic conditions (wet 
ethanol solvent at a relatively high temperature). The conjugative stability of the nitro leaving group 
and the presence of the phenyl group, stabilising the carbocation, further promote this solvolysis 
reaction.  
 
 
 
Scheme 3.4 Formation of tertiary hydroxyl-compound (38) via SN1 solvolysis of tertiary nitro-compound (22) 
following formation of the 7-membered ring. The tertiary nitro-compound (22) is shown as an intermediate, but 
was not isolated under these conditions. 
 
In order to inhibit this competitive solvolysis reaction, the polarity of the solvent was reduced (by 
using 50: 50, ethanol : toluene) and the temperature of the reaction was lowered to 308 K. As 
expected, the reaction progressed much more slowly, but the desired nitro-compound was isolated 
following silica gel column chromatography. It displayed an infra-red stretching frequencies (1540 
and 1374 cm-1) which could be assigned to the NO2 symmetric and asymmetric stretches. The [M+H]
+ 
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peak was observed by electrospray mass spectrometry, within the acceptable range of the 
theoretical mass, in a high resolution analysis. The constitution of 22 and 38 has been confirmed by 
means of single crystal X-ray diffraction. The solid state structures of these compounds are discussed 
in more detail in Chapter 4 Section 2.1. 
 
Though unintentional, the synthesis of tertiary hydroxyl-compound (38) could prove useful. The use 
of 38 towards the synthesis of a ligand for 68Ga is discussed in Section 2.2.4 of Chapter 3. 
 
2.2.2 Reductive Deprotection the Tertiary Nitro-Compound, 22.  
 
Earlier work, involving selective de-protection of the nitro group in the AMPED system, had been 
successful using tin(II)chloride in hydrochloric acid. This formed a logical starting point for nitro 
reduction, as the acidic conditions should also promote cleavage of the aryl substituents. Perhaps 
unsurprisingly, given the high temperatures and ionising conditions, exchange of the nitro group for 
a hydroxyl (this time accompanied by cleavage of the aryl substituents) was confirmed by mass 
spectrometry and infrared spectroscopic data. Attempts to suppress the solvolysis reaction, by 
reducing the temperature of the reaction and polarity of the solvent, were unsuccessful.  
 
By using a temperature gradient it was possible to obtain a ~ 4 : 1 ratio in favour of hydroxyl 
derivative, however the yield was poor and the nature of the compounds made them exceedingly 
difficult to separate. Similarly unsuccessful reactions were carried out replacing tin with metals 
known to have similar nitro reducing abilities, namely zinc and iron. 
 
The original reductive benzylation method used in the AMPED system (Scheme 2.1), using Pd(OH)2/C 
catalysed hydrogenation was attempted. However, it did not yield APPED or the nitro-reduced 
product. The hydrogenation was also attempted with Pd/C and ammonium formate, but also failed 
to yield any desired product. A new approach was needed, ideally one which involved sequential 
cleavage of the aryl substituents and nitro reduction. It had already been shown that the aryl 
substituents could be cleaved under acidic conditions, notwithstanding solvolysis of the nitro 
substituent. Given the relative ability of nitro and protonated amine functional groups to behave as 
a leaving group, it was considered prudent to undertake the nitro reduction first. 
 
Ganem and co-workers15 have described the reduction of nitro containing compounds using 
NiB2/NaBH4 prepared in situ from NiCl2 and NaBH4. When this reaction was applied to the tertiary 
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nitro-compound (22), none of the desired product was observed. Instead a product was isolated 
which was interpreted as a ring opened oxime, based on NMR, IR and MS data. We propose that this 
ring opening reaction occurs via a reduction of the nitro group to a nitroso species, followed by an 
anti-periplanar ring opening mechanism aided by protonation of the nitroso group (Scheme 3.5). The 
same product was isolated when selective reduction of the nitro group was attempted at 273 K using 
LiAlH4 in tetrahydrofuran. A further possibility is that the reaction involves radical cleavage of the 
endocyclic C-N bond, potentially initiated by photolysis or triplet oxygen. 
 
 
Scheme 3.5 Proposed mechanism for the formation of the ‘ring opened’ oxime (44) when reduced with 
NiB2/NaBH4 or LiAlH4. R = 2,4-dimethoxyphenyl. 
 
Raney nickel is a reagent commonly used for the hydrogenation of unsaturated carbons and 
desulfurisation reactions. Go and co-workers16 have reported the use of Raney nickel in the presence 
of hydrogen for the reduction of alkyl nitro groups. This method was applied to 22 and found to 
selectively reduce the nitro functionality at room temperature in approximately 2 hours (Scheme 
3.6). The reaction was carefully monitored using TLC to avoid formation of a by-product following 
nitro-reduction. 
 
 Given that the next step would yield the free tri-amine APPED (by cleavage of the aryl arms under 
acidic conditions), which are inherently difficult to purify and handle given its propensity to react 
with carbon dioxide, it was critical that the product isolated from the nitro reduction be of high 
purity. However, the exocyclic amine was susceptible to reaction with carbon dioxide at room 
temperature, and purification by silica gel column chromatography troublesome. A Boc protection of 
the amine was thought to be advantageous because it could be cleaved under the same acidic 
conditions used to cleave the aryl substituents, and engender a compound which should be readily 
purified by chromatography. The Boc protection to yield compound 45 was successful, and is 
reported as a 2-step reaction with the Raney nickel nitro reduction. The deprotected triamine, 
APPED (46), was obtained by stirring the carbamate (45) in trifluoroacetic acid and dichloromethane 
at 298 K overnight (Scheme 3.6). 
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Scheme 3.6 Synthesis of APPED (46) from the tertiary nitro-compound (22). First step involves nitro-reduction, 
to yield the tertiary amine, followed by Boc-protection to give the carbamate (45).In the second step, the Boc 
and aryl substituents are cleaved under acidic conditions. R = 2,4-dimethoxyphenyl. 
 
The triamine, APPED (46), was subsequently reacted with the appropriate α-bromo esters to give the 
protected ligand precursors in a very low overall yield (< 1%) with respect to the tertiary nitro 
compound, 22. The major loss of product occurred at the deprotection step to yield 46. Previous 
reactions to cleave the aryl substituents were efficient, which suggests that either the NHBoc 
deprotection is inefficient or the product (46) is unstable.  
 
The possibility of varying the sequence of the deprotection and N-functionalisation steps was 
investigated. A synthetic route with the same number of overall steps, that avoided formation of 46 
and the Boc-protection step was developed (Scheme 3.7). 
 
 
 
Scheme 3.7 Synthetic route used for the stepwise deprotection and N-alkylation of the tertiary nitro compound 
(22). Shown as an example, is the synthesis of the triester derivative of APPED (27). 
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In this revised sequence, the first step was cleavage of the aryl arms using trifluoroacetic acid, 
followed by N-alkylation with t-butyl bromo-acetate. The constitution of this intermediate, 24, has 
been confirmed using single crystal X-ray diffraction. This was followed by nitro reduction using 
Raney nickel catalysis to yield 25 in sufficient purity. Alkylation of the resulting exocyclic primary 
amine gave the mono-N-substituted ester, 26. The synthesis was carried out successfully with an 
improved yield. The major benefit of this method is the synthetic flexibility it introduces. Unlike 
every reported synthesis of chelators based on the AMPED core, the exo- and endo-cyclic amines 
can now be elaborated selectively and with relative ease. Whilst completing this work, the use of 
Raney nickel to achieve selective deprotection of the nitro group on the AMPED core has been 
reported elsewhere.2 
 
2.2.3 Alkylation of the Exocyclic Amine  
 
In the case of AMPED derivatives the exocyclic amine was very reactive and accessible to incoming 
nucleophiles. This characteristic was highlighted on a number of occasions. For example; alkylation 
with t-butyl bromo-acetate to yield tri-N-alkylated AMPED, 5 (Scheme 2.3), required mild conditions, 
and could not be undertaken without concomitant formation of the tetra-N-alkylated product, 3. 
The reactivity and accessibility of the ‘third’ position of Nexo was also highlighted by the propensity of 
compound 5 to lactamise readily under the acidic conditions used to deprotect the ester groups 
(Chapter 2 Scheme 2.3). As discussed previously, this could be prevented by insertion of a methyl 
group onto the mono functionalised exocyclic amine. This methylation reaction also reflected the 
reactivity and accessibility of the exocyclic amine of AMPED. Relatively mild conditions (< 1 molar 
equivalent methyl iodide, dichloromethane solvent, 273 K) were required to hinder formation of a 
quaternary ammonium salt, resulting from over-methylation of the exocyclic amine. 
 
These three reactions of the AMPED system make for an interesting comparison with the analogous 
reactions for the APPED system. The exocyclic amine of APPED derivatives appear to be significantly 
sterically hindered than the AMPED analogues. For example, when the APPED (core) is N-alkylated 
with t-butyl bromo-acetate under the same conditions, only the tri-N-alkylated product (27) was 
obtained. Formation of the tetra-N-alkylated product (26) required a higher temperature (343 K) and 
even then was only produced in a relatively low yield (12 %). This influence of the inserted phenyl 
substituent on the exocyclic amine, was also evident during methylation of the mono-substituted 
exocyclic amine of 7. Considerably harsher conditions (1.5 equivalents of methyl iodide, acetonitrile 
solvent, 295 K) were required and no quaternary products where observed (Scheme 3.8). 
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Furthermore, lactamisation of 27 was considerably slower than that of the AMPED analogue (5) 
which suggests that the lone pair of electrons of the exocyclic amine is less accessible to the acetate 
substituent on the endocyclic amine, or that the conformation of the ring is less favourable to the 
formation of the lactam ring.  
 
 
 
Scheme 3.8 Synthesis of ligand L
7
 from the triester (27), by methylation and subsequent ester hydrolysis. Also 
shown is the ester hydrolysis of 27, which resulted in the formation of the desired tri-N-acid APPED derivative 
as well as the unwanted lactamised by-product.   
 
This observation suggested that synthesis of a chelator with a mono-N-substituted exocyclic amine 
which is stable enough to be used for 68Ga-labelling is feasible with the APPED core. Mass 
spectroscopic data showed that both the lactamised and desired product were formed (in a 2 : 1 
ratio) during ester deprotection of 27 using trifluoracetic acid. This is a significant improvement 
compared to the de-esterfication of the AMPED analogue under the same conditions (Scheme 2.3). 
These products were inherently difficult to separate, and thus an efficient synthesis which would 
prevent formation of the lactamised product was required. This was achieved by substituting the t-
butyl esters for ethyl esters, (a method not dissimilar to that applied to the synthesis of 10), which 
could be deprotected using sodium hydroxide in a 1 : 1 THF/water mixture (Scheme 3.9). The 
synthesis of ligand L8 was achieved following the same procedure, by substituting the ethyl bromo-
acetate for enantiomerically pure (R)-trifluoromethyl-sulphonate.   
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Scheme 3.9 Synthetic protocol used for the preparation of ligand L
6
; designed to avoid formation of the 
lactamised by-product. Ligand L
8
 was synthesised using the same route, substituting the ethyl bromo-acetate 
for (R)-trifluoromethyl-sulphonate. 
 
Acid catalysed ester hydrolysis of the tetra-N-alkylated derivative (26) was also troublesome. Mass 
spectroscopic data suggests that the desired product forms, accompanied by the formation of two 
other species. According to the [M+H]+ peaks, these have been tentatively identified as fragments 
resulting from solvolysis at the tertiary carbon (C1) and cleavage of the endocyclic N—C bond under 
the protic ionising conditions (Scheme 3.10). In Chapter 2, the tetra acid derivative of AMPED (3) was 
identified as largely unsuitable for 68Ga(III) complexation. For this reason, the synthesis of the APPED 
analogue was not pursued by other methods.  
 
 
 
Scheme 3.10 Proposed products resulting from the ester hydrolysis of the tetra-N-ester (26), based on LC ES
+
 
mass spectroscopic data. 
 
Figure 3.4 depicts the three novel N3O3 chelators synthesised, which are based on the novel APPED 
core structure. It is possible to synthesise these ligands via the triamine APPED core (46); a route 
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which is analogous to the synthesis of AMPED based ligands. However, from our experience this 
route is inefficient for the APPED system. We have found that the sequential deprotection and 
decoration of the exo- and endo-cyclic amines is considerably more efficient, and also provides a 
greater degree of synthetic versatility. In hindsight, there is also a strong case for the use of base-
hydrolysable esters over the alternatives; specifically t-butyl esters should be avoided.  
 
 
 
Figure 3.4 Ligands featuring the novel APPED core synthesised for evaluation of their suitability for application 
in 
68
Ga-PET. 
 
2.2.4 Synthesis of hydroxyl derivatives  
 
The solvolysis reaction (Scheme 3.4) which resulted in the exchange of the nitro functional group for 
the hydroxyl was unplanned. However, the synthesis of an ‘ether-like’ analogue of L8, does offer an 
interesting comparison to the N3O3 chelators described in this chapter. By virtue of its lower basicity 
(pKa(NHR) ~ 6 vs pKa(OR) ~ 16) the hydroxyl group is a weaker σ-donor than the amine, and as a 
result the dative bond which forms to gallium would be weaker.  In this respect, it is reasonable to 
predict that the stability and radio-labelling kinetics would be less favourable. However, the hydroxyl 
group has a much smaller A-value than the amine (3 and 7 kJ/mol-1 respectively), giving an even 
greater bias to the phenyl moiety attached to the tertiary carbon (C1). Of further benefit; the 
hydroxyl derivative is considerably easier to synthesise, and is not prone to internal lactamisation 
which plagued the AMPED and APPED system. The tri-akylated ligand (L9), the ‘ether-like’ analogue 
of L6, was synthesised in 4 steps from 22 (Scheme 3.12). 
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Scheme 3.12 Synthesis of ligand L
9
, making use of the solvolysis-substitution reaction at the tertiary carbon of 
the reaction. R = 2,4-dimethoxyphenyl 
 
The nitro-hydroxyl exchange was attempted on different nitro intermediates, but found to work best 
by refluxing pure 22 in wet ethanol to give the hydroxyl analogue, 38. The alkylation with t-butyl 
bromo-acetate requires harsh conditions, and the di-N-alkylated compound (40) was isolated as a 
by-product.  
 
3 Radiochemical Evaluations 
 
In chapter 2 the synthesis and radiochemical evaluation of a series of ligands based on the AMPED 
scaffold was discussed. Two of the ligands in particular, L2 and L3, display 68Ga-radiolabelling 
characteristics and stability (of the radiolabelled complex) which compare favourably with the best 
ligands in literature.17-21 
 
This very promising system does have a couple of disadvantages, which have been attributed to 
structural characteristics of the ligands. In fact, the structural features which make L2 and L3 more 
suitable than the other ligands (L1, L4 and L5), are also the source of the disadvantages. More 
specifically, the reduced steric demand at the exocyclic amine was found to correlate favourably 
with radiolabelling efficiency and the enhanced stability of the radiolabelled complex. The best 
attributes were obtained for ligand L3, which has a mono-functionalised exocyclic amine. However, 
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ligand L3 is hampered by its inherent tendency to lactamise under acidic conditions (Chapter 2 
Section 1). Given that radiolabelling occurs over the pH range 4.0 – 7.0 the ability of the ligand to 
complex 68Ga is not disadvantaged, because the rate of lactamisation is very slow in this pH range.  
Ligand L2 overcomes this problem, but it forms multiple radiolabelled species. Although the minor 
species only accounts for between 5 and 10 % of radiolabelled complex (depending on labelling 
conditions), the presence of multiple species is an undesirable feature. This limits the potential for 
bioconjugation, both in terms of the point of attachment (using the exocyclic amine may not be 
feasible) and the chelators that may be useful. 
 
In Section 1 of this chapter the synthesis of ligands featuring a modified scaffold (APPED) was 
described, which has increased steric bulk at quaternary ring carbon (C1). The hypothesis was that 
doing so would have two specific advantageous effects. Firstly, increased steric demand of this 
substituent would favour the chair-like conformation of the ligand in the Ga(III) complex, and 
thereby reduce the likelihood of formation of multiple radiolabelled species. This was especially a 
problem for radiolabelling at pH < 3.5, and in ligands where the exocyclic amine is di-N-alkylated. 
Secondly, the increased steric bulk close to Nexo would inhibit the internal lactamisation reaction 
which was the downfall of these promising ligands.  
 
Synthetic observations indicate that introduction of the phenyl substituent did have the desired 
effect of reducing the rate of lactamisation (for structurally related ligands in each series). For 
example; ligand L6, which is structurally related to the AMPED based ligand (AAZ3A: Figure 2.1) 
which was deemed too unstable under acidic conditions, is sufficiently stable to be considered.  
Furthermore, L8 also shows a slower rate of internal lactamisation than that observed for L3.  
 
The series of four chelators, L6-9 (Figure 3.5), featuring the modified AMPED core, was synthesised 
and evaluated for potential application in 68Ga-PET. The suitability of these ligands has been 
assessed in the same manner as that described for ligands L1-5 (Chapter 2 Section 3). Firstly, the 
radiolabelling efficiency of the ligands was determined over the pH range 2.3 – 7.0 at 298, 323 and 
368 K. Secondly, the stability of the radiolabelled complexes was evaluated at physiological pH and 
temperature in presence of apo-transferrin, DTPA, iron(III) and newborn calf serum. Ligands deemed 
suitable were evaluated in a series of competition experiments, and the dependence of the 
radiolabeling yield on ligand concentration investigated.  
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Figure 3.5 Ligands featuring the modified AMPED core synthesised for evaluation as potential 
68
Ga-PET 
imaging agents. 
 
3.1 Radiolabelling Studies with Ligands L6-9 
 
The radiolabelling (pH 4.0 - 7) and radiolabelled complex stabilities displayed by L2 and L3 were 
extremely favourable. Thus, the same or very similar characteristics are desirable in this series. Of 
further importance is to define the radiolabelled speciation characteristics, in comparison to their 
AMPED based analogues.  
 
3.1.1 Radiolabeling at pH < 3.6 
 
The radiolabelling of L6-9 was assessed at pH ~ 2.3 in the absence of a suitable buffer. Radiolabelling 
at pH 3.3 was not evaluated because only limited information could be extracted. Also, the protocol 
was unsuitable for the synthesis of radiolabelled complexes due to the resulting low radioactivity 
concentration of the solution.  The results of the radiolabelling experiments for ligands L6-9 at 298, 
323 and 368 K are shown below (Figure 3.6). Also shown for comparison is the radiolabelling kinetics 
for L2 and L3, the AMPED analogues of L7 and L8 respectively. 
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Figure 3.6 Temperature dependent radiolabelling kinetics of ligands L
6-9
 at pH 2.3, shown as a percentage of 
the radioactivity associated with the radiolabelled complexes, at 1, 3, 5 and 10 minutes intervals. ~ 100 MBq 
activity at t = 0 min. [
68
Ga] = 0.18 nM. [L
n
] = 10 µM. Vtot = 5 mL. 
 
There is a greater than two fold increase in the radiolabelling kinetics of L7 and L8 relative to L2 and L3 
at 298 K. Ligand L6 shows a similar radiolabelling profile at room temperature, and all three ligands 
show > 90 % labelling within 10 minutes at 323 K. In contrast, L9 showed comparatively very slow 
radiolabelling even at 368 K, with a maximum radiolabelling yield of 55%. This considerable decrease 
in the radiolabelling kinetics with respect to its structural analogue, L6, is likely to be a result of the 
reduced donor ability of the ether oxygen. 
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Examination of the eluted radio-TLC plates reveals some interesting information regarding the 
speciation of the radiolabelled ligands. Radiolabelling of ligand L7 at pH 2.3 gave rise to two 
radiolabelled species (ratio 9 : 1). Similarly, radiolabelled complexes [Ga.L6]2.3 and [Ga.L
8]2.3 were 
also characterised by two species, but with considerable less biased ratios of 3 : 2 and 3 : 1 
respectively.  
 
Thus, in addition to the increase in the rate of radiolabelling through modification of the AMPED 
scaffold, we also note that there has also been a perturbation in the speciation of the radiolabelled 
complexes. Previously it was found that radiolabelling of ligand L3 at pH 2.3 resulted in formation of 
single radiolabelled complex species. Under the same conditions, the structural analogues L6 and L8 
each give rise to two radiolabelled species with ratios of 3 : 2 and 3 : 1 respectively. Whether or not 
the change in the ratio of the isomeric species was in favour of the more stable species will be 
assessed in section 3.2 of this chapter. Radiolabelling with ligand L7 at pH 2.3 displayed improved 
radiolabelling kinetics compared to the AMPED analogue, L2. However, there was no significant 
change to the speciation of the radiolabelled complex. 
 
As a consequence of these speciation problems, the radiolabelled complexes of ligands L6-8 formed 
at pH ~ 2.3 were considered unsuitable for application in 68Ga-PET.  
 
3.1.2 Radio-labelling at pH > 3.6 
 
Radiolabelling experiments were carried out for ligands L6-9 at 298, 323 and 368 K and at pH 4.0, 5.3 
and 7.0. Following the results obtained for ligands L1-5 where faster radiolabelling occurred above pH 
3.6, a significant increase in the rate of radiolabelling rate was expected. The results for the 
radiolabelling at 298 K for L6-9 are compared (Table 3.1), examining the time taken to reach the 
maximum yield. Also shown are the results obtained for ligands L2 and L3 under the same conditions 
using identical buffer solutions in each case.   
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Table 3.1 Maximum radio-labelling yield (%) achieved and the time taken (minutes) at 295 K for 
 
L
2,3,6-9
 at pH 
4.0, 5.3 and 7.0. [
68
Ga]=0.66 nM. [L
n
] = 10 µM. Vtot = 1.4 mL. 100 MBq activity at t = 0 min.  
 
 
 
pH 
Maximum radiolabelling yield (%) at 295 K 
a 
Time taken to achieve maximum yield (min) 
 
L
6 
 
L
7
 L
8
 L
9
 L
2
 L
3
 
4.0 97 
3 
65* 
10 
99 
3 
3 
10 
98* 
1 
99 
3 
5.3 98 
3 
92* 
10 
99 
3 
6 
10 
97* 
1 
98 
3 
7.0 97 
3 
20* 
10 
98 
3 
4 
10 
97* 
1 
98 
3 
a
 an asterisk indicates the presence of more than one radiolabelled species 
 
Ligand L9 shows incomplete labelling at pH > 3.6, even at elevated temperatures, with very little 
enhancement of the radiolabelling yield observed at higher pH.  
 
Surprisingly, radiolabelling of L7 proved to be problematic. Quantitative labelling was not observed at 
any of the pH’s evaluated, and only a ± 5 % change in the yield was observed with increasing the 
temperature to 368 K. Furthermore, the speciation of the radiolabelled ligand became less biased 
compared to radiolabelling at pH 2.5, with approximately equivalent proportions of the two species 
being formed. 
 
Ligands L6 and L8 produced the expected change in rates compared to pH 2.5, achieving quantitative 
labelling at room temperature over the pH range 4.0 – 7.0 in less than 3 minutes. At face value, it 
may seem that insertion of the phenyl group onto the scaffold has had a negative impact on the rate 
radiolabelling at pH ≥ 4, compared to the AMPED analogues. However, closer examination of the 
time interval data shows that the radiolabelling yield at the 1 minute time interval was greater than 
92 % for both ligands, over the pH range 4.0 – 7.0. This is only a very small difference compared to L2 
and L3, and not significant taking into account that in each case radiolabelling would be conducted 
over 5 minutes, to ensure it goes to completion. Importantly, both L6 and L8 gave rise to a single 
radiolabelled species when each was labelled at pH 4.0, 5.3 and 7.0. 
 
In terms of radiolabelling efficiency (rate and speciation) at pH ≥ 4, L6 and L8 display properties that 
are very similar to that of the very promising candidate ligand L3. For these structures, the 
phenyl/methyl permutation has had little apparent influence on the near ideal radiolabelling 
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efficiency. The same is not true for L7, where the modification has had a detrimental effect on the 
radiolabelling (pH > 3.6) efficiency and radiolabelled complex speciation as compared to L2. Ligands 
L7 and L9 were deemed unsuitable and were not evaluated further. The poor radiolabelling 
behaviour of L7 may be a result of the crowded nature of Nexo, which hinder ligand rearrangement 
for metal binding.  
 
3.2 Stability of Radiolabelled Complexes [68Ga.L6] and [68Ga.L8] 
 
Despite the unfavourable speciation associated with the radiolabelling of ligands L6 and L8 at pH 2.3, 
the stability of the radiolabelled complexes has been assessed.  The results may provide some 
insight into the nature of the different species; specifically, whether or not the phenyl/methyl 
permutation has resulted in an increase in the proportion of the more stable isomer.  
 
As before, a labelling system is used where the italicised subscript after the radiolabelled complex 
indicates the pH at which it was formed. For example, [68Ga.L6]2.5, indicates that the radiolabelled 
complex was formed at pH 2.5, and [68Ga.L6]4.0-7.0 indicates that the radiolabelled complex was 
formed at pH 4.0, 5.3 or 7.0. 
 
The protocol used to evaluate the stability of [68Ga.L6] and [68Ga.L8] was exactly the same as that 
described for [68Ga.L6] and [68Ga.L8] (Chapter 2 Section 2.3). Briefly, the stability of the radiolabelled 
complexes was tested in a series of challenge experiments with DTPA (5000-fold excess), Fe(III) 
(5000-fold excess), apo-transferrin (130-fold excess) and in newborn calf serum. All solutions were 
prepared in 1.0 M PBS solutions, and the stability evaluations were carried out at physiological pH 
(7.4) and temperature (310 K). The relative amount of the intact radiolabelled complex and free 68Ga 
was determined at 10, 20, 30, 60, 90 and 120 min, using a radio-TLC method with 0.5 M sodium 
citrate (pH 4) as the eluting solvent.  Stability evaluations were performed in triplicate for each 
radiolabelled complex synthesised at pH 2.3, 4.0, 5.3 and 7. Two control experiments were 
performed in every case; one in the absence of the ligand, and the other in the absence of the 
challenge. 
 
The stability of each complex with respect to the apo-transferrin challenge experiment is 
summarised in Table 3.2. No evidence of instability was observed for any of the radiolabelled 
complexes during the Fe(III), newborn calf serum and DTPA challenge experiments.  
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Table 3.2 Stability of the investigated 
68
Ga-radiolabeled ligands at 120 minutes in a competition experiment in 
the presence of 130-fold excess apo-transferrin. Challenge experiments were conducted at physiological pH 
(7.4) and temperature (310 K). 
 
pH at which 
radiolabelled complex 
was synthesised 
Percentage of Radiolabel/s intact after 120 min (%) 
 
[
68
Ga.L
2
] [
68
Ga.L
3
] [
68
Ga.L
6
] [
68
Ga.L
8
] 
2.3 10 8 19 47 
4.0 95 97 97 98 
5.3 95 98 99 96 
7.0 93 94 97 99 
 
Considering first [68Ga.L6]2.5 and [
68Ga.L8]2.5, a significant degree of instability was observed in each 
case. Careful examination of the interval data and relative proportions of the radiolabelled species 
shows that the major radiolabelled species only was unstable, whilst the minor species remained 
completely intact. Overall [68Ga.L6]2.5 and [
68Ga.L8]2.5, had 19 and 47 % of the combined radiolabelled 
ligand species intact after 120 min, respectively. This is in agreement with the results obtained for 
[68Ga.L2]2.5, where the major isomer was exclusively unstable in the presence of apo-transferrin.  
 
For the ligands L2, L3, L6 and L8 there is an apparent higher stability of the radiolabelled complexes 
formed at pH 2.5 from ligands which feature the APPED core. The relative ratios of the radiolabelled 
complex isomers for each ligand, formed at pH 2.5, suggests that the observed increase in stability 
arises from an increase in the relative proportion of the more stable species, i.e. the methyl-phenyl 
permutation has resulted in an increase in the amount of the more stable isomer formed. 
 
No evidence (i.e. there was no noticeable evidence of 68Ga signal greater than background activity, 
other than that of the complex) for complex instability was observed for the radiolabelled complexes 
[68Ga.L6]4.0-7.0 and [
68Ga.L8]4.0-7.0 over 2 hours in all of the stability challenge experiments. The 
radiolabelled complexes [68Ga.L6]4-7.0 and [
68Ga.L8]4-7.0 have very similar stability profiles to that of 
[68Ga.L3]4-7.0.  
 
In the case of L7, the rate of radiolabelling at pH 2.3 increased slightly with respect to the AMPED 
analogue L2, with the ratio of the radiolabelled species formed seemingly unaffected. However, 
radiolabelling of L2 at pH ≥ 4.0 was not quantitative, accompanied by the formation of two 
radiolabelled species. This is in contrast to L2, where the relative proportion of the radiolabelled 
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species decreased above pH 4.0, and radiolabelling was quantitative at room temperature within 1 
minute. 
 
Modification of the AMPED core by insertion of a phenyl moiety has had differing effects on the 
radiolabelling efficiency, speciation and radiolabelled complex stability. Positively, the radiolabelling 
efficiency and stability of [68Ga.L6]4-7.0 and [
68Ga.L8]4-7.0 have maintained the high standard set by L
2 
and L3. In addition to this, there has also been an improvement in the speciation and stability of 
[68Ga.L6]2.3 and [
68Ga.L8]2.3 compared to [
68Ga.L3]2.3. Unfortunately, the formation of multiple 
radiolabeled species, and resulting instability, associated with [68Ga.L6]2.3 and [
68Ga.L8]2.3 means that 
the ligands L6 and L8 are unsuitable for 68Ga-radiolabelling under these more acidic conditions. Thus, 
the useful pH range for radiolabelling is 4.0 – 7.0.  
 
3.3 Trends in Speciation of the 68Ga-Radiolabelled Complexes 
 
From the results discussed in chapter 2, it was evident that there was a correlation between the 
formation/presence of multiple radiolabelled complex species for a given ligand and the steric bulk 
at the exocyclic amine, for radiolabelling in the pH range 4.0 – 7.0. Indeed a single radiolabelled 
complex species was observed for the mono-Nexo-functionalised ligand L
3. In addition, there was a 
general increase in the proportion of a second ‘unstable’ radiolabelled complex species with 
increasing steric bulk at the Nexo (chapter 2).  
 
Competition between the methyl and Nexo groups for the equatorial position in the seven membered 
heterocyclic ring was thought to be associated with formation of radiolabelled constitutional 
isomers based on different conformations of the ligand. It was thought that the increased steric 
demand of Nexo caused it to prefer an equatorial orientation, disfavouring formation of the more 
stable chair-like conformation. The key hypothesis was that by increasing the steric demand at the 
quaternary carbon site, the Nexo group would be ‘pushed’ into an ‘axial’ position, which allows the 
nitrogen lone pair to bind to the metal cooperatively with the endocyclic nitrogens. 
 
In good agreement with this hypothesis, it was observed that the radiolabelled complex speciation 
and stability profile of [Ga.L6]2.3 and [Ga.L
8]2.3 was better than that of the AMPED derivatives 
[Ga.L2]2.3 and [Ga.L
3]2.3, with introduction of the phenyl group promoting formation of the more 
stable radiolabelled  species. This effect was not observed for ligand L7, where the ratio appears to 
approximately the same as its AMPED based analogue ligand L2. However, care should be taken with 
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an interpretation since the stability of [Ga.L7]2.5 has not been determined, and thus whether the 
ratio of stable to unstable isomers is the same or been reversed, i.e. It is possible that the minor 
isomer of [Ga.L7]2.5 is unstable, whilst the opposite was observed for [Ga.L
2]2.5.  
 
Multiple radiolabelled species were not observed for [Ga.L6]4-7.0 and [Ga.L
8]4-7.0. However this was not 
the case for [Ga.L7]4-7.0, for which the speciation profile and kinetics of radiolabelling got worse as 
the labelling pH was increased.  
 
3.4 Further Radiochemical Evaluation of L6 and L8: Competition and Concentration Studies 
 
Each evaluation reported in this section was carried out in exactly the same manner as those 
described in Chapter 2 Section 3.5. Specifically, each evaluation was performed at 298 K and pH 4 
(0.2 M acetate buffer).  
 
3.4.1 NOTA Competition 
 
Equimolar amounts (20 µM) of NOTA and the ligand of interest (L6 or L8) were premixed in 1 mL of 
0.2 M acetate buffer (pH 4), and radiolabelled with ~ 100 MBq 68Ga (0.66 nM). The relative ratio of 
[Ga.NOTA] and [Ga.Ln] determined at 1, 3, 5, 10 and 120 min time intervals. All available 68Ga(III) was 
complexed within 1 minute, and no change to relative proportions of the radiolabelled complexes 
was detected over 2 hours at room temperature (at pH 4.0 and 7.4). This indicates that no trans-
chelation had taken place, and the complexes are kinetically stable (under these conditions). Ligand 
L6 chelated 76 % of the available radioactivity, whilst L8 accounted for 53 %, with NOTA making up 
the difference in each case. Of the ligands evaluated thus far (i.e. L2, L3, L6 and L8), L6 shows the 
fastest radiolabelling kinetics, as determined by this challenge experiment, with a rate three times 
faster than that of NOTA under the given conditions. Ligands L3 and L8 display the slowest rate of 
radiolabelling. This may be a consequence of the reduced ‘mobility’ of the carbocyclic arms due to 
steric inhibition involving rearrangement of the propionate substituents. The fast 68Ga-radiolabelling 
kinetics of NOTA has been attributed to the pre-organisation of the ring conformation and 
associated donor groups to 68Ga-complexation. The fact that L6 displays such fast radiolabelling 
kinetics (relative to the other AMPED based ligands) suggests that the introduction of the phenyl 
group may have pre-organised the ligand towards 68Ga-complexation. Indeed, the fact that L8 labels 
faster than L3 is also consistent with this hypothesis. 
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3.4.2 Metal Ion Competition 
 
The radiolabelling efficiency of L6 and L8 was evaluated in the presence of increasing concentrations 
of calcium(II), iron(III) and copper(II) as their chloride salts. The standard labelling protocol at pH 4 
was applied, i.e. [Ln] = 10 µM, [68Ga] = 0.66 nM ~ 100 MBq, Vtot = 1.4 mL, 10 min. 
 
A tolerance to added Ca(II), similar to that of ligands L2 and L3, was observed for ligands L6 and L8, 
with concentrations of 8.0 M having no effect on the radiolabelling kinetics. This is 4000 times fold 
the concentration of Ca(II) in vivo.22 Quantitative radiolabelling of L6 and L8 was achieved within 10 
minutes in the presence of 4 equivalents of Fe(III) with respect to the concentration of the ligand. 
The degree of radiolabelling decreased to approximately 70 and 55 % in the presence of 5 and 10 
equivalents of Fe(III) respectively. Ligands L6 and L8 were more sensitive to the presence of added 
Cu(II) than the AMPED based ligands tested. No radiolabelled complex was formed after 10 minutes 
in the presence of one equivalent of Cu(II), with respect to the ligand. However, each ligand 
radiolabelled quantitatively when the amount of Cu(II) was reduced to 0.75 equivalents. This 
equates to ~1.1x106 times more copper(II) than 68Ga(III), indicating that there is a high degree of 
selectivity of the ligands for gallium(III) over copper(II) under these conditions. As an indication of 
the relative amount of 68Ga present; the ligand is in a ~ 1.5x104 fold excess (assuming 68Ga : Ln is 1 : 1 
in the complex). 
 
It is interesting to note that L6 and L8 apparently display a higher affinity for Cu(II), but lower 
sensitivity to Fe(III), compared to the AMPED based ligands.  
 
3.4.3 Dependence of Radiolabelling Yield on Ligand Concentration 
 
The influence of ligand concentration on radiolabelling with ~ 100 MBq 68Ga (0.66 nM) was 
investigated over 10 min at 298 K and pH 4 (0.2 M acetate buffer) using the standard protocol.  
 
Ligands L6 and L8 displayed quantitative radiolabelling within 10 minutes at a ligand concentration of 
7.0 μM. At 3.5 μM ligand, the radiolabelling yields for L6 and L8 decreased to 51 and 80 % 
respectively, whilst no radiolabelled complex was observed for either ligand at 1.0 μM. Further 
experiments to accurately determine the limiting ligand concentrations (lowest concentration of the 
ligand able to give a quantitative yield under these conditions) have not been carried out. These 
values indicate that there is a greater dependence of the rate of radiolabelling on the ligand 
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concentration for L6 and L8 than for the AMPED based ligands L2 and L3. These values compare 
favourably with the acyclic chelator CP25618, which displays the lowest limiting concentration for 
quantitative 68Ga radiolabelling in literature (10 μM, 298 K, pH 6.4, 10 min). 
 
4 Preliminary in vivo Biological Examination of [68Ga.L2] and [68Ga.L8] 
 
Preliminary investigations of the in vivo behaviour of radiolabelled complexes [68Ga.L2] and [68Ga.L7] 
have been carried out in male Spargue Dawley rats, along with [68Ga.NOTA] for comparison. 
Dynamic, whole body and static brain autoradiography scans have been performed for each 
radiolabelled complex.  
 
The data collected for the dynamic and brain scans of [68Ga.L8] failed to reconstruct, due to a corrupt 
data file. Furthermore, the rats used in the in vivo assessment of [68Ga.L8], were considerably heavier 
than those used for [68Ga.L2] and [68Ga.NOTA]. Therefore, the in vivo studies of [68Ga.L2] and 
[68Ga.NOTA], are discussed separately from [68Ga.L8]. 
 
4.1 μ-PET of [68Ga.L2] and [68Ga.NOTA] 
 
The radiolabelled complexes of [68Ga.L2] and [68Ga.NOTA] were synthesised at pH 4.0 using the 
standard protocols described previously, and the pH adjusted to 7 using 0.1 M aqueous sodium 
hydroxide. Each radiolabelled complex was injected into two rats (~ 23 MBq, made up to 500 – 700 
μL with 0.9 % saline solution) weighing between 330 and 380 g.  
 
The dynamic scans confirm fast renal excretion of the radiolabelled complexes in both each case 
(Figure 3.7(i)). In the first frames (0 – 20 s), the radioactivity injection is visible by the high levels of 
the inferior vena cava, with simultaneous increasing uptake in the kidneys. Accumulation of 
[68Ga.NOTA] in the kidneys occurs slightly faster than [68Ga.L2], with the subsequent excretion to the 
bladder occurring at a slower rate. This is supported by the time averaged counts for the bladder 
(Figure 3.7(i)). In the last frames of 180 - 240 s for [68Ga.L2], the final renal excretion to the bladder is 
marginally visible by the radioactivity in the ureter. 
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Whole body scans were recorded 10 min post-injection, for a duration of 15 min (Figure 3.7(ii)). The 
full body scans for [68Ga.L2] and [68Ga.NOTA] show strong accumulation in the bladder as a result of 
fast renal excretion. The very high radioactivity in the bladder prevents visualisation of any other 
structure or organs except the kidneys, which are slightly visible. This biodistribution profile 
demonstrates that the 68Ga is not released from the radiolabelled complexes in vivo. Injection of 
unchelated 68Ga usually results in the distribution of radioactivity throughout the whole animal, 
resulting from complexation by naturally occurring transferrin.18 
 
Static scans of the brain were collected for the first 25 min post injection (Figure 3.7(iii)). Both 
radiolabelled complexes showed uptake in the nose tissue and Harderian glands behind the eyes; 
behaviour which is frequently observed for radiolabelled complexes. The uptake is considered 
non-specific, and the mechanism still awaits clarification. There was no observable uptake in the 
brain, as indicated by the white spot in brain region on the grayscale images.  
 
The in vivo stability of [68Ga.L2] was supported by two features: its similarity to the biodistribution 
profile of the exceptionally stable [68Ga.NOTA], the absence of any observable bone uptake, which is 
known to be a site of accumulation for weakly chelated gallium.18, 23 
 
4.2 μ-PET of [68Ga.L8] 
 
Assessment of [68Ga.L8] in vivo was carried out in two rats weighing 430 and 440 g. The first rat was 
injected with 31 MBq of [68Ga.L8] (made up to 800 μL with 0.9 % saline) synthesised at pH 4.0 (0.1 M 
acetate buffer), and adjusted to pH 7 using 0.1 M aqueous sodium hydroxide. The second rat was 
injected with 34 MBq of [68Ga.L8] (made up to 900 μL with 0.9 % saline) synthesised at pH 7.0 (1.0 M 
HEPES solution). In each case, the radiolabelled complexes were synthesised according to protocols 
described previously.  
 
Whole body scans were recorded at 10 min post injection. Similar to [68Ga.L2] and [68Ga.NOTA] there 
is substantial accumulation in the bladder and the absence of any observable bone uptake, 
indicating that in both cases the integrity of the radiolabelled complex is maintained in vivo. In both 
evaluations there is also evidence of, comparably much lower, accumulation at another site in the 
abdomen where the kidneys are expected to be found (Figure 3.8). In both [68Ga.L8] rats studies 
there was a single lower accumulation site instead of two as would be expected for kidney 
accumulation. Co-localisation in both kidneys was observed for [68Ga.L2] and [68Ga.NOTA]. Further 
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studies are needed to fully characterise this accumulation. Interestingly, the accumulation occurs on 
opposite flanks in the two studies conducted. Furthermore, both [68Ga.L8]4.0 and [
68Ga.L8]7.0 have 
shown similar in vivo behaviour suggesting that speciation is the same despite the different 
radiolabelling conditions. This is consistent with the results of the radiolabelling experiments.  
 
 
 
Figure 3.8 in vivo 
68
GA μ-PET full body scans 10 min post injection of 
68
Ga labelled ligands L
2
, NOTA and L
8
 
(radiolabelled at pH 4.0 and 7.0). Full body scans of [
68
Ga.NOTA] and [
68
Ga.L
2
] show bladder and kidney 
accumulation. [
68
Ga.L
8
] radiolabels accumulate in the bladder, and show additional retention in a region where 
the kidneys are expected to be located. Only one additional accumulation site is detected in each, which 
precludes a conclusive assignment.  
 
5 Summary 
 
In Chapter 2, it was shown that ligand L3 is a very promising candidate for 68Ga-PET studies, with near 
ideal radiolabelling, complex speciation and stability profiles. However, the results suggested that 
synthesised and potential ligands were limited by their propensity to undergo internal lactamisation 
under acidic conditions. These inherent properties limit the ligands use both synthetically and in 
application.  
 
The introduction of a phenyl substituent at the quaternary carbon, addresses some of the issues 
associated with ligand stability. Thus, L6, whose AMPED analogue was unstable with respect to 
lactamisation, was synthesised and could be used to form radiolabelled complexes.  The two ligands 
L6 and L8, which feature the modified core, give rise to stable, single radiolabelled complex species 
that form within 3 minutes at room temperature over the pH range 4.0 – 7.0. In addition to this, 
remarkable radiolabelling resilience was shown to the presence of added NOTA, iron(III), copper(II) 
and calcium(II) in µM concentrations (i.e., greatly exceeding the 0.66 nM concentration of 68Ga). 
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Furthermore, the radiolabelled complexes were stable with respect to trans-complexation by NOTA 
over 2 hours at pH 4 and 7.4.  
 
In agreement with the hypothesis, introduction of the phenyl group had a positive impact on the 
speciation and stability of radiolabelled complexes formed at pH 2.3 (for ligands with a mono-
substituted exocyclic amine). Despite this improvement, radiolabelled complex speciation and 
stability is still a problem. This precludes their use for in vivo application following synthesis at pH 
2.3. Unexpectedly, radiolabelled complexes formed using ligands with a di-substituted exocyclic 
amine displayed worse speciation and stability as a result of the introduction of the phenyl group. 
This suggests that there are other factors influencing the speciation of the radiolabelled complexes 
beyond competition for the equatorial site at the quaternary ring carbon. 
 
The ligands featuring the modified APPED core offer an improvement on the AMPED based ligands. 
The structural modification has not been to the detriment of the radiolabelling properties of the 
mono-substituted exocyclic amine ligands nor their radiolabelled complex stabilities, and has 
improved the stability of the free ligands towards lactamisation. Of additional benefit, the synthetic 
methodology used to make these ligands is more selective, thereby allowing greater synthetic 
versatility.  
 
Ligands featuring the modified APPED scaffold and a mono-substituted amine are better overall than 
their AMPED analogues, and compare favourably with the most promising literature compounds 
(including TRAP20, 24, 25, CP25618, H2DEDPA
17, 23 and HBED21 – see Section 3.2.2 of Chapter 2 for specific 
detail and structures). The rate of 68Ga incorporation by Ln (n = 2, 3, 6, 8) is greater, at lower 
temperatures and concentrations, than established 68Ga-PET ligands, DOTA24, 26 and NOTA.24, 27 The 
unique feature of these ligands is their ability to radiolabel over a wide pH range, which includes pH 
7.0, within 3 minutes at room temperature, using comparably low concentrations of the ligands. 
 
Assessment of [68Ga.Ln] (n = 2 and 8) in vivo in rats, confirmed the in vitro stability studies, with renal 
clearance and rapid excretion to the bladder 10 minutes post injection.  
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Chapter 4 
Conformational Analysis of the Ring, and  
‘Cold’ Gallium(III) Complexes  
 
In this Chapter the trends observed in the radiochemical experiments are rationalised, and the structures of 
the ‘cold’ gallium complexes are investigated. Specifically, in section one, the rates of radiolabelling, 
radiolabelled complex speciation and their stability is addressed. In section two, crystallographic and NMR 
data are used to assess the influence of the phenyl substituent on the ring conformation in comparison to 
the analogous AMPED system. In section three, NMR spectroscopic and crystallographic data are used to 
discuss the ‘cold’ gallium complexes of the preferred ligands.  
 
1 Conformational Analysis of the 7-Membered Ring  
 
The radiolabelling studies detailed in Chapters 2 and 3 indicated that the most favourable chelators 
are those which possess a mono-substituted exocyclic amine. In fact, the results showed that further 
substitution resulted in a lower stability of the radiolabelled species, and was also directly linked to 
the formation of multiple radiolabelled species. Furthermore, there was a considerable decline in 
the forward rate of labelling and in the dissociative stability of the radiolabelled complexes, when 
labelling was carried out at pH < 3.5. At this pH, the diprotonated species is almost exclusively 
present. The pKa which precedes formation of this species is assigned to protonation of the exocyclic 
amine, with deprotonation of this species to give mono-N-protonated species beginning at pH ~ 4 
(Chapter 2 Section 2). Indeed, protonation of this group is expected to have a marked effect on the 
labelling kinetics, because the presence of the positive charge makes complexation more difficult. 
However, it does not explain why when the ligands were labelled at pH < 3.5 the stability of the 
radiolabelled complexes is compromised, and in some cases multiple radiolabelled species were 
observed. Notably, this was a problem for ligands based on AMPED, and to a lesser extent for ligands 
based on the APPED (Figure 4.1). 
 
The conformational flexibility of saturated heterocyclic 7-membered rings is well documented, as are 
the ring substituent effects on the relative energy of the preferred conformers.1-5 It is evident from 
the labelling studies that substituents at the Nexo position are playing an important role on 
radiolabelled complex stability and, presumably, on ligand conformation in solution. Understanding 
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these substituent effects and the different conformations is an important step in developing better 
ligands for use in 68Ga-PET. 
 
 
 
Figure 4.1 Structures, and abbreviated names, of tri-amine ligands to which reference is made in the text. 
 
In Chapter 3 Section 2, it was shown that the presence of a phenyl group at the quaternary carbon of 
the ring had resulted in a significant decrease in the reactivity of Nexo. This decrease in reactivity is 
directly related to the increase in steric bulk about the quaternary carbon imparted by the phenyl 
group. An important consideration of the novel APPED core is the influence that the modification at 
this carbon has on the orientation of the ring substituents and the preferred conformation adopted 
by the ring. In this chapter, crystallographic and NMR data are used to assess the influence of the 
phenyl substituent on the conformation of the ring and ring substituent orientation, with 
comparison to the analogous AMPED system. 
 
1.1 Cycloheptane to Diazepine 
 
In the case of cycloheptane, the low energy conformations are made up of a series of twisted-chair 
(TC) and chair (C) conformations with relatively small energy barriers to the ring puckering which link 
conformers of the same family (Figure 4.2). The TC-conformation of cycloheptane is most favoured, 
and has a single unique isoclinal position as well as three distinct pseudo-axial and pseudo-
equatorial positions.2, 3, 6 
 
 
 
Figure 4.2 Possible conformations of cycloheptane and other 7-membered rings. Chair and twisted-chair 
conformers are of lower energy than the boat and twisted-boat conformers. 
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A preference towards a TC conformation is also observed for 1,4-diazepane (such as those studied 
here), of which there are four possibilities. The introduction of an exocyclic amine at the 1-position 
lowers the overall symmetry of the ring, and as a result increases the number of possible TC-
conformers further.2, 4 Due to the presence of destabilizing non-bonding interactions, arising from 
the eclipsed conformation of the N-CH2-CH2-N fragment, neither chair nor boat conformations are 
observed for 1,4-diazepane rings of free ligands.2-4 In fact, Hegetschweiler noted that often the low 
stability of complexes containing ligands based on the DAZA core is a result of the unfavourable 
eclipsed orientation which is required for tri-dentate coordination of the DAZA core.6, 7 Thus, strictly 
speaking, for the free ligands the chair and boat conformations exist only as high energy transition 
states.2, 4 For free ligands based on the DAZA core, where the exocyclic amines have the same 
functionalisation and R1 is variable, there are seven possible TC-conformers (Figure 4.3).  
 
 
 
Figure 4.3 Possible conformers of 6-R1-6-amino-1,4-diazepane based ligands. Groups attached to the exocyclic 
amine are identical and arbitrary. Functionalisation of the endocyclic amine is also arbitrary. R
1
 is only shown 
for the ‘Nexo isoclinal’ conformer.
3, 6
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One of the conformers has the exocyclic amine in an isoclinal position (TC4), and 3 each with the 
amine in axial (TC1-3) and equatorial (TC5-7) positions. An axially and equatorially positioned 
substituent is defined as having deviation (θ) from the mean plane of  the ring of 0° ≥ θ ≤ 30° and 60° 
≥ θ ≤ 90° respectively (where the mean ring plane is determined using all the atoms of the ring).  
Ring substituents between these two ranges (30° > θ < 60°) are defined as isoclinal substituents.2 
 
Hegetschweiler et al published the crystal structure of the triply protonated salts of DAZA and 
AMPED.6, 7 In the crystal structure of (H3DAZA)
3+, the exocyclic amine adopts an equatorial position in 
the TC-conformer shown by TC6.
6 Two crystal structures have been obtained for (H3AMPED)
3+ in 
which the exocyclic amine adopts an isoclinal position or an equatorial position, depicted in TC-
conformers TC4 and TC7 respectively.
6 The fact that different conformations are observed for AMPED 
implies there are low energy barriers to exchange between conformers; however an influence of 
packing interactions cannot be excluded.6 
 
In stable metal complexes of these ligands, the seven-membered rings are assumed to exist in a 
chair-like conformation, with the endocyclic amine occupying an axial orientation in order to allow 
ligation of the Nexo-lone pair, giving rise to a tri-dentate fac-N3 coordination mode. Indeed, such a 
conformation has been observed for a number of complexes containing tri- and hepta-dentate 
ligands based on the DAZA core.6, 8-13 Therefore, in order to produce a stable complex, the free ligand 
has to be able to populate a higher energy transition state chair conformation. There are two main 
concerns to accessing this high energy C-conformation. Firstly, the benefits of metal binding must 
outweigh the unfavourable destabilizing non-bonding interactions arising from the eclipsed nature 
of the N-CH2-CH2-N fragment inherent to the chair conformation preferred for metal binding. 
Secondly, the exocyclic nitrogen should adopt an axial position in the chair conformation.  
 
It is worth noting at this juncture, that this ligand system behaviour is in stark contrast to the 
situation with chelators based on 9-N3; in which the ring is conformationally rigid, with the strain 
already present in the free ligand. As a result, the conformational strain does not oppose metal 
binding, and the ligand is described as being pre-organised for metal complexation.14 Due to the 
inherent characteristics of 7-membered rings, such pre-organization is not possible; however it is 
possible to consider some form of pre-orientation. To promote the rapid formation of a stable 
complex, the free ligand should be in a conformation such that the energy barriers to the desired 
metal bound chair conformation are kept to a minimum. In the case of DAZA, this involves ensuring 
that the exocyclic amine adopts an axial position in the free ligand. 
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The chair-conformer of the ligand which is expected to give rise to stable metal complexes is 
illustrated in Figure 4.4, Ceq, along with its ring inversion product, Cax. The ‘ring-flip’ equilibrium 
between Cax and Ceq is represented by a dashed line to show that conversion between the two takes 
place through one of the lower energy TC-conformations, TCx (Figure 4.3). Which twisted-chair 
conformation is favoured is determined, in part, by the nature of the ring and Nexo-substituents used. 
In turn, this determines which of the chair conformations is of lowest energy. It is important to re-
iterate that in the absence of a metal ion, conformations Cax and Ceq are higher energy transition 
states between different twist-chair conformers. This scheme is meant only to highlight that two 
chair conformations are possible and are related by a ring inversion. In terms of metal complexation, 
Ceq is preferred because it presents a fac-N3 coordination donor set with the N-substituents (e.g. 
acetate groups) held in closer proximity. The arrangement of the N-donors in Cax means that, at best, 
two of the three N-groups could partake in metal binding. It is reasonable to predict that, if the 
formation of Cax (from the free ligand: TCx) is energetically more favourable than Ceq, then metal 
complexation by Ceq will be hindered. Under such conditions, the inherent structural strain within a 
[Mn+(Ceq)
m-]n-m complex (arising from Nexo preferring an equatorial orientation) is expected to have 
negative implications on the stability of the complex. Therefore, it could be hypothesised that, in 
order to promote the desired Ceq conformer in the metal-ligand complex, a ligand TC-conformation 
which has the exocyclic amine either isoclinal or axial is preferred, i.e. TC-conformations represented 
by TC1-4 (Figure 4.3).  
 
In Figure 4.4, TCx represents possible conformations of the seven-membered ring, with the R1 and 
Nexo substituents taking up pseudo-axial, pseudo-equatorial or isoclinal positions. There are seven 
low energy conformations, which exist as energetically equivalent pairs (enantiomers) related by a 
ring puckering (Figure 4.3). The pair of twist chairs that is most stable, and hence favoured, is 
determined by the nature of the substituents R1 and Nexo. The chair conformation most likely to form 
in a metal complex is that which has the lowest energy barrier with the preferred TC-conformer. One 
of the main factors which control the relative sizes of these energy barriers to the higher energy 
chair conformations will be the competition between R1 and Nexo for the equatorial position.  
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Figure 4.4 Shows two possible chair conformations (Ceq and Cax) for metal bound DAZA based ligands. The ring 
inversion equilibrium is shown as a dashed line to indicate that the conversion proceeds via a lower energy 
twisted chair conformer (TCx). Note: Ceq and Cax represent possible conformations of the ligand when bound to 
a metal. The free ligands will invariably adopt one of the lower energy TC conformations.  
 
If Nexo and R
1 had similar steric demands (or A-values: a measure of the steric bulk of a substituent), 
then a relatively flexible ring would ensue with a fairly disperse population of TC-conformers; the 
energy barrier to both chair conformers would be similar. In terms of metal complexation, such a 
situation is not necessarily unfavourable; however, a certain degree of ‘pre-orientation’ is beneficial. 
This is especially true, when it is considered that the N-CH2-CH2-N moiety must adopt an 
unfavourable eclipsed conformation, if the DAZA core is to serve as a tri-dentate ligand. 
  
Simply put, in the absence of other interactions, the substituent with the greater steric demand 
should prefer to adopt the equatorial site. Thus, the chair conformation Ceq in Figure 4.2 will be 
favoured in the situation where R1 has a greater A-value than Nexo, because its formation is of lower 
energy than that of Cax from the twisted-chair conformation. Similarly, when Nexo is considerably 
more sterically demanding, it is expected that the energy barrier from the twisted chair (TCx) to Cax 
will be lower than that to Ceq. The substituent with the greater steric demand will prefer the 
equatorial position in the TC (and hence chair) conformers, and thus a less disperse conformer set is 
expected. In the presence of a more sterically demanding substituent, the conformational rigidity of 
the ring will also be increased.   
 
Hegetschweiler explored suitability of tri-dentate ligands based on the DAZA core for metal ion 
complexation.6, 7 They realised the importance of the orientation of Nexo in terms of complex 
formation and stability, and the possible effects of having this substituent in the ‘wrong’ (equatorial) 
orientation. They attempted to promote the more favourable axial orientation of the exocyclic 
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amine, with the aim of improving the metal binding ability of the tri-dentate ligand. Previous 
research involving TACH, showed that the ‘wrong’ (or unfavourable) equatorial orientation of the 
amine substituents could be changed by introduction of strategically placed methyl ring substituents 
(Figure 4.5).15-17  The methyl groups of Me3TACH promoted the axial orientation of the amine ring 
substituents (Figure 4.5).6, 7, 16, 17 
 
 
 
Figure 4.5 Structures of tri-amine ligands TACH
15
 and Me3TACH
16, 17
, showing the preferred orientation of the 
exocyclic amines at pH > 3. The axial arrangement of the amines in Me3TACH, is more conducive to metal 
complexation, and forms a more stable complex. 
 
Similarly, addition of a methyl substituent at the 1-position of DAZA (to give AMPED) might promote 
an axial orientation of Nexo, and as a result improve the metal binding ability of the ligand.
6 
Hegetschweiler’s results indicated that although this modification was beneficial, there was only a 
small gain in the stability of AMPED complexes compared to the DAZA analogues.6 Whilst the ligands 
described in this thesis are considerably different, in that they are hexa- and hepta-denate, they 
possess the same DAZA core as those described by Hegetschweiler. Thus, it was expected that 
similar principles would apply. Of course, the oxygen donors of the ligands reported here will assist 
with metal ion complexation, perhaps making the formation of metal-ligand complexes more 
favourable. Indeed, the results presented in Chapter 2 and 3 suggest that this is the case.  
 
1.2 Influence of pH on Radiolabelling and Radiolabelled Complex Speciation 
 
At low pH (< 3.5) the rate of labelling of the AMPED ligands deteriorated significantly, and in all cases 
the stability of the radiolabelled complexes was compromised. Obviously, deprotonation must 
precede formation of the M―N bond, and low pH slows complexation down as the proportion of the 
free amine decreases. However, there is a further factor relating to the relative steric bulk of R1 and 
Nexo which should also be considered. According to the pKa curve for methylated triacid AMPED 
ligand L2 (Chapter 2 Section 2), deprotonation of the exocyclic amine starts at pH ~ 4 and the 
equilibrium between the mono- and di-protonated ligand species is controlled by a pKa of 5.7 (± 0.1). 
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When protonated, the A-value for the Nexo-substituent will increase from about 6 to 10 kJ/mol, in 
polar media, as the protonated N-H group can serve as a good H-bond donor to water molecules, 
increasing the local solvation shell.18 
 
For ligands based on the AMPED core, at pH > 4 the R1 (methyl) and Nexo (NRXRY) substituents can be 
considered to have comparable A-values of 7 and 6 kJ/mol respectively.18 Thus each complex 
conformer is likely to be populated significantly as they have comparable energies in their chair 
conformations. 
 
The forward rate of radiolabelling and the subsequent radiolabelled complex stability observed at 
pH ≥ 4 are relatively high, whilst at pH < 3.5, both the rate of radio-labelling and the stability 
diminish significantly. Under these conditions Nexo becomes completely protonated and its A-value 
can be estimated to increase to 10 kJ/mol.18 As a result, the desired chair conformation is no longer 
that of lowest energy. The ligand may still bind the metal in the Ceq conformation; however this 
would be in competition a lower energy Cax conformation. This internal conflict, between the 
favoured conformation required by the metal (i.e. that conformation which allows for fast 
radiolabelling and the formation of stable complexes) and the lower energy conformation of the 
ligand, may have a negative impact on the stability of the complex formed, complex speciation and 
rate of ligand radiolabelling. 
 
The relative population of the two conformers can be estimated using the Boltzmann population 
distribution equation – (1). 
 
  
  
   (
  
  
)
 (1) 
 
kT298K ~ 2.5 kJ/mol and ΔEpH < 3.5 ~ - 4 kJ/mol  
 
      
      
    for pH < 3.5  
 
It is evident that the larger A-value of the Nexo substituent results in a significant preference for the 
less favoured conformer (Ceq). The A-values of the quaternary carbon substituents are not 
significantly different, and as a consequence the conformers are expected to have similar energies.  
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However, the rate of exchange between complex conformers Ceq-Cax is controlled by an energy 
barrier, which must be crossed in order for the conformers to interchange. The size of the energy 
barrier is of upmost importance. A small energy barrier would allow for rapid interconversion of 
conformers and thus formation of the more favoured Ceq radiolabelled complex species would be 
disfavoured, i.e. complexation in the favoured ligand conformation would be able to rapid 
interconvert to the more favourable ligand conformation which has Nexo axially orientated. If the 
barrier to interconversion is large then the complex is essentially kinetically trapped with the bound 
ligand in the Cax conformation, which prevents interconversion/rearrangement to the desired Cax 
complex species.  
 
At low pH (< 3.5) the ligands are present exclusively as the diprotonated species, with a proton on 
the exocyclic amine and the other forming a bifurcated hydrogen bond across the endocyclic amines. 
In this form, the ligand can be considered to approximate a metal complex of the ligand in the Ceq 
conformation. Specifically, the bifurcated proton mimics/models the presence of a metal ion by 
restricting motion in the region of the ethylene diamine bridge (N-CH2-CH2-N). 
 
The energy barrier to Cax-Ceq complex interconversion can be approximated using dynamic variable 
temperature 1H NMR studies of ligand L2 at pH < 3.5, and these have been performed over the 
temperature range 298 – 358 K (See Figure 4.6). 
 
The exchange between ligand conformers in which the substituents of the quaternary carbon 
exchange orientations is expected to proceed via a ‘ring inversion’. This hinges about the C2 and C7 
carbon atoms, i.e. inversion of the position C2-C1-C7 fragment of the ring (Atom labelling scheme on 
Figure 4.7). Consistent with this axial-equatorial exchange of the quaternary carbon substituents, the 
diastereotopic protons of C2 and C7 also exchange orientations (Figure 4.7). The diastereotopic 
protons at C2 and C7 form a AAᶦBBᶦ-doublet (Figure 4.6) at room temperature. As the temperature of 
a solution of the ligand is increased the rate of conformer exchange increases, and eventually a high 
energy transition state is achieved between the lower energy conformers. At this point, the two 
conformers are in rapid exchange on the NMR timescale, and as a result the protons of C2 and C7 are 
also rapidly exchanging orientations. This is manifested as a coalescence of the AAᶦBBᶦ-doublet, and 
is an approximation of the energy required for ring-inversion, leading to conformer exchange (Figure 
4.7).  
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Figure 4.6 
1
H NMR spectra (D2O, 600 MHz, pH 2.0) of L
2
, recorded at 5 K intervals from 298 to 358 K. The peaks 
of interest are labelled 
 
 
 
 
 
Figure 4.7 Shows the atom labelling scheme to accompany the discussion of the VT 
1
H NMR. The two 
conformers shown are in fast exchange above 358 K. 
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The energy and rate of coalescence (conformer exchange) can be estimated using equation (2) and 
(3): 
 
    
 
 
 (        
 )  (2) 
              (
  
  
)   (3) 
 
Where:  kc = rate constant for coalescence (sec
-1) 
  Tc = temperature at which coalescence occurs (K) 
  Δν = limiting separation of the of the AAᶦBBᶦ-doublets (Hz) 
  JAB = coupling constant (Hz) 
  ΔGc = Gibbs free energy of coalescence (kJ.mol
-1) 
 
Close examination of the 1H NMR spectra recorded at 358 K reveals the presence of small satellites 
on either side of the signal at 3.4 ppm. These indicate that the AAᶦBBᶦ-doublet had not yet coalesced 
before the temperature limit of the solvent was reached. There are only very small changes in Δν (84 
Hz at 298 K) and JAB (-16 Hz at 298 K) between 298 and 308 K suggesting that, to a good 
approximation, the values at 298 K represent the limiting values. Values for the Gibbs free energy of 
activation and rate constant for coalescence were approximated using equations (1) and (2) to give 
kc > 146 sec
-1 and ΔGc > 73 kJ.mol
-1 respectively.  
 
The energy barrier to conformer exchange (> 73 kJ.mol-1) is relatively large, and rate of exchange 
between them (146 sec-1) slow. The consequence of this is that the formation of a radiolabelled 
complex with the ligand in this less favourable conformation, Cax, is kinetically trapped despite the 
fact that the radiolabelled complex species is less stable, i.e. once complexed a significant energy 
input is required in order for the ligand to assume the preferred conformation. Furthermore, in 
order to obtain the desired radiolabelled complex directly, a significant energy input will be needed 
during radiolabelling. This is consistent with the observation that speciation (and hence resulting 
stability) did not change with increasing radiolabelling temperature and time, and once complete 
there was no observable exchange between the different species.  
 
The presence of related ligand conformers has been observed for the tri-dentate ligand Me3TACH. At 
high pH (~12) the amine ring substituents are all axially arranged, and thus pre-orientated for 
efficient and stable tri-dentate metal complexation.6 As the pH is lowered to pH ~ 3, each of the 
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nitrogen atoms is protonated, which increases the steric bulk (A-value) of the substituents.6, 7, 16 The 
Coulombic repulsion force also favours their equatorial reference. As a result, the ring adopts a 
conformation in which the amine substituents prefer sterically less demanding equatorial positions, 
which is an unfavourable arrangement for metal complexation.6 
 
Whether the instability of complexes, slower radiolabelling rates and poor radiolabelling yields 
resulting from complexation with ligands preferring Cax over Ceq arises from the formation of a 
complex in this conformation, or from the steric strain placed on the structure when it rearranges to 
Ceq (to facilitate metal complexation), is unknown. The fact that we frequently observe two 
distinguishable spots on the radio-TLC, suggests that the former is the case. In the Cax conformation, 
we predict that the chelator shows ‘EDDA-like’ (EDDA = ethylenediamine-diacetic acid) complexation 
of Ga(III), in which N-acetate and endocyclic amines are involved in complexation of the metal 
(Figure 4.8). Alternatively, it is possible that ‘EDDA-like’ complexation involves the exocyclic amine, 
an endocyclic amine and their acetate groups. Bi-dentate coordination of the AMPED ligand has 
been observed for [Cu(H-AMPED)Br3], where the free endocyclic amine assumes a more favourable 
non-eclipsed orientation with respect to the coordinated endocyclic amine.6 In either case, this 
would account for the poor stability of the complexes formed at low pH, as well as the multiple 
radiolabelled species observed. This behaviour is also consistent with the finding that it was not 
possible to alter the speciation of a formed radiolabel by increasing the pH or temperature. i.e. once 
a given complex has formed from either Ceq or Cax, conversion to the other conformer would have to 
proceed via a high energy process (the complex species are kinetically trapped). In order for this to 
occur, de-metallation would have to occur first.  
 
 
 
Figure 4.8 Shows the proposed structures of the constitutional isomeric species formed during complexation of 
68
Ga at pH < 3.5. The energy barrier to exchange between the species is large, and the rate of interconversion 
slow. At pH < 3.5 this equilibrium is predicted to be biased to the right. 
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Turning our attention now to the kinetics and stability of the APPED based ligands, certain 
differences in behaviour were observed. The decline in the rate of labelling for pH 2.3, was similar to 
that observed for AMPED based ligands. In contrast, the radiolabelled complexes formed with 
APPED-derived ligands at pH 2.3 were more stable than their AMPED analogues and showed 
improved rates of radiolabelling. The increase in stability is associated with the formation of more of 
the stable radiolabelled complex species. 
 
The differing steric demand of the quaternary carbon substituents can be used to rationalise the 
results obtained from the radiolabelling and stability experiments, of APPED and AMPED based 
ligands. The phenyl moiety has an A-value (12 kJ/mol) that is greater than that of a protonated Nexo 
(~10 kJ/mol).18 Therefore, the population of the favoured conformer, Ceq, is expected to be greater 
for APPED than AMPED under the same conditions. As a result, more of the desired radiolabelled 
complex species is formed, giving rise to an overall greater stability. The ‘EDDA’-like complexation 
(Figure 4.8) is expected to have a slower rate of formation than the desired hexadentate 
complexation. The phenyl group increases the likelihood for formation of the hexadentate complex, 
and therefore the APPED based ligands radiolabel more quickly than the AMPED based ligands at pH 
2.3. This is also the reason why the APPED based ligands have a better stability profile.  
 
It is evident that the relative steric bulk of quaternary substituents define the preferred ring 
conformation, and play vital roles in determining the stability of the complex formed, as the 
complexation of gallium is essentially irreversible. For ligands based on the DAZA core (such as 
AMPED and APPED based ligands) the radiolabelling pH also plays an important role in determining 
the stability of the complex formed. 
 
2 Crystallographic and 1H NMR Spectroscopic Analysis  
 
Information regarding the conformation of the ring and relative orientations of the quaternary 
carbon substituents can be extracted from solid state single crystal structures and solution state 
NMR spectroscopy. In this section, these two techniques are used to investigate what effect 
introduction of a phenyl group has had on the ring conformation and relative orientations of the 
quaternary carbon substituents, by comparing AMPED and APPED based analogues.  
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2.1 Solid State Structure analysis 
 
Two crystal structures of derivatives featuring the APPED core were obtained, along with a crystal 
structure of a compound featuring the AMPED core. Specifically, they relate to the protected tertiary 
nitro compounds (1 and 22) and the di-Nendo-t butyl acetate ester compound (12). In addition, a 
crystal structure of compound featuring the APPED core modified by the substitution of the Nexo for 
a hydroxyl group (40) was obtained.  
 
Crystals suitable for single crystal X-ray diffraction were grown by slow evaporation from 
dichloromethane : ethanol (1 : 1) solutions, and the diffraction patterns obtained at 120 K. A 
diagrammatic representation of each structure is shown in Figure 4.9. The core structures are shown 
in Figure 4.10, with the endocyclic N-substituents and hydrogen atoms removed for clarity. 
 
 
 
Figure 4.9 Diagrammatic representations of ligand intermediates, 1, 22, 24 and 40, for which single crystal 
structures have been determined. The single crystal structure of 24 displayed disorder in the positions of the 
methyl substituents of the t-butyl groups. Carbon atoms of the rings, relevant to the discussion, are labelled 
and applicable to all. 
 
Of particular interest is a comparison of the conformation of the 7-membered rings with specific 
reference to the relative positioning of the quaternary ring carbon substituent. A comparison 
between compounds 1 and 22 is most useful because it considers the effect of introducing the 
phenyl ring. A similar comparison between crystal structures of compounds 24 and 40 is of less 
interest here, but may provide insight into the effect of varying the size of the ‘other’ quaternary 
carbon substituent.   
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The views shown in Figure 4.10(1) are taken along a line drawn from C1 to the middle of the C4-C5 
bond, and highlight the twisted chair conformation of the 7 membered ring, and the positioning of 
the quaternary ring carbon as the isoclinal centre. This is the conformation depicted by TC4 (Figure 
4.3). Also shown is a view along the C4-C5 bond and parallel to a plane passing through C4, C5 and C1, 
which illustrates the isoclinal orientation of the C1-substituents and torsion of the N-CH2-CH2-N 
fragment (Figure 4.10(2)). In each case, the compounds crystallized as a pair of enantiomers, related 
through a puckering of the ring (See Figure 4.10(3) for an illustration). 
 
The angles θ1 and θ2 denote the deviation of the non-carbon (nitro or hydroxyl) and carbon 
substituent from the mean plane of the ring (calculated using all of the atoms of the 7-membered 
ring) respectively, and φ denotes the torsion about the N3-C4-C5-N5 fragment (See Figure 4.9 for 
atom labelling). The important data is summarised in Table 4.1, along with other relevant examples 
from the literature. Also included are the relevant A-values (kJ.mol-1) of the quaternary carbon 
substituents.   
 
Table 4.1 Synopsis of the structural parameters relating to the ring conformation for 1, 22, 24 and 40 (this 
work). Structural parameters of two, triply protonated salts of AMPED are also shown.
6
 
 
 1
a
 22
a
 24
a
 40
a
 H3AMPED
 a,6
 H3AMPED
 b,6
 
θ1(°)
c
 49.3 56.9 57.6 54.7 46.2 31.4 
θ2(°)
c
 47.6 43.4 41.9 43.8 56.3 90 
φ(°)
d
 53.2 54.8 56.4 51.0 60.6 42.1 
A-values
18
 
(kJ/mol) 
Me: 7 
NO2: 5 
Ph: 12 
NO2: 5 
Ph: 12 
NO2: 5 
Ph: 12 
OH: 3-4 
Me: 7 
NH3
+
: 7-9 
Me: 7 
NH3
+
: 7–9 
a
Structure adopts conformation TC4 in which the C1 is the isoclinal centre. 
b
 structure adopts conformation TC7, in which the 
Nexo takes up an equatorial orientation. 
c
θ1 and θ2 are the deviations of the, non-carbon and carbon respectively, quaternary 
carbon substituents from the mean plane of the ring. Mean plane calculated using all of the atoms of the 7-membered ring. 
d
φ denotes the torsion about the N3-C4-C5-N5 fragment. Atom labelling scheme on Figure 4.9. 
 
The most ‘relaxed’ (or favoured) arrangement of the N-CH2-CH2-N fragment has a torsion angle of 
60°, and as expected the values for φ are not very different.6, 7 It is interesting to note that the 
largest and smallest variations from this geometry are found for 24 and 40, whilst the structurally 
similar compounds 1 and 22 are intermediary, and have similar values.  
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All θ1 and θ2 angles are greater than 30° but smaller than 60° consistent with their isoclinal 
assignment.2 Although isoclinally positioned, a comparison of the respective θ1 and θ2 angles of 1 
and 22 is useful. In 1, the values of θ1 and θ2 are comparable, as would be expected from the similar 
steric bulk of the substituents of an isoclinal centre. However, in 22 the values of θ1 and θ2 indicate 
that the introduction has resulted in a shift (~ 8°) of the exocyclic nitrogen to a more pseudo-axial 
position, accompanied by a shift (~ 4°) of the other substituent to a more pseudo-equatorial 
positioning. The change is such that the exocyclic nitrogen is very close to the border (60° with 
respect to the mean plane of the ring) between an axial and isoclinal substituent. 
 
Consistent with the greater A-value difference between the phenyl-methyl group change (ΔA ~ 5 
kJ.mol-1), compared to the nitro-hydroxyl group change (ΔA ~ 1 kJ.mol-1), the changes in the relative 
θ1 and θ2 values are bigger between 1 and 22 compared to 24 and 40. It is noteworthy that the 24 
and 40 displays the opposite trend. Decreasing steric demand of one of the substituents results in it 
adopting a less axial orientation, i.e. in going from nitro to hydroxyl the A-value decreases slightly, 
but the hydroxyl group takes up a less axial orientation.  This may be due to a ‘secondary’ influence. 
There is an intermolecular short contact between the hydroxyl group proton and the carbonyl 
oxygen of one of the ester arms. The O-H•••O distance of 2.685 Å is within range for moderate, 
mostly electrostatic, hydrogen bond.19 It is possible that this interaction may alter the location of the 
hydroxyl group, to produce the unexpected trend. Furthermore, it is also possible that this 
interaction play a role in defining the smaller torsion angle (φ = 51.0°) observed for 40, compared to 
the other structures.  
 
The phenyl group in 40 is less rotated (4.10°) with respect to the other C1-substituent, compared to 
22 and 24 (31.3°and 27.8°respectively). This is possibly a result of the larger π-electron cloud present 
with the nitro group, causing electronic repulsion with the π-electron cloud of the phenyl moiety.  
 
The changes, upon phenyl insertion, outlined in this section reflect the larger steric demand of the 
phenyl group. This is also seen in their respective A-values, were the difference between the 
endocyclic substituents is greater for 22 (Ph vs NO2) than for that of 1 (Me vs NO2). It should be 
emphasised that observations in the solid state are not necessarily applicable in solution. 
Furthermore, a di-functionalised amine will have a larger A-value (7-10 kJ/mol, depending on its 
protonation state and solvent) than that of a nitro group, and hence these observations are not 
necessarily true for the ligands used for metal ion complexation. This can be demonstrated by a 
comparison of the θ1 and θ2 values of 1 and H3AMPED
a.6 Consistent with the protonated exocyclic 
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nitrogen of H3AMPED
a having a greater A-value than that of the nitro substituent of 1; the exocyclic 
nitrogen of 1 adopts a more axial orientation (~3° further from the ring plane) whilst the methyl 
substituent takes up a more equatorial orientation (~9° closer to the ring plane) in comparison to 
H3AMPED
a. In the case of H3AMPED
b this effect is even more profound, with the exocyclic amine 
adopting an equatorial orientation.6 
 
2.2 Solution state NMR studies  
 
Information concerning the relative spatial orientations of the ligand protons can be gained from 1H 
NMR NOESY experiments. In this section the ester precursors, rather than the ligands themselves, 
were analysed and compared in detail because the 1H NMR NOESY experiments of the APPED based 
ligands in D2O were poorly resolved. However, 
1H NMR NOESY experiments on the ligand precursors 
(esterified ligands) were considerably better defined. Critically, the splitting pattern of the ring 
protons was the same for the ester precursors and the free ligands (Figure 4.11). This suggests that 
the conformation of the ring is similar, and a discussion of the nOe correlations of the ligand 
precursors is of relevance. 
 
 
 
Figure 4.11
 1
H NMR spectra (700 MHz) of ligand L
2
 and its 
t
Butyl-protected precursor, 3, showing the 
commonality of the spectral features.  
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Well resolved 2D NOESY NMR spectra were obtained for ligand L2 in D2O. Before addressing the 
NOESY experiments of the ligand precursors, this experiment is discussed in isolation. 
 
2.2.1 1H and 2D NOESY NMR Spectra of L2 
 
Invariably, for this and related compounds, two first order doublets were observed for the 
methylene groups at C2 and C7. See Figure 4.11 for atom labelling scheme and 1H NMR spectrum. 
The splitting arises from geminal-coupling with 2J = -16Hz. It was confirmed by 1H NMR COSY 
correlations that each doublet is mutually coupled (Figure 4.11). The two protons which make up a 
doublet have the same orientations with respect to the ring, i.e. both axial or both equatorial. It is 
possible to assign the axial and equatorial orientation of the ring protons (H2 and H7) using 1H NMR 
NOESY spectroscopy by making two key assumptions. Firstly, at low pH (~ 2.0) it is expected that the 
Nexo substituent with adopt a more equatorial orientation. Secondly, the strongest nOe correlation 
between H2&7 and quaternary methyl corresponds to a proton on C2&7 with the same orientation, 
because these will be nearest each other. The methyl group (H1ᶦ) shows a stronger nOe correlation to 
the lower frequency H2,7 resonance, which is therefore assigned to an axial orientation. Consistent 
with this; the N-methyl (H14) and N-CH2 (H
12) only correlate to the higher frequency H2,7 resonance, 
which is therefore assigned to an equatorial orientation (Figure 4.12).  
 
It was hypothesised previously, that at pH > 3.5 the exocyclic amine changes orientation (becomes 
axially orientated), as a result of a decreased A-value when it is deprotonated (pKa ~ 5.7). Consistent 
with this is that; when the NOESY NMR experiment is repeated at pH 5 there is a significant change 
in the nOe correlations which are observed. Most importantly, the nOe correlations of H1ᶦ, H14 and 
H12 with H2,7 are reversed. At pH 5 the quaternary methyl (H1ᶦ) is closer to the equatorial (H2eq,7eq) 
protons, and the N-methyl (H14) and N-CH2 (H
12) only show an nOe correlation with axial (H2ax,7ax) 
proton resonance. This strongly suggests that there is a change in the relative position of the 
quaternary carbon substituents associated with de/protonation of the exocyclic amine. The 1H NMR 
spectrum recorded at pH 5 has broader proton peaks (than that measured at pH ~2), which may 
indicate that there is a rapid exchange (on an NMR time-scale) between different conformations of 
the ligand. Rapid exchange between conformations reflects a lowered energy barrier to 
interconversion, which is consistent with the exocyclic amine having a lower A-value when 
deprotonated. 
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Figure 4.12 2D NOESY-NMR (700 MHz, D20, 298.1 K, pH 2.0) spectra of L
2
 with the nOe correlations of interest 
highlighted, illustrating assignment of the orientation for protons attached to C
2
 and C
7
. 
 
2.2.2 1H and 2D NOESY NMR Spectra of Ligand Precursors 
 
1H NMR NOESY experiments again provided information of the mutual spatial orientation of protons. 
Although the absence of a correlation is not confirmation that two protons are not close in space, 
this technique can provide some insight into the relative positioning of the ring substituents. Of 
particular interest were the correlations that existed between protons attached to C2 and C7 with 
respect to protons at R1 (Hb) and Nexo (Ha) (Figure 4.13). By analysing which correlations occur, and 
their relative strength, it was possible to make tentative inferences about the relative positions of 
the quaternary carbon substituents relative to the ring.  
 
DAZA based compounds which have additional stereogenic centres on the N-substituents (for 
example 10 and 36. Figure 4.14), will have increased asymmetry as a result. This means that protons 
H2ax, H2eq, H7ax and H7eq were diastereotopic and anisochronous. This allows for more intricate 
evaluation of the 1H NMR and NOESY spectra.  Furthermore, 10 and 36 only differ structurally in the 
nature of the group at the R1-position and so offered a good comparison. Therefore, these two 
ligand precursors were chosen for the comparison (Figure 4.14). 
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Figure 4.13 A representative TC-conformations for ligand precursors 10 and 36. (NOESY correlation of the 
protons shown provides useful information about the rigidity of the system. The structures have been drawn 
such that the quaternary carbon is located on the isoclinal centre, i.e. TC4. This is not necessarily the case, and 
the diagram is meant purely for illustrative purposes from which the orientation of the quaternary carbon 
substituents can be discussed.  
 
 
 
 
Figure 4.14 Shows the structures of protected ligands 10 and 36. Highlighted are the protons of interest for the 
NOESY experiments. Note that the chair conformation is only used for structure illustration, and does not imply 
a chair-like conformation in the solid state or solution. 
 
 
Of particular interest, were nOe correlations between Ha and H
2/7, and, Hb and H
2/7 (Figure 4.14). 
Looking first at 10, six nOe-correlations were observed between this set of protons (Figure 4.15). 
Table 4.2 shows the ratio of these six correlations, determined by integration of the nOe correlation 
enhancement signal.  
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Table 4.2 Shows the 
1
H NMR NOESY correlations and integration, of compound 10, for protons attached to C
2 
and C
7
, with protons of the quaternary carbon substituents (Ha and Hb). The superscript ‘*’ distinguishes 
different protons attached to the same carbon atom.  
 
NOESY correlation Value (relative nOe enhancement) 
Hb-H
2*
 39 
Hb-H
7
 27 
Ha-H
2
 21 
Ha-H
7*
 11 
Hb-H
2
 and Hb-H
7*
 2 
 
Specifically, nOe correlations were observed between Ha and one H
2 and H7 proton. In terms of the 
Hb proton, there were correlations to the protons on C
7 and C2 which do not correlate to Ha. The 
correlations of Ha were stronger than those of Hb. However, these are not strictly relevant because; 
there are three Hb protons and only a single Ha proton, and the two protons (Ha and Hb) differ in their 
position with respect to the quaternary carbon. 
 
A view looking down C1, onto the centre of the N-CH2-CH2-N bridge, is useful in understanding these 
correlations (Figure 4.16). From the diagram it is evident that Hb lies close in space to one of the axial 
protons, but not the other. Similarly, it is also evident that Hb lies close in space to one of the 
equatorial protons, but not the other. The equatorial and axial protons (H2/7) it lies close to are 
attached to different carbons. A similar observation is made for Ha, but it is closer to the axial and 
equatorial protons which are furthest away for Ha. These observations have been confirmed by 
determining approximate Hb-H
2/7 and Ha-H
2/7 through space distances in the crystal structure of 1. 
Specifically, the distances were measured from the nitro-group nitrogen (estimation of Ha) and first 
carbon atom of R1 (estimation of Hb) to the protons of C
2 and C7. The measurements indicated that, 
out of the four protons, the nitro-nitrogen to closest to one axial and one equatorial on different 
carbons, whilst the other substituent is closer to the other two protons. 
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Figure 4.16 Twist-chair conformer of an AMPED based ligand precursor illustrating the observed nOe 
correlations (dashed lines). Also shown is the crystal structure of 1, for comparison. The proton Ha refers to a 
proton in the Nexo-substituent. Amine substituents removed or simplified, and protons not of interest here have 
been removed. 
 
To summarise, Hb has through space interactions to an axial orientated proton on one carbon, and 
an equatorially orientated proton on the other. The same is observed for Ha, but for the opposing ax-
eq set of protons. 
 
If we now turn out attention to similar NOESY correlations for 36, a very different result was found 
(Figure 4.17). Table 4.3 shows the relative ratios for the NOESY correlations observed between Hb 
and H2/7, and Ha and H
2/7. 
 
Table 4.3 Shows the NOESY correlations and relative integration, of compound 36, for protons attached to C
2
 
and C
7
, with protons of the quaternary carbon substituents (Ha and Hb). The subscript ‘*’ distinguishes different 
protons attached to the same carbon atom. 
 
NOESY correlation Value (relative nOe enhancement) 
Ha-H
7* 
 4 
Hb-H
2* 
and Hb-H
7*
 31
a
 
Hb-H
2
  23 
Hb-H
7
  36 
It should be noted that, direct comparison of these correlations with those of 10 is not consistent. The reason being, that Hb is in a different 
position for the two compounds. (See Figure 4.8) Internal comparisons for 36 are more relevant because, Hb and Ha are in very similar 
position relative to the quaternary centre. However, these comparisons are purely qualitative as there are two Hb protons, but only a single 
Ha proton.
a Signals too close to accurately determine individual values 
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There are nOe correlations between Hb and each H
2 and H7 proton, whilst there is only a single very 
weak correlation between Ha and one H
2 proton (Figure 4.17). This behaviour contrasts with what 
was observed for the nOe correlations of 10. The question raised is, “what conformational change, 
induced by the introduction of the phenyl group, allows the Hb (phenyl) to show nOe correlations 
with every proton attached to C2 and C7, yet reduces the number of nOe correlations of Ha (Nexo) to 
one?” It should be taken into account that Hb protons of 36 are expected to be closer to the ring 
than the Hb protons of 10. However, this does not account for the apparent ‘loss’ in correlation 
associated with Ha. 
 
Supported by evidence from crystal structures of 1 and 22, the following hypothesis is tentatively 
offered to explain this behaviour. Introduction of the phenyl group results in a shift of the endocyclic 
nitrogen substituent to a more axial position. As a result, the through-space distance between Ha 
and the nearest Hax and Heq protons increases. In support of this, a larger Nnitro-Hax/eq distance was 
observed for the crystal structure of 22 compared to that of 1. As a consequence, one of the 
distances (most likely that between Ha and the Heq proton of C
2 or C7) is too long to create a 
measureable nOe correlation, and is no longer observed. Accompanying the more axial orientation 
of Nexo, the other substituent takes up a more equatorial orientation. As a result of moving closer to 
the mean plane of the ring, the proton Hb is now closer to all four of the C
2&7 protons and an nOe 
correlation is observed (Figure 4.18). Consistent with this hypothesis, the only correlation observed 
for Ha is to the proton which Hb shows the weakest correlation to. 
 
N
N
Nexo
Heq
Hax
Hax
Heq
Ha
Hb Hb
 
 
Chapter 4: Conformational Analysis of the Ring, and ‘Cold’ Gallium(III) Complexes 
 
 
 
Page 135 
 
  
Figure 4.18 Twist-chair conformer of a PAPED based ligand precursor illustrating the observed nOe correlations 
(dashed lines). Also shown is the crystal structure of 22, for comparison. The proton Ha is in a CH attached to 
Nexo. Amine substituents removed or simplified, and protons not of interest here have been removed. 
 
The most significant feature of this analysis is the decrease in the number of correlations associated 
with Ha, and the increase in the number associated with Hb. In order to make this possible, Hb must 
be closer to, and Ha further from, the plane of the ring. This suggests Nexo adopts the favoured more 
axial site, and the other substituent takes up a more equatorial orientation in APPED- compared to 
AMPED-based compounds.  
 
2.3 Summary 
 
The Gibbs free energy barrier (ΔG#) for interconversion between conformers with Nexo-equatorial 
(Cax) and Nexo-axial (Ceq) is > 73 kJ/mol at pH < 3.5. This suggests that when the rate of metal 
complexation is fast with respect to the rate of interconversion of the isomers, the mixture of 
radiolabelled species observed (i.e. differing in stability and constitution) reflects the relative 
population of ligand conformers. When this conformational equilibrium is biased in favour of a 
major species, that favours cooperative lone pair ligation, a more stable single radiolabelled complex 
is obtained. Comparisons of compounds based on the APPED and AMPED cores, based on single 
crystal structural data and nOe NMR correlations, strongly indicate that introduction of the phenyl 
group promotes the axial orientation of the exocyclic nitrogen substituent. Increased population of 
the desired conformers, accounts for the better radiolabelling of APPED based ligands at pH < 3.5. 
Furthermore, nOe NMR correlations at pH 2.0 and 5.0 for ligand L2 suggest that the desired axial 
orientation of Nexo is preferred as the exocyclic amine becomes deprotonated. This accounts for the 
improved stability of the radiolabelled complexes at pH > 4 and, in part, the quicker radiolabelling.  
 
3 ‘Cold’ Gallium Complexes of [Ga.Ln]  
 
3.1 Single Crystal X-ray Analysis of [Ga.Ln] 
 
In terms of the complexation of ‘cold’ Ga(III), only those ligands deemed suitable following the 
radiochemical evaluations were of interest, i.e. ligands L2, L3, L6 and L8. Low resolution mass spectral 
analysis of these complexations carried out at pH 2.5, revealed formation of the [MLH]+ species, and 
suggested that they were successful. However, attempts to crystallize the complexes were 
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unsuccessful and the 1H NMR spectra in D2O were broad, poorly resolved and could not be 
interpreted.  
 
The radiochemical studies suggested that this may be related to the formation of multiple 
radiolabelled species, which could be avoided by carrying out the complexation at pH ≥ 4. However, 
complexations at pH > 3.6 require the use of a suitable buffer to prevent formation of the insoluble 
Ga(OH)3. The disadvantage of this approach is that the addition of a buffer introduces ‘impurities’, 
which may hinder crystallization of the complexes. Instead, a reaction mixture containing equimolar 
amounts of Ga(NO3)3 and the ligand in water : methanol (2 : 1, 1.5 mL) was prepared, and the pH of 
the solution adjusted to pH ~ 4.5 using aqueous sodium hydroxide (0.1 M). The reaction was heated 
for 1 h at 333 K, and the mixture set aside. The Ga(III) complexes of L2, L3, L6 and L8 crystallised from 
solution as thin plates over the course of 36 h, and were examined by X-ray analysis at 120 K. 
 
3.1.1 Solid State Structures of [Ga.Ln] 
 
The Ga(III) complexes of L2 and L3 crystallize as hemi- and mono-hydrates respectively, whilst those 
of L6 and L8 do not contain any solvent of crystallization in the unit cell. In each complex, the Ga(III) 
ion is coordinated by the N3O3 donor set of the ligand to give charge neutral complexes. Views 
showing the conformation of the 7-membered ring, location of the Ga(III) ion and arrangement of 
the pendant acid arms are shown (Figure 4.19). The lattices of [Ga.L2] and [Ga.L6] contain 
enantiomeric complexes within the unit cell which have opposite ring conformations and helicities of 
the carboxylic pendant arms, either overall Λ or Δ (Table 4.4).  
 
In each complex, two of the pendant arms have the same helicity, whilst the third has the opposite 
sense (Table 4.4). Crystals of [Ga.L6] contain two nearly identical crystallographic independent 
molecules, which only differ significantly in the 15° Λ-twist (i.e., NCCO torsion angle) of one of the 
pendant carboxylic acid arms (Table 4.4). All other structural parameters show less than 5° of 
variation between the two conformers. The enantiomerically pure [Ga.L3] and [Ga.L8] are both 
overall Λ, and have a consistently high degree of N-C-C-O torsion within the pendant arms (Table 
4.4). There is a comparatively small degree of helicity in Λ-[Ga.Ln] (n = 2 and 6), as indicated by the 
smaller N-C-C-O torsion angles.   
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Table 4.4 Torsion angles (°) for the N-C-C-O pendant arms of Λ-[Ga.L
n
] (n = 2, 3, 6, 8). 
 
 Λ-[Ga.L
2
] Λ-[Ga.L
3
] Λ-[Ga.L
6
]a
* 
Λ-[Ga.L
6
]b
* 
Λ-[Ga.L
8
] 
N1-C-C-O1 -15.30 +21.48 +10.53 +6.05 +16.94 
N3-C-C-O5 +10.24 -18.89 -7.63 +8.89 -18.35 
N2-C-C-O3 -24.35 -21.77 -5.77 -20.93 -27.63 
* Subscripts ‘a’ and ‘b’ indicate the two constitutional isomers of [Ga.L6]. 
 
Selected molecular parameters are presented in Table 4.5 for [Ga.Ln] (n = 2, 3, 6 and 8). As indicated 
by the N-Ga-O angles (≠ 180°) and non-parallel O3 and N3 faces, each complex adopts a distorted 
octahedral geometry of the ligand donor atoms around the Ga(III) centre, typical for the 
hexadentate ligand complexes of gallium.20-22 
 
Table 4.5 Selected N-Ga-O angles (°), and the angle formed between the planes of the N3 and O3 donor sets. 
See Figure 4.19 for atom numbering scheme. 
 
 [Ga.L
2
] [Ga.L
3
] [Ga.L
6
]
*
 [Ga.L
8
] 
N3-O3 angle (°) 3.03 3.55 4.24 2.91 
N1-Ga-O3 (°) 157.25 148.73 152.42 146.82 
N2-Ga-O5 (°) 165.16 158.28 161.53 156.20 
N3-Ga-O1 (°) 159.68 155.40 157.84 155.07 
*values are the average of the two crystallographic independent molecules of [Ga.L6]. 
 
The octahedral distortion parameter (Σ) and the average trigonal distortion angle (Θ) illustrate the 
degree of distortion from an ideal octahedron, and are shown for [Ga.Ln] (n = 2, 3, 6 and 8) 
compared to [Ga.NOTA] in Table 4.6. 
 
Table 4.6 Octahedral distortion parameter (Σ) and the average trigonal distortion angle (Θ) for [Ga.L
n
] (n = 2, 3, 
6, 8) and [Ga.NOTA]
23
. 
 
 [Ga.L
2
] [Ga.L
3
] [Ga.L
6
]
*
 [Ga.L
8
] [Ga.NOTA]
23
 
Σ
a
 9.27 8.72 10.3 11.8 6.26 
Θ
b
 10.7 16.9 13.8 13.6 6.45 
 
* values from one of the two crystallographic independent molecules of [Ga.L6] is provided. a Octahedral distortion parameter Σ = Σ(|90–
φi|)/12 [Σ = 0° for an ideal octahedron; φi represents the 12 smallest L–M–L angles.]24; b Average trigonal distortion angle Θ = Σ(|60– i|)/24 
[Θ = 0° for an ideal octahedron; i represents the trigonal angles of the eight faces of the octahedron].25 
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The parameters indicate that the geometry around the Ga(III) in the NOTA complex is less distorted 
octahedron than that of [Ga.Ln]. This may be a consequence of the non-uniform N3 donor set of the 
7-membered ring, and its lower symmetry of the ring relative to that of 9-N3. 
 
In general, the Ga-Nendo bonds are slightly longer for [Ga.L
n] than for [Ga.NOTA]23 by ~ 0.04 Å, whilst 
the average Ga-O distance is approximately the same (±0.01 Å). For [Ga.Ln] complexes, the Nexo-Ga 
distance is shorter than both the Nendo-Ga distances, which are comparable (Table 4.7). This is a 
feature consistently observed for metal complexes featuring a tridentate bound DAZA core, and is 
believed to reflect the flexibility associated with the exocyclic nitrogen group.6, 7, 26 The Ga-N bond 
distances are considerably elongated compared to the M-O bonds, consistent with the difference in 
donor-acceptor strength of the Ga-N and Ga-O bonds (Table 4.7). There is significant variation in the 
Ga-O bond lengths which is likely to be a consequence of a number of factors, including the 
asymmetry of the ring (Figure 4.19(iii)). 
 
Table 4.7 Selected bond distances (Å) for [Ga.L
n
] (n = 2, 3, 6, 8) relating to the coordination sphere of the 
complex. Estimated standard deviation’s in brackets. See Figure 4.19 for atom labelling scheme. 
 
 [Ga.L
2
] [Ga.L
3
] [Ga.L
6
]
*
 [Ga.L
8
] 
Ga-O1  1.939 (2) 1.967 (1) 1.948 (4) 1.969 (3) 
Ga-O3 1.904 (2) 1.895 (2) 1.907 (4) 1.888 (3) 
Ga-O5 1.933 (2) 1.934 (2) 1.917 (4) 1.925 (3) 
Ga-N1 2.140 (2) 2.158 (2) 2.136 (4) 2.115 (3) 
Ga-N2 2.138 (2) 2.150 (2) 2.142 (5) 2.204 (3) 
Ga-N3 2.111 (2) 2.075 (2) 2.110 (4) 2.107 (3) 
*values are the average of the two crystallographic independent molecules of [Ga.L6]. 
 
The only examples in the literature of complexes featuring a carboxylic acid functionalised DAZA 
ligand incorporate lanthanide metal ions.9, 26 These complexes all crystallize as dimeric complexes, a 
consequence of the constrained environment of the DAZA core whose ‘bite-size’ is too small to 
encapsulate the lanthanide ion; and as a result the “face of the metal” is exposed.9, 26 This is 
illustrated by the difference in distances of the of the lanthanide ion from the planes of the N3 and 
O4 donor sets in [Gd.AAZTA] (Table 4.8).
9 The Ga(III) ion is considerably smaller in size, and as a result 
a better fit for the ‘bite’ of the ligands, with more comparable distances between the metal centre 
and N3 and O3 planes (Table 4.8).  
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Table 4.8 Distances (Å) between the metal ion and the mean plane of the N and O donor sets. 
 
 [Ga.L
2
] [Ga.L
3
] [Ga.L
6
]
*
 [Ga.L
8
] [Ga.NOTA]
23
 [Gd.AAZTA]
9
 
M-Oplane (Å) 0.984 1.071 1.028 1.058 1.019 0.132 
M-Nplane (Å) 1.404 1.425 1.423 1.437 1.335 2.091 
*values are the average of the two crystallographic independent molecules of [Ga.L6]. 
 
A comparison of the distances in Table 4.8 for the [Ga.Ln] complexes reveals some variation in the 
positioning of the Ga(III) ion relative to the N3 and O3 donor sets. It is interesting to note that 
although the Ga(III) ion lies closer to the N3 donor set in [Ga.NOTA], it is better encapsulated by the 
ligands in [Ga.L3] and [Ga.L6]. This is not the case for [Ga.L2] where the Ga(III) ion is slightly closer to 
the O3 plane, and further from the N3 plane, compared to [Ga.NOTA]. It is noteworthy that there is a 
considerabley greater degree of rotation of the phenyl group, relative the C-Nexo substituent, for 
[Ga.L8] (68.0°) compared to [Ga.L3] (16.7°). This is likely to be a result of the methyl group of the 
propionic acid pendant arm, which points in the same general direction as the phenyl substituent 
(Figure 4.19(III)).  
 
3.1.2 Conformation of the 7-Membered Ring 
 
It was expected that tridentate binding of the nitrogens in the DAZA core requires a near perfect 
chair conformation (Figure 4.20). Indeed, the vast majority of metal complexes involving tridentate 
DAZA show less than a 2° deviation from the perfectly eclipsed arrangement of the N-CH2-CH2-N 
fragment, which is characteristic of the chair conformation.6-9, 11-13, 26, 27 In Figure 4.20 representative 
examples of complexes containing the DAZA core in the chair conformation are shown. Also 
characteristic of the chair conformation is that the torsion angles are approximately equal in size and 
opposite in sign at symmetry related sites of the ring (Table 4.9).  
 
 
Figure 4.20 Selected examples, and the conformation adopted by the ring of bound DAZA ligands and the 
AAZTA free ligand.
6, 9, 26
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The gadolinium(III) and europium(III) complexes of the AAZTA-EtOH26 ligand adopt a conformation 
with a N-CH2-CH2-N torsion angle of -28.17°, which is similar to that of the [Ga.L
n] complexes 
reported here (Table 4.9). The conformation of the 7 membered ring has been described as a 
pseudo-chair, however the torsion angles (and side-on view: Figure 4.20) suggest that the ring 
conformation is closer to that of the twisted-chair (TC) adopted by the free ligand AAZTA9 (Table 
4.9). 
 
Table 4.9 Torsion angles (°) for the seven membered rings of Λ-[Ga.L
n
] (n = 2, 3, 6, 8 ) and relevant literature 
examples. See Figure 4.19 for atom labelling scheme. 
 
Bond torsion Λ-[Ga.L
2
] Λ-[Ga.L
3
] Λ-[Ga.L
6
]
*
 Λ-[Ga.L
8
] Eu(AAZTA-OH)
26
 AAZTA
a
,
9 
[Eu.AAZTA]
b,9 
N1-C1-C2-N2 (°) 25.65 29.12 29.03 24.81 -28.17 -45.25 -2.95 
C1-C2-N2-C3 (°) -58.76 -56.92 -57.96 -58.51 58.43 40.26 76.97 
C2-N2-C3-C4 (°) 103.20 101.86 101.38 101.65 -100.77 -96.37 -91.55 
N2-C3-C4-C5 (°) -68.32 -68.15 -64.22 -68.95 64.59 70.44 57.72 
C3-C4-C5-N1 (°) 52.14 51.56 46.73 54.11 -48.25 -46.98 -57.87 
C4-C5-N1-C1 (°) -86.73 -82.50 -81.63 -84.79 80.89 67.49 92.06 
C5-N1-C1-C2 (°) 99.60 98.90 101.26 96.52 -94.71 -91.12 -75.10 
* one of the two crystallographic independent molecules of [Ga.L6] is shown. There is no significant difference between the two ring 
conformations.aTwist-Chair conformation. bChair conformation. 
 
A number of factors contribute towards defining the lowest energy conformation adopted by the 
ring. The reduced torsional strain (relative to the chair conformation) within the N-CH2-CH2-N 
fragment is favourable, perhaps made possible by the apparent ‘willingness’ of Ga(III) to adopt a 
distorted octahedral geometry.20 In addition, the presence of the coordinating pendant arms is also 
expected to be influential. The torsion angles of the ring indicate that there is a notable structural 
commonality to the three structures reported here. The absence of any significant conformational 
change resulting from the Me/Ph permutation is evident. Indeed, it is tempting to speculate that this 
modification of the core structure has not only improved the degree of pre-organisation of the 
ligand for metal binding, but also enhanced the rigidity of the desired conformation.   
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3.2 Solution State Multinuclear NMR Studies of [Ga.Ln] (n = 2, 3, and 8) 
 
The Ga(III) (d10) ion is diamagnetic, and thus solution NMR studies of Ga(III) complexes are of 
interest. Crystalline material of [Ga.Ln] (n = 2, 3 and 8) was isolated from the complexation solution, 
re-dissolved in D2O, and NMR studies carried out using a Varian 600 MHz NMRS at 298 K and pH ~ 5. 
Consistent with the solid state structure, mass spectrometry showed the presence of only a 1 : 1 
complex (as the singly protonated species). 
 
Single resonances were found in the 71Ga (I = 3/2, 39.6 % natural abundance, quadrupolar moment = 
0.112) NMR spectra of [Ga.Ln] (n = 2, 3 and 8), and are presented in Table 4.10, with chemical shifts 
relative to [Ga(H20)6]
3+. Also shown, are the ‘width at half-height’ (ω½) values which, for quadrupolar 
71Ga, are a sensitive function of the local molecular symmetry. For example, in the C3-symmetric 
Ga(III) complex of NOTA, very little line broadening is observed (δGa(71) = 171 MHz, ω½ = 210 Hz at 
5.88 T) compared to that of the [Ga(H20)6]
3+ reference (ω½ = 53 Hz at 5.88 T).
28 
 
For [Ga.NOTA], the narrow line width of the 71Ga NMR signal is consistent with a complex in which 
the metal ion donor set is tightly bound and highly symmetrical. Intrinsic line broadening in the 
spectra of quadrupolar nuclei (“Quadrupolar relaxation”) is a result of interaction of the nuclear 
quadupole moment with the electric field gradient at the nucleus. The magnetic dipole and electric 
dipole are strongly coupled, because quadrupolar transitions change the electromagnetic 
environment. Therefore, relaxation of the nuclear electric quadupole, associated with changes in the 
local electric field gradient (due to molecular motion in the fluid state) also relaxes the nuclear spin. 
For octahedral complexes with facial N3 and O3 donor sets, the gradient in the x-y plane tends to 
zero and the resultant field gradient at the nucleus is highly anisotropic. This results in minimal 
quadrupolar relaxation, and hence, minimal line broadening.28 
 
71Ga-NMR ω½-values and the octahedral distortion parameters (Σ and Θ: Table 4.6), are all a measure 
of the relative symmetry in the different complexes. In terms of the relative order of the complexes, 
the parameters are in excellent agreement. This indicates that, the structures in solution and solid 
state are similar. 
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Table 4.10 Variation of 71Ga NMR spectral parameters (δGa and ω½) for [Ga.L
n
] (n = 2, 3, 8), [Ga.(10N3-
triacetate)]
28
 and [Ga(H20)6]
3+
. Recorded at 182.91 Hz (14.09 T) and 298 K in D2O, unless otherwise stated. 
 
Complex δGa (ppm)
a 
ω½ (Hz) 
[Ga(H20)6]
3+
 0 877 
[Ga.L
2
] 129 983 
[Ga.L
3
] 123 1174 
[Ga.L
8
] 124 1815 
[Ga.(10N3-triacetate)]
b,28
 133 2000 
a
Relative to [Ga(H20)6]
3+
, i.e. Ga(NO3)3 in D2O.
b
At 5.88 T and 298 K in D2O. 
 
As an illustrative example the 1H NMR spectrum of [Ga.L2] is discussed below. The 1H NMR (14.1 T) 
spectrum is particular well resolved, which makes it possible to unambiguously assign all protons, 
except for H4 and H5 (Figure 4.21), with the help of 2D COSY, HSQC- and HMBC-NMR experiments. 
The methyl signals, H1ᶦ and H14, resonate as singlets at 1.03 and 2.43 ppm respectively. The 
remaining protons are all diastereotopic, with a coupling pattern that was typical of two AB-doublet 
for H2,7 (ring methylene protons), two AB-multiplets for H4,5 (ethylene bridge CH2’s) and an AB-
doublets for H8,10,12 (acetate CH2’s) structure. The splitting pattern indicates that the complex has a 
very rigid structure.  
 
With respect to the free ligand (at the same pH), the 1H NMR signals of the two methyl signals (H1ᶦ 
and H14) of the ligand in the bound complex show shifts to lower frequency, whilst remaining 
protons resonate to higher frequency (Figure 4.21 top left). In the free ligand, L2, rapid exchange 
between enantiomers, on the NMR time-scale, was manifested as a single AB-doublet (4H) for H8 
and H10, i.e. there are 2 pairs of equivalent diastereotopic protons. A similar splitting pattern is 
observed for H2-H7.  
 
However, in the case of the bound ligand each ‘pair’ of diastereotopic protons resonate as separate 
AB-doublets, consistent with a lower time averaged symmetry. The same is observed for H4-H5, 
which resonate as more complex multiplets, due to the presence of vicinal and geminal proton 
coupling constants of different value. In the proton decoupled 13C NMR spectra, the signals of the 
carbons which appeared as single resonances in the free ligand (C4-C5, C2-C7 and C8-C10) resolve into 
separate signals in the bound ligand, as expected.   
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In the case of C3-symmetric complexes, for example [Ga.NOTA], it is possible to assign the A and B 
ring protons to their axial and equatorial orientations. Using 2D NOESY and Pureshift (homonuclear 
broadband decoupling) NMR experiments, together with the crystal structure of [Ga.L2], the 
diastereotopic protons of H2 and H7 were assigned to axial and equatorial orientations, as well as 
their correct location, with reference to the position adopted by the Nexo-acetate pendant arm 
(Figure 4.21 top right). The Pureshift 1H NMR experiment collapses homonuclear signals into singlets 
(Figure 4.21 bottom left). This significantly improves signal ‘separation’ and makes interpretation of 
the 2D spectra more accurate. The Pureshift 1H NMR spectrum of [Ga.L2] has been plotted as the 
horizontal trace of the 2D NOESY plot.  
 
According to the 2D NOESY plot, the Nexo-Me group (H
14) shows nOe correlations with a single proton 
on C7 (δH = 3.46 ppm), C
8 (δH = 3.71 ppm) and C
12 (δH = 3.21 ppm). From the crystal structure, it is 
evident that H14 is closest to an equatorially orientated proton on C7, indicating that the signal at 
3.46 ppm originates from H7eq. One of the protons on C12 (δH = 3.89 ppm) has an nOe correlation to a 
proton of C2 (δH = 3.59 ppm). Similarly, this indicates that the signal at 3.59 ppm originates from H
2eq. 
Consistent with these assignments and the crystal structure, H1ᶦ shows an nOe correlation with the 
other proton on C2 (H2ax). These correlations confirm the connectivity assignments made using 2D-
HSQC and –HMBC NMR experiments. It was not possible to unambiguously assign the protons of H4 
and H5, due to complexity and the similar chemical shifts of their AB-multiplets.  
 
3.3 Summary 
 
Solid state structures of the complexes reveal that the Ga(III) is a considerably better fit for the 
cavity of these ligands, than the larger Lanthanide ions. There is a high degree of commonality to the 
conformation of the ring in [Ga.Ln] (n = 2, 3, 6). The ring binds in a tridentate fashion, adopting a 
somewhat unusual pseudo-twisted-chair conformation. The conformation of the ring is expected to 
have less inherent strain than the more frequently observed Chair-conformation, due to the more 
staggered arrangement of the N-CH2-CH2-N fragment. The AMPED based examples, [Ga.L
n] (n = 2 
and 3) have a less distorted octahedral geometry about the Ga(III) ion, as shown by crystallographic 
and 71Ga-NMR spectroscopic data. The 1H NMR spectra of the complexes are characterised by well 
resolved and sharp proton resonances, indicative of a rigid structure. The 2D NOESY NMR of [Ga.L2] 
is fully consistent with the solid state crystal structure. 
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Chapter 5  
Conclusion and Future Work 
 
1 Conclusion 
 
A set of four structurally related ligands (L2, L3, L6 and L8: Figure 6.1) has been prepared, which show 
considerable potential for practical application in the development of 68Ga tracers for molecular 
imaging with PET. Three of the ligands quantitatively radiolabel within 3 minutes at room 
temperature over the pH range 4 – 7, to give a single radiolabelled species. The mild conditions 
make these ligands amenable to biomolecule conjugation. The very fast complexation and 
quantitative yields, which simply radiolabel purification, are major advantages for the application of 
the short-lived 68Ga-radionuclide. The radiolabelled complexes are stable in the presence of excess 
DTPA, apo-transferrin, iron(III) and in newborn calf serum over 2 hours under physiological 
conditions. The bio-distributions of [68Ga.L2] and [68Ga.L8] confirm the stability of all complexes 
determined in vitro with a renal clearance pathway. The ligands display remarkable selectivity for 
gallium(III) over iron(III), calcium(II) and copper(II). Therefore, these ligands form a good basis for the 
development of 68Ga-radiolabelled bioconjugates. Radiolabelling of the ligands below pH 3.5 is 
possible, but gives rise to multiple radiolabelled species of differing stability, which precludes their 
application in vivo. The presence of multiple species has been attributed to the formation of 
kinetically trapped complexes, resulting from different conformations of the free ligand. By 
substituting the quaternary methyl for a phenyl moiety, the population of the conformation which 
favours stable 68Ga chelation is increased. However, radiolabelling under these conditions is still not 
practicable below pH 3.5. The Me-Ph permutation also serves to stabilise the preferred ligand 
design, by inhibiting internal lactamisation.  
 
 
 
Figure 6.1 Ligands with properties which make them very promising ligands for application in 
68
Ga-PET. 
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2 Future Work  
   
In terms of carrying this research forward, it is hoped to develop derivatives of these ligands suited 
for bioconjugation. A significant amount of research has been carried out functionalising the 
quaternary carbon.1-6 Using this approach has proved successful in terms of conjugation and 
maintaining the chelating ability of the ligand.1-6 Other possible points of attachment include the 
exocyclic amine and α-carbon of the imino-acetate. Making use of the α-carbon of the iminoacetate 
as a point of attachment (L11/12) has not yet been explored for AAZTA derivatives, but is a commonly 
applied method of conjugation applied to NOTA and DOTA ligand derivatives.7, 8 On this basis, it 
would be fairly straightforward to propose some target compounds (Figure 6.2).  
 
 
 
Figure 6.2 Possible modifications to AMPED based ligands L
2
 and L
3
 to yield ligands suitable for bioconjugation.  
 
Using the AMPED scaffold as a basis may have some potential downfalls. Ligands L10,11 have an 
inherent tendency to lactamise, and L12 may encounter speciation problems. A sensible approach 
would be to make use of the modified scaffold (APPED), which has been shown to inhibit both of 
these problems. Of further benefit is the novelty of the scaffold, which will assist should a patent 
application be pursued.  
 
Derivatisation of L6 and L8 at the para-position (L13: Figure 6.3) of the phenyl group are very 
attractive targets, although they require significant synthetic effort. To test the suitability of the 
scaffold as a concept, it would be sensible to consider a simpler strategy. In particular, initial efforts 
should be focused on the synthesis of L14. This structure will take advantage of the favourable 
properties of the novel APPED scaffold, which include improved ligand stability and the formation of 
a single radiolabelled species. Propionic acid pendant arms are proposed because they; increase the 
overall lipophilicity (which may reduce any untoward effects on the pharmacokinetics of the 
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targeting vector), and inhibit ligand lactamisation. Conjugates based on L13 would be interesting 
secondary targets, because they may be benefits of the having the spacer group isolated from the 
donor groups. Specifically, using the pendant propionate arm as the point of attachment may have a 
untoward effect on the stability and/or complexation kinetics of the ligand. 
 
 
 
Figure 6.3 Possible modifications to APPED based ligands L
6
 and L
8
 to yield ligands suitable for bioconjugation.  
 
Progress towards these BFC’s has already started, with the synthesis of a hex-6-yne derivative of L12. 
The unconjugated ligand displays very favourable radiolabelling properties, nearly identical to those 
of L2 (its ‘parent’ ligand), and the radiolabelled complex is stable in the presence of excess apo-
transferrin. Furthermore, the protected ligand has been coupled to pteroic (folic) acid via a copper 
catalysed click reaction. Certain tumour cells overexpress folate receptors, for which the pteroic acid 
has a high affinity.9 Hydrolysis of the tert-butyl esters to give the bifunctional chelate is currently 
underway.  
 
 
 
Figure 6.4 Shows the structures of the unconjugated ligand, and pteroic acid conjugated ligand precursor 
currently being investigated as an AMPED based bifunctional chelator for 
68
Ga.  
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Chapter 6 
Experimental 
 
This chapter described the procedures followed, instrumentation used, and compounds synthesised during 
the course of this project. 
 
1 General Procedures 
 
Commercially available reagents were used as supplied from the suppliers. Solvents were laboratory 
grade, dried using a suitable drying agent when required. Reactions requiring anhydrous conditions 
were carried out under an atmosphere of argon using standard Schlenk-line techniques. For all non-
radioactive procedures, “water” refers to high purity water (< 0.04 μS.cm-1) obtained from a 
PuriteSTILL Plus® purification system. 
 
Thin-layer chromatography was carried using silica gel plates (Merck 5554). The plates were 
visualised, as appropriate, using UV (254/365 nm) irradiation or Dragendorff’s reagent. Preparative 
column chromatography was carried out using silica gel (Merck Silica Gel 60, 230400 mesh). 
 
pH Measurements were carried out at 295 K using  Jenway 3320 or Jenway 3020 pH meter with a 
Sigma-Aldrich micro-pH combination electrode. Commercially available buffer solutions (Sigma-
Aldrich) were used to calibrate the pH meter at pH 4.00 ± 0.02, 7.00 ± 0.02 and 10.00 ± 0.02 prior to 
use. For measurements conducted in D2O, the pD was calculated from the pH meter reading using: 
pD = pH + 0.41.1  
 
1D and 2D NMR spectra (1H, 13C and 71Ga) were recorded on a Varian VXR-400 spectrometer (1H at 
399.97 MHz, 13C at 100.578 MHz), Varian VNMRS-700 spectrometer (1H at 699.73 MHz, 13C 175.95 
MHz) or a 600 MHz Varian (Agilent) Premium Compact (1H at 599.78 MHz, 13C at 150.82 MHz, 71Ga at 
182.91 MHz). Unless otherwise stated, spectra were collected at 295 K in commercially available 
deuterated solvents, and referenced internally to the residual solvent proton resonances. All 
chemical shifts are given in ppm, with coupling constants and peak-width-at-half-heights in Hz. 
Splitting patterns are described as singlet (s), broad singlet (Br. s), doublet (d), triplet (t), quartet (q) 
or multiplet (m). A fairly common occurrence for the compounds characterised is the presence of 
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AAᶦBBᶦ-coupling, arising from equivalent diastereotopic protons on symmetry related carbon atoms. 
Unless otherwise stated, proton resonances arising (entirely or in part) from A or Aᶦ are simply 
assigned as HA. Similarly, proton resonances with contributions from B or Bᶦ are assigned as HB. The 
use of superscript comma (,) in the assignment indicates that a resonance arises from more than one 
proton (i.e. H2,7 is a proton resonance which arises from both H2 and H7). The use of a superscript 
solidus (/) indicates that the assignment could not be defined with certainty (i.e. H2/7 is a proton 
resonance that arises from either H7 or H2). 
 
Electrospray (ES) and high resolution (HS) mass spectrometry were performed on a Thermo-Finnigan 
LTQ FT system, operating in positive or negative mode as stated, using methanol as a carrier solvent. 
Ultra performance liquid chromatography (UPLC) electrospray mass spectrometry was performed on 
a LCT Premier XE mass spectrometer, operating in positive or negative mode as stated, equipped 
with an Acquity UPLC system. The Acquity photodiode array detector provides absorbance data from 
210 nm to 400 nm. Carrier solvent is a methanol : water gradient (5 % methanol  95 % methanol) 
elution, and a BEH C18 column (1.7 μm particle size, 2.1 x 50 mm dimensions). 
 
Infra-red (IR) spectra were recorded on a Perkin Elmer Spectrum RX1 with ATR attachment.  
 
Melting points were recorded on a Reichart-Köfler block and are uncorrected.  
 
2 Single Crystal X-ray Studies 
 
Single crystal X-ray data was collected on a Bruker SMART-CCD 6000 diffractometer (ω, 0.3 – 0.5 ° / 
frame) at 120 ±2 K. The temperature was controlled using an Oxford Cryostream open-flow nitrogen 
cryostat. The structures were solved by the Patterson method, and refinement by full-matrix least 
squares on F2 for all data using SHELXTL2 and OLEX23 software. All non-disordered non-hydrogen 
atoms were refined with anisotropic displacement parameters. All hydrogen atoms were placed into 
calculated positions and refined in ‘riding’-mode.  
 
3 Radiochemical Procedures 
 
All radiochemical investigations have been conducted by the author, at the Johannes-Gutenberg 
Universtat: Institut für Kernchemie, (Mainz, Germany) through collaboration with Professor Frank 
Rösch. 
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3.1 General 
 
All chemicals used for the radiochemical experiments were procured from commercial suppliers in 
the highest available purity. Purite® water used was filtered through a Millex® Millipore filter 
membrane (0.54 µm) prior to use. No metallic implements or apparatus were used so as to avoid 
any metal contamination, and standard safety protocols strictly adhered to. For radio-TLC analysis, 
Merck Silica F254 TLC plates were used, and the eluted plates radio-imaged using a flatbed Canberra 
Packard Instant Imager. All radioactive 68Ga solutions were kept inside lead blocks. Whenever 
possible, radioactive solutions and TLC plates were kept behind suitable lead shielding ‘bricks’. All 
solids were weighed using a 5 decimal-place mass-balance. All solution volumes were measured 
using suitable Eppendorf® pipettes, except in the preparation of buffers were a volumetric flask was 
used. 
 
In this study a 350 MBq 68Ga/68Ge-generator based on titanium dioxide, produced by Cyclotron Co., 
Obninsk, Russian Federation, was used. The generator was eluted with 8 mL of 0.1 M HCl. Prior to 
radiolabelling, post-processing of the generator eluate was carried out using a cation exchange 
technique described elsewhere.4 Using this approach the eluate volume was reduced to 400 µL, and 
the presence of metal impurities (68Ge and non-radioactive metals) lowered in the protocol that 
takes less than 5 min to complete. Following post-processing, the eluate was diluted, such that 400 
µL contained ~ 100 MBq of radioactivity (at t = 0). In all radiochemical experiments the 
reactions/evaluations where carried out in sterile unused containers as specified. 
 
All stabilities and radiolabelling yields have been evaluated using a radio-TLC plate method. 
Background radioactive signal can be as high as 5 % of the total radioactivity on the plate. Therefore, 
unless the population distribution map shows evidence of a ‘radioactive spot’ on the plate, any 
signal < 5 % is assumed to be background. For this reason radiolabelling yields > 96 % are deemed 
‘quantitative’. 
 
3.2 Radiolabelling Protocols 
 
The radiolabelling kinetics of the ligands was evaluated at 298, 323 and 368 K at pH 2.3, 3.3, 4.0, 5.3 
and 7.0. Stock solutions of the ligands (1 mg/mL) were prepared in water. Radiolabelling 
experiments carried out at pH 4.0 and 5.3 were acetate buffered, and the experiments conducted at 
pH 7.0 were HEPES buffered. Various concentrations of the buffer solutions were evaluated for the 
Chapter 6: Experimental 
 
 
 
Page 154 
 
  
lowest concentration that had sufficient buffering ability upon addition of the post-processed 68Ga 
solution. The acetate ‘buffers’ were prepared by combining calculated amounts of acetic acid and 
sodium acetate to give a 0.2 M buffer solution, adding sufficient HCl or NaOH to give the desired pH. 
The HEPES buffer was prepared by adjusting the pH of a 1.0 M sodium-HEPES solution to 7.2 using 
1.0 M sodium hydroxide. Suitable dilution of the post-processed generator eluate was used to 
achieve pH 2.3 and 3.3. Preparations of the radiolabelling solutions for the different conditions are 
described below. 
 
pH 2.3:  
The ligand (50 nmol) was added of water (4.6 mL) in a glass vial, and the mixture preheated at the 
desired temperature for 2 min. To this mixture the post-processed generator eluate (400 µL, ~ 100 
MBq) was added and a timer started. 
 
pH 3.3: 
Followed a similar protocol to that described for ‘pH 2.3’, except 50 µL (~ 12 MBq) of the post-
processed generator eluate was used. 
 
pH 4.0, 5.3 and 7.0: 
The ligand (14 nmol) was added to 1 mL of the appropriate buffer solution (1 mL) in a 2 mL 
Eppendorf® vial, and the mixture preheated for 2 min at the desired temperature. To this mixture 
the post-processed generator eluate (400 µL, ~ 100 MBq) was added and a timer started. 
 
Radiolabelling solutions were continuously agitated using a rotary shaker with a temperature control 
function. At 1, 3, 5 and 10 min time intervals after addition of the post-processed 68Ga; 1 µL fractions 
of the reaction mixture were withdrawn using an Eppendorf® pipette and spotted, in duplicate, on 
separate TLC plates (Merck Silic Gel F254). To ensure correct interpretation of the radiolabelling the 
duplicate TLC plates were eluted separately with a 0.5 M sodium citrate buffer solution (pH 4.0) and 
a 90 % MeOH in 10 % aqueous NaCl solution. Using the citrate buffer, un-complexed 68Ga forms a 
68Ga-citrate complex which elutes to the top of the TLC plate (Rf ~ 0.9), while the radiolabelled 
product remains on or close to the baseline. Using the 90 % MeOH saline solution the un-complexed 
68Ga remains on the baseline, whilst the radiolabelled product moves approximately half way up the 
TLC plate. Exact Rf values depend on the characteristics of the radiolabelled product, and were not 
recorded. From the eluted TLC plates it was possible to determine the ratio of complexed to un-
complexed 68Ga at the different time intervals. Each radiolabelling evaluation was repeated two 
Chapter 6: Experimental 
 
 
 
Page 155 
 
  
more times. Control experiments, in which the ligand is not added, were conducted in parallel with 
the radiolabelling experiments.  
 
3.3 Stability Studies 
 
No post-radiolabelling purification of the radiolabelled products was carried out because only 
ligands which showed quantitative radiolabelling were evaluated in the stability experiments. 
 
The stability of the radiolabelled complexes was assessed in the presence of DTPA, Fe(III) (each 5000 
equivalents), apo-transferrin (130 equivalents) and new born calf serum. The evaluations were 
carried out over 2 h at 310 K and pH 7.4 (1.0 M PBS), and the solutions agitated using a rotary 
shaker. All stability studies were performed twice and in duplicate for each ligand-radiolabelling pH 
combination of interest. Two control experiments where performed in each case; one in the absence 
of the ligand and the other in the absence of the challenge. These were used to establish the Rf 
values of the free 68Ga, 68Ga-transferrin and 68Ga-DTPA complexes, as well as any complexation of 
the free 68Ga in the new-born calf serum. Stock solutions of DTPA, FeCl3 (both 1.0 µM) and apo-
transferrin (1 mg/ml) were prepared in 1.0 M PBS (pH 7.4) solution. The newborn calf serum was 
used as received.  
 
The challenge solution (200 µL) was preheated at 310 K for 10 minutes in a 2 mL Eppendorf® vial, 
and the radiolabelled complex (50 µL of the appropriate radiolabelling solution) added. At 15, 30, 60, 
90 and 120 min time intervals following addition of the radioactivity, 2 µL fractions were withdrawn 
using an Eppendorf® pipette and spotted, in duplicate, on separate TLC plates. To ensure correct 
interpretation of the stability evaluation, the duplicate TLC plates were eluted separately with a 0.5 
M citrate buffer solution (pH 4) and a 90 % MeOH 10 % NaCl solution. From the eluted TLC plates it 
was possible to determine the amount of intact radiolabelled complex at the different time points. 
 
3.4 NOTA Competition Experiment 
 
This evaluation was only undertaken for  ligands deemed suitable for 68Ga PET, as determined from 
their radiolabelling properties and radiolabelled complex stability. 
 
The conditions used for the NOTA-challenge experiments were selected so that they reflected the 
optimum conditions for radiolabelling of NOTA. The challenge was performed at 298 K and pH 4 (0.2 
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M citrate buffer) over the course of 10 minutes, with a 20 µM concentration of both NOTA and the 
ligand of interest. Under the conditions used each ligand (in isolation) would show quantitative 
radiolabelling within 1 min at room temperature.  
 
Equimolar amounts (28 nmol from 1 mg/mL stock solutions) of NOTA and the ligand were added to 1 
mL of a 0.2 M acetate buffer solution (pH 4) in a 2 mL Eppendorf® vial, and the mixture left to 
equilibrate on a rotary shaker for 2 min at 298 K. The post-processed 68Ga (400 μL) was added, and 1 
μL fractions of the radiolabelling solution spotted on a TLC plate at 1, 3, 5, 10 and 120 min time 
intervals. The TLC plates were eluted using a 0.5 M citrate solution (pH 4). With this mobile phase 
the un-complexed 68Ga elutes to the top of the plate, the [68Ga.NOTA] complex about a third of the 
way up (Rf ~ 0.35) and the radiolabelled ligand L
n evaluated remains on, or close to, the base line. 
From the eluted TLC plates it was possible to determine the relative ratios of different complexes at 
each time interval. Control experiments were carried out in parallel in the absence of each and both 
ligands. All challenge experiments were repeated twice.  
 
3.5 Metal Ion Competition Experiments 
 
This evaluation was only undertaken for ligands deemed suitable for 68Ga PET, as determined from 
their radiolabelling properties and radiolabelled complex stability. 
 
Stock solutions of CaCl2, FeCl3 and CuBr2 were prepared in 0.2 M acetate buffer pH 4. The challenge 
was performed at 298 K and pH 4 (0.2 M acetate buffer) over the course of 10 minutes, with a 10 µM 
(14 nmol) of the ligand. A known amount of the metal ion of interest (starting at 1 equivalent with 
respect to the ligand: 14 nmol) was added to the ligand, and the volume made up to 1 mL using 0.2 
M acetate buffer (pH 4). The post-processed 68Ga (400 μL) was added, and a 1 μL fraction of the 
radiolabelling solution spotted on a TLC plate at 1, 3, 5, 10 min time intervals. The TLC plates were 
eluted using a 0.5 M citrate solution (pH 4). The concentration of the metal ion was varied to 
establish the concentration of the metal ion which prevents quantitative radiolabelling in 10 min 
(‘limiting concentration’). Control experiments were carried out in parallel in the absence of the 
ligand and metal ion separately. All challenge experiments were repeated twice.  
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3.6 Concentration Kinetics Radiolabelling Experiment 
 
This evaluation was only undertaken for ligands deemed suitable for 68Ga PET, as determined from 
their radiolabelling properties and radiolabelled complex stability. 
 
The concentration dependence of radiolabelling was determined by gradually reducing the ligand 
concentration from 20 μM. A stock solution (50 μM) of the ligand was prepared in 0.2 M acetate 
buffer (pH 4). 1 mL of the desired ligand concentration was prepared by suitable dilution using 0.2 M 
acetate buffer (0.2 M) and the solution equilibrated at 298 K for two minutes. The challenge was 
performed at 298 K and pH 4 (0.2 M acetate buffer) over the course of 10 minutes. The post-
processed 68Ga (400 μL) was added, and a 1 μL fraction of the radiolabelling solution spotted on a 
TLC plate at 1, 3, 5 and 10 min time intervals. The TLC plates were eluted using a 0.5 M citrate 
solution (pH 4). The concentration of the ligand was decreased until quantitative radiolabelling was 
no longer achieved. All experiments were repeated once. 
 
3.7 μPET Studies 
 
Animal imaging experiments were performed in Sprague Dawley rats (n = 2 per radiolabelled 
complex.  
 
Body weights:  
 330 - 380 g, male for [68Ga.L2] and [68Ga.NOTA].  
 430 - 440 g, male for [68Ga.L8]4.0 and [
68Ga.L8]7.0. 
The rats were placed under isoflurane anaesthesia (2% isoflurane, 98% oxygen). All experiments had 
previously been approved by the regional animal ethics committee and were conducted in 
accordance with the German Law for Animal Protection. (Tiergenehmigung Schmitt) 
 
The complexes [68Ga.L2], [68Ga.NOTA] and [68Ga.L6]4.0 were prepared at pH 4 (0.2 M acetate buffer) 
using the entire undiluted post-processed generator eluate (~ 300 MBq; 400 μL). Apart from the 
amount of 68Ga used, the radiolabelling protocol as previously described. Prior to injection, the pH 
was adjusted to pH 7. The labelling solution (~ 25 MBq) was made up to 0.8-0.9 mL using saline 
solution, and injected into the tail vein by bolus injection.  
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The complex [68Ga.L8]7.0 was prepared at pH 7 (1.0 M Na-HEPES buffer) using the entire undiluted 
post-processed generator eluate (~ 300 MBq; 400μL). Apart from the amount of 68Ga used, the 
radiolabelling protocol as previously described. The pH did not need to be adjusted prior to 
radiolabelling. The labelling solution (~ 25 MBq) was made up to 0.8-0.9 mL using saline solution, 
and injected into the tail vein by bolus injection.  
 
µPET imaging was performed on a µPET Focus 120 small animal PET (Siemens/Concorde, Knoxville, 
USA). Animals were placed in head-first-supine position. After a 15 min transmission scan with an 
external 57Co source, dynamic PET studies were acquired over 45 min in 2 D mode followed by a 15 
min whole body scan. 
 
 For analysis the PET ‘listmode’ data were depicted into 14 - 20 frames with varying time frames and 
reconstructed using an OSEM algorithm. PMOD software (PMOD Technologies LTD.) was used to 
visualize the images. 
 
4 Synthetic Procedures 
 
4.1 Compounds Relating to the Syntheses of AMPED Based Ligands, L1-5 
 
1,4-Dibenzyl-6-methyl-6-nitro-1,4-diazepane, 1.5 
 
 
A solution of N,N'-dibenzylethylenediamine (2.00 g, 18.4 mmol) and para-formaldehyde (0.75 g, 25.0 
mmol) in absolute ethanol (40 mL) was refluxed under an atmosphere of argon for 2 h. Nitroethane 
(0.94 g, 12.5 mmol) was added dropwise over 20 min, and the mixture boiled under reflux overnight 
under an atmosphere of argon. The solvent was removed under reduced pressure, and the resulting 
oil re-dissolved in chloroform (20 mL), filtered, and washed successively with aqueous potassium 
carbonate solution (2 x 20 mL, 0.1 M) and water (20 mL), dried over MgSO4, filtered and solvent 
removed under reduced pressure. Purification by silica gel column chromatography 
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(dichloromethane) afforded an off-white solid (2.20 g, 78 %). RF = 0.40 (SiO2, dichloromethane). m.p. 
= 49.5 - 50 C. 1H NMR (CDCl3, 400 MHz): δH 1.34 (3H, s, H
1'); 2.60 (4H, m, H4,5); 2.95 (2H, d, J 13, 
H2/7); 3.59 (2H, d, J 13, H2/7); 3.64 (2H, d, J 13, H8); 3.78 (2H, d, J 13, H8); 7.26-7.33 (10H, m, H10,14). HR 
MS ES+ (m/z): found 340.2017 [M + H]+; C20H26N3O2 requires 340.2025. The structure of 1 was 
confirmed by single crystal X-ray diffraction: C20H25N3O2, Mr = 339.43, monoclinic (C2/c); a = 
32.4876(13) Å, b = 6.0545(2) Å, c = 20.2683(8) Å, V = 3710.1(2) Å3,α = 90.00°, β = 111.467(10)°, γ = 
90.00°, Z = 8; μ = 0.085 mm-1, Dcalc. = 1.219 mg.mm
-3, T 120(2) K; 4452 independent reflections (Rint = 
0.0342), R1 = 0.0482, ωR2 = 0.1252 (I > 2σ(I)). CCDC # 906039. 
 
6-Methyl-1,4-diazepan-6-amine, 2.5 
 
 
A catalytic amount of Pd(OH)2/C was added to a solution of the nitro-diamine 1 (0.10 g, 0.29 mmol) 
in methanol (20 mL), and the mixture agitated under an atmosphere of hydrogen for 48 h using a 
Parr hydrogenator (30 psi H2).  Thin layer chromatography (SiO2, dichloromethane) was used to 
confirm complete reduction of the nitro group and cleavage of the benzyl N-sbstituents. Argon was 
bubbled through the solution for 15 min to purge remaining hydrogen, and the Pd(OH)2/C removed 
using a Celite® filter. The solvent was removed under reduced pressure to afford a yellow oil. (0.031 
g, 81 %) Rf  = 0.10 (CH2Cl2 / MeOH 19% / NH3 1%, SiO2). 
1H NMR (CDCl3, 200 MHz): δH 1.03 (3H, s, H
1ˈ); 
1.98 (4H, br. s, NH and NH2); 2.68 (4H, br. s, H
2,7);  2.92 (4H, m, H4,5). MS ES+ (m/z): found 129.2 
[M+H]+;C6H16N3 requires 129.1266. [Note: Compound 1 readily reacts with carbon dioxide in the 
atmosphere and should therefore be stored at < 0°C under an atmosphere of argon; or alternatively 
as the hydrochloride salt. As a consequence of this instability, compound 2 was always handled 
under argon, and subsequent reactions were carried out under an inert atmosphere.] 
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Tert-butyl 2,2'-(1,4-bis(2-tert-butoxy-2-oxoethyl)-6-methyl-1,4-diazepan-6-ylazanediyl)diacetate, 3.5 
 
 
Tert-butyl-bromoacetate (0.272 g, 1.40 mmol) was added to a solution of 2 (0.030 g, 0.23 mmol) and 
potassium carbonate (0.193 g, 1.40 mmol) in acetonitrile (25 mL), and the mixture stirred for 24 h at 
368 K under an atmosphere of argon.  The solvent was removed under reduced pressure, and the 
resulting oil re-dissolved in chloroform (25 mL) and washed successively with aqueous potassium 
carbonate solution (2 x 25 mL, 0.1 M) and water (25 mL), dried over magnesium sulfate, filtered and 
solvent removed under reduced pressure. Purification by silica gel column chromatography (hexane 
 5 % ethyl acetate) afforded a yellow oil (0.081 g, 60 %). Rf = 0.35 (hexane : ethyl acetate; 65 : 35). 
1H NMR (CDCl3, 700 MHz): δH 1.06 (3H, s, H
1ˈ); 1.40 (36H, m, H11,15); 2.58 (2H, d, J 14, H2/7); 2.63 (2H, 
m, H4/5); 2.73 (2H, m, H4/5); 2.98 (2H, d, J 14, H2/7); 3.23 (4H, s, H12); 3.64 (4H, s, H8). HR MS ES+ (m/z): 
found 586.4055 [M + H]+;C30H56N3O8 requires 586.4059. 
 
2,2'-(1,4-Bis(carboxymethyl)-6-methyl-1,4-diazepan-6-ylazanediyl)diacetic acid Bistrifluoroacetate 
salt, L1.2CF3COOH.
6  
 
 
The tetra-ester 3 (0.200 g, 0.34 mmol) was dissolved in trifluoroacetic acid / dichloromethane (1 : 1, 
2 mL) and left to stir for 2 days at room temperature. The solvent was removed under reduced 
pressure, the residue re-dissolved in dichloromethane : methanol (1 : 1, 2 mL) and evaporated. This 
procedure was repeated twice, and then with methanol. The resulting solid was dissolved in water 
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(10 mL) and washed with dichloromethane (10 mL). Removal of solvent under reduced pressure 
afforded the bis-trifluoroacetate salt of the title compound as a white solid (0.165 g, 82 %). 1H NMR 
(D2O, pD = 2.09, 700 MHz): δH1.04 (3H, s, H
1'); 3.35 (2H, d, J 15, H2,7); 3.59 (4H, m, C2,7,4,5); 3.65 (4H, s, 
H12); 3.71 (2H, m, H4,5); 3.84 (2H, d 17, H8); 3.84 (2H, d, J 17, H8). HR MS ES+ (m/z): found 384.1 [M + 
Na]+; C14H23N3NaO8 requires: 384.1383 Elemental analysis (%): found C (36.8) H (4.32) N (6.99) 
[C14H23N3O8].2CF3COOH requires C (36.7) H (4.28) N (7.13). 
 
Tert-butyl 2,2'-(6-(2-tert-butoxy-2-oxoethylamino)-6-methyl-1,4-diazepane-1,4-diyl)diacetate, 5.  
 
 
Tert-butyl-bromoacetate (0.113 g, 0.58 mmol) was added to a solution of 2 (0.030 g, 0.23 mmol) and 
potassium carbonate (0.25 g, 0.70 mmol) in acetonitrile (25 mL), and the mixture stirred for 24 h at 
298 K under an atmosphere of argon. The reaction was monitored using UV-vis TLC, to follow 
formation of the unwanted tetra-alkylated by-product 3.  The solvent was removed under reduced 
pressure, and the resulting oil re-dissolved in chloroform (25 mL) and washed successively with 
aqueous potassium carbonate solution (2 x 25 mL, 0.1 M) and water (25 mL), dried over MgSO4, 
filtered and solvent removed under reduced pressure. Purification by silica gel column 
chromatography (hexane  25 % ethyl acetate) afforded a yellow oil (0.06 g, 22 %). Rf = 0.20 (SiO2; 
hexane : ethyl acetate; 65 : 35). 1H NMR (CDCl3, 700 MHz): δH 0.85 (3H, s, H
1'); 1.37 (27H, m, H11,15); 
2.54 (2H, d, J 14, H2,7) 2.59 (2H, d, J 14, H2,7); 2.72 (4H, m, H4,5); 3.18 (2H, s, H12); 3.22 (4H, s, H8). 13C 
NMR (CDCl3, 176 MHz): δC 22.79 (C
1'); 28.20 (C11/15); 28.35 (C11/15); 45.13 (C12); 56.05 (C1); 57.35 (C2,7); 
61.99 (C8); 64.81 (C4,5); 80.77 (C10/14); 80.89 (C10/14); 171.06 (C9/13); 171.97 (C9/13). HR MS ES+ (m/z): 
found 472.3380 [M + H]+; C24H46N3O6 requires 472.3378. 
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(±)-2,2'-(6-Methyl-8-oxo-1,4,7-triazabicyclo[4.3.1]decane-4,7-diyl)diacetic acid, 6.7 
 
 
The triester 5 (0.100 g, 0.21 mmol) was dissolved in trifluoroacetic acid : dichloromethane (1 : 1, 2 
mL) and left to stir for 2 days at room temperature. The solvent was removed under reduced 
pressure, the residue re-dissolved in dichloromethane : methanol (1 : 1, 2 mL) and evaporated. This 
procedure was repeated twice, and with methanol. The resulting solid was then dissolved in water 
(10 mL) and washed with dichloromethane (10 mL). Removal of the solvent under reduced pressure 
afforded, after drying in vacuo, a white solid (0.093 g). 1H NMR (D2O, pD = 2.07, 700 MHz): δH 1.29 
(3H, s, H1'); 3.25 (1H, d, J 14, H2,7); 3.39 (1H, d, J 14, H2,7); 3.46 (2H, M, H4/5); 3.59 (2H, m, H2/7,4/5); 3.79 
(6H, m, H2/7,4/5, 8, 10); 4.11 (2H, s, H12). 13C NMR (D2O, pD = 2.07, 176 MHz): δC 21.88 (C
1'); 43.75 (C4/5); 
50.67 (C1); 53.66 (C8); 57.58 (C4/5); 58.56 (C2/7); 60.49 (C2/7); 115.40 (C10/12); 117.06 (C10/12); 166.15 
(C9/11/13); 170.65 (C9/11/13); 173.50 (C9/11/13). MS ES+ (m/z): found 308.2 [M+H]+;C12H19N3NaO5 requires 
308.1222  
 
Tert-butyl 2,2'-(6-((2-tert-butoxy-2-oxoethyl)(methyl)amino)-6-methyl-1,4-diazepane-1,4-
diyl)diacetate, 7. 
 
 
Iodomethane (0.030 g, 0.21 mmol) was added to a solution of 5 (0.100 g, 0.21 mmol) and 
postassium carbonate (0.029 g, 0.21 mmol) in anhydrous dichloromethane cooled in an ice-bath. 
After 15 min the mixture was allowed to warm to room temperature, and left for a further 5 h. The 
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solvent was removed under reduced pressure and the resulting oil re-dissolved in chloroform (20 
mL), filtered, and washed successively with aqueous potassium carbonate solution (2 x 20 mL, 0.1 M) 
and water (20 mL), dried over MgSO4, filtered and solvent removed under reduced pressure. 
Purification by silica gel column chromatography (hexane  20 % ethyl acetate) afforded a yellow oil 
(0.042 g, 41 %). RF = 0.30 (SiO2, hexane : ethyl acetate; 80 : 20). 
1H NMR (CDCl3, 700 MHz): δH 1.05 
(3H, s, H1'); 1.42 (27H, m, H11,15); 2.30 (3H, s, H16); 2.55 (2H, d, J 14, H2,7); 2.68 (2H, m, H4/5); 2.79 (2H, 
m, H4/5); 2.93 (2H, d, J 14, H2,7); 3.24 (2H, d, J 17, H8); 3.27 (2H, d, J 17, H8); 3.41 (2H, s, H12). 13C NMR 
(CDCl3, 176 MHz): δC 23.75 (C
1'); 28.11 (C15); 28.31 (C11); 37.30 (C16); 54.26 (C12); 58.98 (C4,5); 60.70 
(C1); 62.34 (C8); 63.55 (C2,7); 80.20 (C14); 80.73 (C10); 170.87 (C9); 171.99 (C13). HR MS ES+ (m/z): found 
486.3540 [M + H]+; C25H48N3O6 requires 486.3543. 
 
2,2'-(6-((Carboxymethyl)(methyl)amino)-6-methyl-1,4-diazepane-1,4-diyl)diacetic acid 
Bistrifluoroacetate salt, L2.2CF3COOH. 
 
 
The triester 7 (0.150 g, 0.31 mmol) was dissolved in trifluoroacetic acid / dichloromethane (1:1, 2 
mL) and left to stir for 2 days at room temperature. The solvent was removed under reduced 
pressure, the residue re-dissolved in dichloromethane and evaporated. This procedure was repeated 
twice, and then with methanol. The resulting solid was dissolved in water (15 mL) and washed with 
dichloromethane (15 mL). Removal of solvent under reduced pressure afforded, after drying the bis-
trifluoroacetic acid salt of the title compound as a white solid (0.081 g, 83 %). 1H NMR (D2O, pD = 
1.98, 700 MHz): δH 1.22 (3H, s, H
1ˈ); 2.91 (3H, s, H12); 3.25 (2H, m, H4,5); 3.31 (2H, m, H4,5); 3.39 (2H, d, 
J 16, H2,7); 3.52 (2H, d, J 16, H2,7); 3.75 (4H, s, H8); 3.90 (2H, s, H10). 13C NMR (D2O, pD = 1.98, 176 
MHz): δc 15.43 (C
1ˈ); 38.149 (C12); 53.36 (C1); 53.64 (C12); 58.12 (C4/5); 58.50 (8); 67.42 (2/7); 168.99 
(C9); 171.48 (C11). HR MS ES+ (m/z): found 318.1677 [M + H]+; C13H24N3O6 requires: 318.1665. 
Elemental analysis (%): found C (37.3) H (4.53) N (7.59) [C13H23N3O6].2CF3COOH requires C (37.4) H 
(4.62) N (7.70). 
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(2S,2'S)-Diethyl 2,2'-(6-((S)-1-ethoxy-1-oxopropan-2-ylamino)-6-methyl-1,4-diazepane-1,4-
diyl)dipropanoate, 9. 
 
 
Ethyl (2R)-2-{[(trifluoromethyl)sulfonyl]oxypropanoate (0.98 g, 3.9 mmol) was added to a solution of 
potassium carbonate (0.54 g, 3.9 mmol) and 2 (0.10 g, 0.78 mmol) in acetonitrile (20 mL), and the 
reaction mixture stirred at 308 K for 18 h. The solvent was removed under reduced pressure and the 
resulting oil re-dissolved in chloroform (30 mL) and washed successively with aqueous potassium 
carbonate solution (2 x 30 mL, 0.1 M) and water (30 mL), dried over MgSO4, filtered and solvent 
removed under reduced pressure. Purification by silica gel column chromatography (hexane : ethyl 
acetate, 95 : 5) afforded the title compound as a colourless oil (0.11 g, 34%). Rf = 0.40 (hexane : ethyl 
acetate; 65 : 35). 1H NMR (CDCl3, 600 MHz, ppm): δ 0.88 (3H, s, H
1ˈ); 1.25 (18H, m, H9,14,19 & H12,17,22); 
2.46 (2H, t, J 15, H2/7); 2.55 (1H, m, H4/5); 2.63 (1H, m, H4/5); 2.69 (2H, t, J 15, H2/7); 2.73 (1H, m, H4/5); 
2.84 (1H, m, H4/5); 3.34 (2H, m, H8,13); 3.45 (1H, q, J 7, H18); 4.12 (6H, m, H11,16,21). 13C NMR (CDCl3, 151 
MHz, ppm): δ 14.40 (C9/14/19 or C12/17/22); 14.43 (C9/14/19 or C12/17/22); 15.24 (C9/14/19 or C12/17/22); 15.70 
(C9/14/19 or C12/17/22); 16.52 (C9/14/19 or C12/17/22); 21.68 (C9/14/19 or C12/17/22); 20.34 (C1ˈ); 50.34 (C18); 55.33 
(C4/5); 56.40 (C4/5); 59.96 (C11/16/21); 60.08 (C11/16/21); 60.59 (C11/16/21); 61.85 (C2/7); 63.81 (C8/13); 63.95 
(C8/13); 64.07 (C2/7); 65.80 (C1); 173.56 (C10/15); 173.59 (C10/15); 177.39 (C20). HR MS ES+ (m/z): found: 
430.2926 [M + H]+; C21H40N3O6 requires 430.2917. 
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(2S,2'S)-2,2'-(6-((S)-1-Carboxyethylamino)-6-methyl-1,4-diazepane-1,4-diyl)dipropanoic acid 
trisodium salt , Na3.L
3. 
 
 
Sodium hydroxide (0.003 g, 0.072 mmol) dissolved in water (0.5 mL) was added to a solution of the 
tri-ester 9 (0.010 g, 0.023 mmol) in THF (0.5 mL), and the mixture stirred at 298 K. The reaction was 
monitored using LC-ESI MS, to follow ester cleavage. Once complete, the solvent was removed by 
lyophilisation. Water (5 mL) was added and removed by lyophilisation, and the procedure repeated 
two more times. The resulting solid was washed with ice-cold dichloromethane (0.5 mL), and dried 
in vacuo to afford the tris-hydrated tris-sodium salt of the title compound as a white solid (0.009 g, 
92 %). 1H NMR (CDCl3, pD 12.24, 600 MHz, ppm): δ 0.84 (3H, s, H
1'); 1.04 (3H, d, J 7, H9); 1.06 (3H, d, 
J 7, H15); 1.08 (3H, d, J 7, H12); 2.22 (1H, d, J 15, H2); 2.27 (1H, d, J 15, H7); 2.59 (1H, m, H4,5); 2.74 (1H, 
d, J 15, H7); 2.78 (1H, d, J 15, H2); 2.98 (1H, q, J 7, H8); 3.06 (1H, q, J 7, H11); 3.16 (1H, q, J 7, H14). 13C 
NMR (CDCl3, , pD 12.24, 151 MHz, ppm): δ 15.64 (C
9); 16.25 (C15); 21.26 (C12); 22.09 (C1'); 52.33 (C14); 
55.91 (C1); 57.29 (C4/5); 57.45 (C4/5); 59.70 (C2); 60.29 (C7); 66.50 (C8); 66.75 (C11); 181.22 (C10); 181.25 
(C13); 184.42 (C16). HR MS ES+ (m/z): found 368.1807 [M + Na]+; C15H27N3NaO6 requires 368.1798. 
Elemental analysis (%): found C (38.6) H (6.73) N (8.94) Na3[C15H24N3O6].3H2O requires C (38.7) H 
(6.50) N (9.03) 
 
(2S,2'S)-Diethyl 2,2'-(6-(((S)-1-ethoxy-1-oxopropan-2-yl)(methyl)amino)-6-methyl-1,4-diazepane-1,4-
diyl)dipropanoate, 11.  
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Methyl iodide (0.026 g, 0.18 mmol) was added to a solution of 9 (0.05 g, 0.12 mmol) and potassium 
carbonate (0.017 g, 0.12 mmol) in dichloromethane (15 mL), and the mixture stirred for 18 h at 303 
K under an atmosphere of argon.  The solvent was removed under reduced pressure and the 
resulting oil re-dissolved in chloroform (15 mL) and washed successively with aqueous potassium 
carbonate solution (2 x 15 mL, 0.1 M) and water (15 mL), dried over MgSO4, filtered and solvent 
removed under reduced pressure. Purification by silica gel column chromatography (hexane  15 % 
ethyl acetate) afforded the title compound as a yellow oil (0.007 g, 15 %). Rf = 0.45 (hexane : ethyl 
acetate; 65 : 35). 1H NMR (CDCl3, 600 MHz, ppm): δH 1.05 (3H, s, H
1ˈ); 1.24 (18H, m, H9,14,19 & 
H12,17,22); 2.38 (1H, m, H4); 2.41 (3H, s, H23); 2.45 (1H, d, J 14, H7); 2.54 (1H, m, H5); 2.62 (1H, d, J 14, 
H2); 2.67 (1H, m, H5); 2.84 (1H, m, H4); 2.93 (1H, d, J 14, H2); 3.06 (1H, d, J 14, H7); 3.38 (1H, q, H13); 
3.42 (1H, q, H8); 4.09 (7H, m, H18,11,16,21). 13C NMR (CDCl3, 151 MHz, ppm): δC 14.17 (C
12/17/22); 14.37 
(C12/17/22); 14.40 (C9); 14.48 (C12/17/22); 16.72 (C14); 16.90 (C19); 23.74 (C1ᶦ); 29.99 (C23); 54.34 (C18); 
54.42 (C5); 55.49 (C4); 59.93 (C11/16/21); 59.95 (C11/16/21); 60.07 (C11/16/21); 61.67 (C1); 63.29 (C2); 63.61 
(C13); 64.30 (C8); 65.06 (C7); 173.53 (C10/15); 173.70 (C10/15); 175.21 (C20). HR MS ES+ (m/z): found: 
444.3071 [M + H]+; C22H42N3O6 requires 444.3074. 
 
(2R,2'S)-2,2'-(6-(((S)-1-Carboxyethyl)(methyl)amino)-6-methyl-1,4-diazepane-1,4-diyl)dipropanoic 
acid trisodium salt, Na3.L
4. 
 
 
Sodium hydroxide (0.003 g, 0.072 mmol) dissolved in purite water (0.5 mL) was added to a solution 
of the triester 11 (0.010 g, 0.023 mmol) in THF (0.5 mL), and the mixture stirred at 298 K. The 
reaction was monitored using LC-ESI MS, to follow ester cleavage. Once complete, the solvent was 
removed by lyophilisation. Water (5 mL) was added and removed by lyophilisation, and the 
procedure repeated two more times. The resulting solid was washed with ice cold dichloromethane 
(0.5 mL), and dried in vacuo to afford the di-hydrated tri-sodium salt of the title compound as a 
white solid (0.008 g, 87 %). 1H NMR (D2O, pD 12.07, 600 MHz, ppm): δ 0.92 (3H, s, H
1ˈ); 1.06 (6H, 
d+d, H9,12); 1.13 (3H, d, J 7, H15); 2.29 (4H, d+s, H2,17); 2.54 (4H, m, H4,5); 2.66 (1H, d, J 15, H7); 2.84 
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(1H, d, J 15, H7); 2.97 (1H, d, J 15, H2); 3.01 (1H, q, J 7, H8); 3.12 (1H, q, J 7, H11); 3.61 (1H, q, J 7, H14). 
13C NMR (D2O, pD 12.07, 151 MHz, ppm): δ 13.77 (C
9/12); 15.30 (C15); 16.35 (C9/12); 18.67 (C1ᶦ); 29.44 
(C17); 54.74 (C4,5); 57.37 (C1); 59.14 (C7); 59.70 (C2); 62.14 (C14); 66.46 (C8); 66.93 (C11); 181.41 (C10/12); 
181.66 (C10/13); 182.10 (C16). HR MS ES+ (m/z): found 382.1950 [M + Na]+; C16H29N3NaO6 requires 
382.1954. Elemental analysis (%): found C (40.3) H (6.79) N (8.68); Na3[C16H26N3O6].2H2O requires C 
(40.1) H (6.73) N (8.76). 
 
Methyl 4-(aminomethyl)benzoate hydrochloride, 13.HCl.8 
 
 
4-methylamine benzoic acid (3.00 g, 20 mmol) was dissolved in a mixture of methanol (30 mL) and 
35 % hydrochloric acid (1 mL), and the solution stirred overnight at 348 K. Upon cooling to room 
temperature and standing for 3 h, needle-like white crystals formed which were filtered, washed 
with ice cold methanol (5 mL) and dried in vacuo to afford the hydrochloride salt* of the title 
compound (3.92 g, 98 %).  1H NMR (CD3OD, 700 Mhz): δH 3.91 (3H, s, H
7); 4.22 (2H, s, H5); 7.58 (2H, 
d, J 8, H2/3); 8.06 (2H, d, J 8, H2/3). 13C NMR (CD3OD, 176 MHz): δC 166.16 (C
6); 138.34 (C4); 131.62 
(C1); 130.27 (C3); 129.05 (C2); 52.97 (C7); 42.76 (C5). HR MS ES+ (m/z): found 166.0884 
[M+H]+;C9H12NO2 requires 166.0868. *based on the synthetic procedure followed. 
 
Methyl 4-(acetamidomethyl)benzoate, 14.z 9 
 
 
Acetyl chloride (0.39 mL, 5.4 mmol) was slowly added to a stirring solution of 13 (0.500 g, 2.5 mmol) 
and triethylamine (0.76 mL, 5.5 mmol) in THF at 273 K. The temperature was maintained for 15 min, 
and then gradually warmed to room temperature, and the mixture stirred overnight. The insoluble 
salts were removed by filtration, and solvent removed under reduced pressure to afford a white 
solid (497 mg, 97 %). 1H NMR (CDCl3, 700 MHz): δH 2.11 (3H, s, H
7); 3.91 (3H, s, H9); 4.45 (2H, s, H5); 
7.35 (2H, d, J 8, H2/3); 7.98 (2H, d, J 8, H2/3). 13C NMR (CDCl3, 176 MHz): δC 170.63 (C
6); 166.24 (C8); 
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144.01 (C1); 130.31 (C2); 129.79 (C4); 128.45 (C3); 52.07 (C9); 43.44 (C5); 23.68 (C7). HR MS ES+ (m/z): 
found 208.0958 [M+H]+; C11H14NO3 requires 208.0974. 
 
N-(4-(Hydroxymethyl)benzyl)acetamide, 15.9 
 
 
The para-acetamide benzylic ester 14 (2.000 g, 9.61 mmol) in THF (180 mL) was added dropwise to a 
1.0 M solution of LiAlH4 in THF (19.2 mL, 19.2 mmol) cooled to 195 K. The mixture was stirred for 10 
min, and allowed to warm to room temperature. The reaction was quenched with sodium hydroxide 
(~ 25 mL, 10 M), filtered, and concentrated under reduced pressure. The crude residue was re-
dissolved in dichloromethane (75 mL) and washed successively aqueous potassium carbonate (2 x 50 
mL, 0.1 M) and water (2 x 50 mL), dried over magnesium sulphate, filtered and solvent reduced 
pressure. Purification by silica gel column chromatography (dichloromethane  1 % methanol) 
afforded an off white solid (1.015 g, 59%). RF = 0.25 (dichloromethane : methanol; 99 : 1). 
1H NMR 
(CDCl3, 400 MHz): δH 1.91 (3H, s, H
7); 4.32 (2H, s, H8); 4.80 (2H, s, H5); 4.90 (1H, br. s, HNH); 7.30 (2H, 
d, J 8, H2/3); 7.88 (2H, d, J 8, H2/3). HR MS-ES+ (m/z): found: 180.1019 [M+H]+; C10H14NO2 requires 
180.1025. 
 
N-(4-(Bromomethyl)benzyl)acetamide, 16. 
 
 
The para-acetamide benzylic alcohol 15 (1.000 g, 5.6 mmol) was dissolved in hydrogen bromide (37 
% in acetic acid) and toluene (1 : 1, v : v, 100 mL), and stirred for 30 min at 298 K. The solvent was 
removed under reduced pressure, and the progress of reaction monitored using 1H NMR, following 
the chemical shift of the methylene-bromo (H8) protons. Purification by silica gel column 
chromatography (gradient elution: dichloromethane  1 % Methanol) afforded an off white solid. 
(1.22 g, 90 %) RF = 0.45 (dichloromethane : methanol, 99 : 1). 
1H NMR (CDCl3, 700 MHz): δH 2.04 (3H, 
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s, H7); 4.45 (2H,s , H8); 5.10 (2H, s, H5); 5.92 (1H, br. s, HNH); 7.29 (2H, m, H2/3). HR MS ES+ (m/z): 
found 242.0180 [M+H]+; C10H13NOBr requires 242.0180. 
 
Tert-butyl 2,2'-(6-((4-(acetamidomethyl)benzyl)(2-tert-butoxy-2-oxoethyl)amino)-6-methyl-1,4-
diazepane-1,4-diyl)diacetate, 17 
 
 
The para-acetamide benzylic bromide 16 (0.053 g, 0.22 mmol) was added to a solution of 5 (0.050 g, 
0.11 mmol) and caesium carbonate (0.072 g, 0.22 mmol) in acetonitrile (25 mL), and the mixture 
stirred for 18 h at 353 K under an atmosphere of argon.  The solvent was removed under reduced 
pressure and the resulting oil re-dissolved in chloroform (20 mL) and washed successively with 
aqueous potassium carbonate solution (2 x 20 mL, 0.1 M) and water (20 mL), dried over MgSO4, 
filtered and solvent removed under reduced pressure. Purification by silica gel column 
chromatography (hexane  35 % ethyl acetate) afforded the title compound as a yellow oil (0.030 g, 
45 %). Rf = 0.65 (hexane : ethyl acetate; 50 : 50). 
1HNMR (CDCl3, 700 MHz): δ 1.13 (3H, s, H
1ᶦ); 1.33 
(9H, s, H15); 1.43 (18H, s, H11); 1.99 (3H, s, H23); 2.65 (2H, d, J 14, H2,7); 2.69 (2H, m, H4,5); 2.77 (2H, m, 
H4,5); 3.11 (2H, d, J 14, H2,7); 3.24 (2H, d, J 17, H8); 3.28 (2H, d, J 17, H8); 3.39 (2H, s, H12); 4.06 (2H, s, 
H16); 4.36 (2H, d, J 6, H21); 7.16 (2H, d, J 8, H19); 7.33 (2H, d, J 8, H18). 13C NMR (CDCl3, 176 MHz): δ 
23.26 (C23); 24.54 (C1ᶦ); 27.96 (C15); 28.20 (C11); 43.61 (C21); 52.15 (C12); 53.05 (C16); 59.11 (C4,5); 61.20 
(C1); 62.42 (C8); 65.36 (C2,7); 80.03 (C14); 80.73 (C10); 127.66 (C19); 128.64 (C18); 136.19 (C20); 140.98 
(C17); 169.65 (C22); 170.91 (C9); 172.82 (C13). HR MS ES+ (m/z): found 633.4230 [M + H]+; C34H57N4O7 
requires 633.4227; found 655.4043[M + Na]+; C34H56N4NaO7 requires 655.4047. 
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2,2'-(6-((4-(acetamidomethyl)benzyl)(carboxymethyl)amino)-6-methyl-1,4-diazepane-1,4-
diyl)diacetic acid Tristrifluoro acetate salt, L5.CF3COOH. 
 
 
The triester 17 (0.020 g, 0.032 mmol) was dissolved in trifluoroacetic acid : dichloromethane (1 : 1, 2 
mL) and left to stir for 2 days at room temperature. The solvent was removed under reduced 
pressure, the residue re-dissolved in dichloromethane : methanol (1 : 1, 2 mL) and evaporated. This 
procedure was repeated twice, and also with methanol. The resulting solid was dissolved in water 
(10 mL) and washed with dichloromethane (10 mL). Removal of solvent under reduced pressure 
afforded the tris- triflouroacetate salt as an off-white solid (0.020 g, 67 %). 1HNMR (D2O, pD 2.37, 
700 MHz): δH 1.32 (3H, s, H
1'); 3.33 (2H, m, H4/5); 3.47 (2H, d, J 15, H2/7); 3.49 (2H, m, H4/5); 3.62 (2H, 
d, J 15, H2/7); 3.74 (2H, d, J 17, H8); 3.80 (2H, d, J 17, H8); 4.03 (2H, s, H10); 4.23 (2H, s, H17); 4.33 (2H, s, 
H12); 7.18 (2H, d, J 8, H15); 7.36 (2H, d, J 8, H14). 13C NMR (D2O, pD 2.37, 176 MHz): δC 16.45 (C
1'); 
21.81 (C19); 42.65 (C17); 43.08 (C10); 53.25 (C4/5); 54.62 (C12); 58.76 (C8); 59.35 (C2/7); 66.91 (C1); 127.68 
(C15); 128.75 (C16); 131.38 (C14); 139.89 (C13); 170.93 (C11); 171.21 (C8); 174.12 (C18). HR MS ES+ (m/z): 
found 465.2953 [M + H]+; C22H33N4O7 requires 465.2941. Elemental analysis (%): found: C (42.9) H 
(4.51) N (6.72); [C22H32N4O7].3CF3COOH requires C (41.7) H (4.37) N (6.95). 
 
4.2 Compounds Relating to the Syntheses of APPED Based Ligands, L6-9 
 
2,4-Dimethoxybenzaldehyde, 19.  
 
 
Manganese(II) dioxide (11.4 g, 10x by mass) was added to a solution of 2,4-dimethoxyl benzyl 
alcohol (1.140 g, 6.78 mmol) in chloroform (100 mL), and the mixture stirred at 298 K for 18 h. The 
mixture was filtered through Celite®, using ethanol (20 mL) and chloroform (20 mL) to wash the 
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filtered solids, and the solvent removed under reduced pressure. The residue was recrystallised from 
ethanol, and dried in vacuo, to afford the title compound as an off white crystalline solid (0.853 g, 76 
%). m.p. 71 °C. 1H NMR (CDCl3, 700 MHz): δH 3.86 (3H, s, H
8/9); 3.88 (3H, s, H8/9); 6.43 (1H, s, H3); 6.52 
(1H, d, J 9, H5); 7.80 (1H, d, J 9, H6); 10.27 (1H, s, H7). 13C NMR (CDCl3, 176 MHz): δC 55.62 (C
8/9); 98.05 
(C3); 105.77 (C5); 119.12 (C4); 130.58 (C6); 163.58 (C1/2); 166.14 (C1/2); 188.06 (C7). MS ES+ (m/z): 
found 167.1 [M + H]+;C9H11O3 requires 167.0708. 
 
N1,N2-Bis(2,4-dimethoxybenzyl)ethane-1,2-diamine, 20. 
 
 
Under an inert atmosphere of argon, 2,4-dimethoxybenzaldehyde (3.00 g, 18 mmol) was dissolved in 
dry methanol (100 mL) containing 3 Å molecular sieves. The mixture was stirred at room 
temperature for 30 minutes before N,N’-ethylenediamine (0.59 g, 9.9 mmol) was added, and the 
mixture left to stir at room temperature overnight. The methanol was removed under reduced 
pressure and chloroform (200 mL) added, before the molecular sieves were removed by filtration. 
Removal of the chloroform under reduced pressure yielded the diimine as a yellow solid. The di-
imine formed during this reaction is sensitive to water and was used in the next step without further 
purification and characterisation. Under an inert atmosphere of argon, sodium borohydride (2.70 g, 
71 mmol) was added gradually over 30 minutes to a solution of the di-imine dissolved in dry 
methanol (40 mL). The solution was left to stir overnight at room temperature. The methanol was 
removed under reduced pressure and the solid re-dissolved in chloroform and washed successively 
with aqueous sodium hydroxide solution (0.1 M) and water. Removal of the chloroform under 
reduced pressure and subsequent drying in vacuo yielded a golden yellow oil which crystallized 
overnight to give a dark yellow solid. (3.03 g, 93 %) m.p. 56°C. 1H NMR (CDCl3, 500 MHz): δH 2.72 
(4H, s, H1); 3.75 (4H, s, H3); 3.78 (6H, s, H11); 3.82 (6H, s, H10); 6.44 (4H, m, H5,6); 7.12 (1H, d, J 8, H8). 
13C NMR (CDCl3, 125 MHz): δC 48.71 (C
1); 48.83 (C3); 55.55 (C11); 55.68 (C10), 98.71 (C5/6); 103.72 
(C5/6); 121.32 (C4); 130.56 (C8); 158.84 (C9); 160.29 (C7). HR MS ES+ (m/z): found: 361.2134 [M + H]+; 
C20H29N2O4 requires 361.2127. 
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(Nitromethyl)benzene, 21.10 
 
7
1
6 5
4
32
O2N
 
Silver nitrite (1.710 g, 40 mmol) was added to (bromomethyl)benzene (1.710 g, 10 mmol) in water 
(100 mL) contained in a flask covered in aluminium foil to exlude light. The mixture was stirred 
vigoursly at 298 K for 18 h. Ethyl acetate (100 mL) was added and the organic layer extracted. The 
aqueous layer was washed three more times with fresh ethyl acetate (50 mL), the organic layers 
combined and the solvent removed under reduced pressure. Purification by silica gel column 
chromtagraphy (hexane) afforded the title compound as a colourless oil (0.342, 325 %). Rf = 0.75. 
1H 
NMR (CDCl3, 700 MHz): δH 5.43 (2H, s, H
7); 7.48 (5H, m, H2,3,4,5,6). HR MS ES- (m/z): found 136.0398 
[M - H]-; C7H6NO2 requires 136.0399. 
 
1,4-Bis(2,4-dimethoxybenzyl)-6-nitro-6-phenyl-1,4-diazepane, 22. 
 
 
Nitromethylbenzene (0.32 g, 2.3 mmol) was added dropwise over 30 minutes to a solution of the 
N,N'-bis(2,4-dimethoxybenzyl)ethane-1,2-diamine 20 (0.83 g, 2.3 mmol) and paraformaldehyde (0.24 
g, 8 mmol) in ethanol/toluene (50/50: 30 mL), and the reaction mixture stirred at 313 K overnight.  
The solvent was removed under reduced pressure and the resulting oil re-dissolved in chloroform 
(30 mL) and washed successively with aqueous potassium carbonate solution (2 x 30 mL, 0.1 M) and 
water (50 mL), dried over magnesium sulfate, filtered and the solvent removed under reduced 
pressure. Purification by silica gel column chromatography (hexane  15 % ethyl acetate) yielded, 
after drying in vacuo, a white solid (0.134 g, 11 %). Rf = 0.55 (hexane : ethyl acetate; 65 : 35), m.p. 62 
- 67 °C. 1H NMR (CDCl3, 700 MHz): δH 2.85 (4H, m, H
4,5); 3.52 (2H, d, J 14, H8); 3.73 (2H, d, J 14, H2,7); 
3.76 (6H, s, H16); 3.77 (2H, d, J 14, H2,7); 3.78 (6H, s, H15) 3.85 (2H, d, J 14, H8); 6.42 (4H, m, H11,13); 
7.17 (2H, d, J 9 , H10); 7.28 (3H, m, H3',4'); 7.37 (2H, t, J 4, H2'). 13C NMR (CDCl3, 176 MHz): δC 55.33 
(C16); 55.33 (C15) 56.79 (C2,7); 57.94 (C4,5); 64.77 (C8); 97.98 (C1'); 98.38 (C11); 104.00 (C13); 119.62 (C9); 
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124.87 (C2'); 128.20 (C4'); 128.55 (C3'); 131.12 (C10); 140.04 (C1); 158.71 (C16); 159.91 (C15). HR MS ES+ 
(m/z):  found 522.2603 [M + H]+; C29H36N3O6 requires 522.2604. The structure of 22 was confirmed 
by single crystal X-ray diffraction: C29H35N3O6, Mr = 521.60, monoclinic (P21/n); a = 8.8932(2) Å, b = 
19.1927(5) Å, c = 15.3402(3) Å, V = 2616.02(11) Å3, β = 92.411(2)°, Z = 4, μ = 0.093 mm-1, Dcalc. = 1.324 
mg/mm3, T 120(2) K; 7279 independent reflections (Rint = 0.0449), R1 = 0.0478, ωR2 = 0.1084 (I > 2σ 
(I)). CCDC # 906040. 
 
6-Nitro-6-phenyl-1,4-diazepane , 23. 
 
NH
NH
NO2
4
52
7
11'
2'
3'
4'
 
Trifluoroacetic acid (2 mL) was added to a solution of 22 (0.15 g, 0.29 mmol) in dichloromethane (2 
mL), and the mixture stirred at room temperature. The reaction was monitored using LC-ESI MS, to 
follow removal of the dimethoxybenzyl substituents. Once complete, the solvent was removed by 
lyophilisation. Excess triflouroacetic acid was removed through repeated addition and removal of 
dicholormethane (3 x 10 mL) and subsequently methanol (3 x 10 mL). Filtration of a methanol 
solution (20 mL), using a 0.45 μm syringe filter, and subsequent removal of the methanol under 
reduced pressure yielded a brown oil. The oil was re-dissolved in chloroform : isopropyl alcohol (80 : 
20, 20 mL) and washed successively with aqueous sodium hydroxide (2 x 20 mL, 0.5 M) and water 
(10 mL), dried over MgSO4, filtered and solvent removed under reduced pressure to yield a pale 
yellow oil, (0.029 g, 45 %). 1H NMR (CD3OD, 600 MHz): δH 1.44 (4H, m, H
4,5); 3.71 (2H, d, J 15, H2,7); 
4.30 (2H, d, J 15 H2,7); 7.35 (1H, t, J 8 H4');  7.38 (2H, t, J 8, H3'); 7.42 (2H, d, J 8, H2'). 13C NMR (CD3OD, 
151 MHz): δC 45.78 (C
4,5); 53.89 (C2,7); 94.44 (C1'); 124.88 (C4'); 124.96 (C3'); 128.23 (C2'); 135.16 (C1). 
HR MS ES+ (m/z): found: 222.1240 [M + H]+; C11H16N3O2 requires 222.1243. 
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Tert-butyl 2,2'-(6-nitro-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 24. 
 
 
Tert-butyl bromoacetate (0.10 g, 0.52 mmol) was added dropwise to a mixture of potassium 
carbonate (0.072 g, 0.52 mmol) and 23 (0.029 g, 0.13 mmol)  in acetonitrile (10 mL). The reaction 
mixture was stirred at 308 K for 24 hours, and the solvent removed under reduced pressure. The 
resulting oil was re-dissolved in chloroform (20 mL) and washed successively with aqueous 
potassium carbonate solution (2 x 20 mL, 0.1 M) and water (20 mL), dried over MgSO4, filtered and 
solvent removed under reduced pressure. Purification by silica gel column chromatography (hexane : 
ethyl acetate, 95 : 5) yielded a white solid (0.036 g, 62 %). Rf = 0.49 (hexane : ethyl acetate; 65 : 35). 
m.p. 78 - 90 °C. 1H NMR (CDCl3, 700 MHz): δH 1.44 (18H, s, H
11); 2.93 (2H, m, H4,5); 3.03 (2H, m, H4,5); 
3.38 (2H, d, J 17, H8); 3.56 (2H, d, J 17, H8); 3.63 (2H, d, J 15, H2,7); 3.96 (4H, d, J 15, H2,7);  7.24 (2H, d, 
J 8, H2'); 7.31 (2H, m, H3',4'). 13C NMR (CDCl3, 176 MHz): δC 28.20 (C
11); 55.93 (C4,5); 60.33 (C8); 62.87 
(C2,7); 81.15 (C10); 97.99 (C1'); 124.62 (C2'); 128.52 (C4'); 128.81 (C3'); 138.68 (C1); 170.90 (C9). HR MS 
ES+ (m/z): found: 450.2612 [M + H]+; C23H36N3O6 requires 450.2604. The structure of 24 was 
confirmed by single crystal X-ray diffraction: C23H35N3O6, Mr = 449.54, monoclinic (P21/c); a = 
21.3378(19) Å, b = 11.5579(10) Å, c = 10.3203(9) Å, V = 2503.9(4) Å3,β = 100.329(9)°, Z = 4; μ = 0.086 
mm-1, Dcalc. = 1.192 mg.mm
-3, T 120(2) K; 5463 independent reflections (Rint = 0.1564), R1 = 0.0899 , 
ωR2 = 0.1741 (I > 2σ(I)). 
 
Tert-butyl 2,2'-(6-amino-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 25. 
 
 
A water slurry of Raney nickel (0.010 g) was washed with methanol (3 x 25 mL) and ethanol added 
(10 mL). The suspension was transferred into a solution of 24 (0.050 g, 0.11 mmol) in ethanol (25 
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mL). The flask was evacuated and back-filled with hydrogen gas using four vacuum-purge cycles, and 
the mixture stirred at 298 K under an atmosphere of hydrogen. The reaction was monitored by UV-
vis TLC for formation of the primary amine. Once complete (~ 3 h), the solution was decanted, and 
the solid washed with methanol (3 x 20 mL). The washings and decanted solution were combined, 
removed under reduced pressure and re-dissolved in methanol (25 mL). Remaining Raney nickel and 
insoluble by-products were removed by filtration through a base washed Celite® filter, and the 
solvent was removed under reduced pressure. The resulting oil was re-dissolved in chloroform : 
isopropyl alcohol (80 : 20, 20 mL) and washed successively with aqueous sodium hydroxide (2 x 20 
mL, 0.5 M) and water (15 mL), dried over MgSO4, filtered and the solvent removed under reduced 
pressure to yield a colourless oil (0.017 g, 37 %). 1H NMR (CDCl3, 700 MHz): δH 1.42 (18H, s, H
11); 2.16 
(2H, br. s, NH2); 2.61 (2H, d, J 14, H
2,7); 2.94 (4H, m, H4,5); 3.31 (2H, d, J 14, H2,7); 3.36 (4H, s, H8); 7.21 
(2H, t, J 8, H4'); 7.30 (1H, t, J 8, H3'); 7.60 (2H, d, J 8, H2'). 13C NMR (CDCl3, 176 MHz): δC 28.18 (C
11); 
56.93 (C4,5); 58.19 (C1); 61.76 (C8); 69.25 (C2,7); 80.88 (C10); 125.23 (C3'); 126.46 (C4'); 128.09 (C2'); 
146.90 (C1'); 170.87 (C9). HR MS ES+ (m/z): found 420.2859 [M + H]+; C23H38N3O4 requires 420.2862. 
 
Tert-butyl 2,2'-(1,4-bis(2-tert-butoxy-2-oxoethyl)-6-phenyl-1,4-diazepan-6-ylazanediyl)diacetate 
, 26. 
 
 
Tert-butyl-bromoacetate (0.14 g, 0.72 mmol) was added to a solution of 25 (0.050 g, 0.12 mmol) and 
potassium carbonate (0.13 g, 0.96 mmol) in acetonitrile (20 mL), and the mixture stirred for 18 h at 
323 K under an atmosphere of argon.  The solvent was removed under reduced pressure and the 
resulting oil re-dissolved in chloroform (20 mL) and washed successively with aqueous potassium 
carbonate solution (2 x 20 mL, 0.1 M) and water (2 x 20 mL), dried over MgSO4, filtered and solvent 
removed under reduced pressure. Purification by silica gel column chromatography (hexane  5 % 
ethyl acetate) afforded the title compound as a yellow oil (0.009 g, 12 %). Rf = 0.75 (hexane : ethyl 
acetate; 65 : 35). 1HNMR (CDCl3, 700 MHz): δ 1.42 (18H, s, H
11/15); 1.43 (18H, s, H11/15); 2.72 (2H,m, 
H4,5); 2.84 (2H, m, H4,5); 3.11 (2H, d, J 15, H2,7); 3.29 (4H, d + d, H2,7 + 8); 3.36 (2H, d, J 17, H8); 3.59 (4H, 
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s, H12); 7.17 (1H, t, J 8, H4ᶦ); 7.27 (2H, t, J 8, H3ᶦ); 7.73 (2H, d, J 8, H2ᶦ). 13C NMR (CDCl3, 176 MHz): δ 
28.08 (C11/15); 28.19 (C11/15); 53.66 (C12); 59.12 (C4,5); 62.04 (C8); 65.41 (C2,7); 67.37 (C1); 80.06 (C10/14); 
80.84 (C10/14); 126.46 (C4ᶦ); 127.08 (C2ᶦ); 128.05 (C3ᶦ); 147.73 (C1ᶦ); 170.54 (C9); 172.13 (C13). HR MS ES+ 
(m/z): found 648.4247 [M + H]+; C35H58N3O8 requires 648.4224; found 670.4068 [M + Na]
+; 
C35H57N3NaO8 requires 670.4043. 
 
Tert-butyl 2,2'-(6-(2-tert-butoxy-2-oxoethylamino)-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 27. 
 
 
Tert-butyl-bromoacetate (0.29 g, 1.6 mmol) was added to a solution of 25 (0.050 g, 0.3 mmol) and 
potassium carbonate (0.31 g, 2.1 mmol) in acetonitrile (30 mL), and the mixture stirred for 18 h at 
313 K under an atmosphere of argon.  The solvent was removed under reduced pressure and the 
resulting oil re-dissolved in chloroform (20 mL) and washed successively with aqueous potassium 
carbonate solution (2 x 20 mL, 0.1 M) and water (20 mL), dried over magnesium sulfate, filtered and 
solvent removed under reduced pressure. Purification by silica gel column chromatography (hexane 
 5 % ethyl acetate) yielded a yellow oil (0.051 g, 32 %). Rf = 0.60 (hexane : ethyl acetate; 65 : 35). 
1H NMR (CDCl3, 700 MHz): δH 1.37 (18H, s, H
11); 1.38 (9H, s, H15); 1.89 (1H, br. s, NH); 2.83 (2H, d, J 
15, H4,5); 2.87 (4H, s, H2,7); 3.04 (2H, s, H12); 3.27 (2H, d, J 15, H4,5); 3.33 (4H, s, H8); 7.14 (1H, t, J 7, 
H4'); 7.24 (2H, t, J 7, H3'); 7.45 (2H, d, J 7, H2'). 13C NMR (CDCl3, 176 MHz): δC 28.10 (C
11); 28.21 (C15); 
45.57 (C12); 56.44 (C2,7); 61.62 (C8); 62.08 (C1'); 65.54 (C4,5); 80.88 (C10,14); 126.51 (C2'); 126.67 (C4'); 
128.26 (C3'); 144.48 (C1); 171.01 (C9); 171.75 (C13). HR MS ES+ (m/z): found: 534.3556 [M + H]+; 
C29H48N3O6 requires 534.3543. 
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Tert-butyl 2,2'-(6-((2-tert-butoxy-2-oxoethyl)(methyl)amino)-6-phenyl-1,4-diazepane-1,4-
diyl)diacetate, 28. 
 
 
Methyl iodide (0.032 g, 0.023 mmol) was added to a solution of 27 (0.03 g, 0.056 mmol) and 
potassium carbonate (0.032 g, 0.023 mmol) in acetonitrile (30 mL), and the mixture stirred for 24 
hours at 303 K, under an atmosphere of argon.  The solvent was removed under reduced pressure 
and the resulting oil re-dissolved in chloroform (20 mL) and washed successively with aqueous 
potassium carbonate solution (2 x 20 mL, 0.1 M) and water (20 mL), dried over magnesium sulfate, 
filtered and solvent removed under reduced pressure. Purification by silica gel column 
chromatography (hexane  5 % ethyl acetate) yielded a yellow oil (0.01 g, 45 %). Rf = 0.60 (SiO2, 
hexane : ethyl acetate; 65 : 35). 1H NMR (CDCl3, 700 MHz): δH 1.38 (18H, s, H
11); 1.39 (9H, s, H15); 
2.23 (3H, s, H16); 2.70 (2H, m, H4,5); 2.80 (4H, m, H4,5); 3.06 (2H, d, J 15, H2,7); 3.13 (2H, d, J 15, H2,7); 
3.26 (2H, d, J 17, H8); 3.30 (2H, d, J 17, H8); 3.47 (2H, s, H12);  7.11 (1H, t, J 8, H4'); 7.21 (2H, t, J 8, H3'); 
7.63 (2H, d, J 8, H2'). 13C NMR (CDCl3, 176 MHz): δC 28.12 (C
11); 28.20 (C15); 45.57 (C12); 38.40 (C16); 
54.73 (C12); 58.84 (C4,5); 62.19 (C8); 64.11 (C2,7); 66.55 (C1'); 80.10 (C14); 80.84 (C10); 126.27 (C4'); 
126.94 (C2'); 127.96 (C3'); 148.05 (C1); 170.63 (C9); 172.37 (C13). HR MS ES+ (m/z): found: 548.3704 [M 
+ H]+; C30H50N3O6 requires 548.3700. 
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2,2'-(6-((carboxymethyl)(methyl)amino)-6-phenyl-1,4-diazepane-1,4-diyl)diacetic acid 
Bistrifluoroacetate salt, L7.2CF3COOH. 
 
 
The triester 28 (0.050 g, 0.091 mmol) was dissolved in trifluoroacetic acid / dichloromethane (1 : 1, 2 
mL) and left to stir for 2 days at room temperature. The solvent was removed under reduced 
pressure, the residue re-dissolved in dichloromethane : methanol (1 : 1, 2 mL) and evaporated. This 
procedure was repeated twice, and with methanol. The resulting solid was dissolved in water (10 
mL) and washed with dichloromethane (10 mL). Removal of solvent under reduced pressure and 
drying in vacuo afforded a white solid (0.039 g, 71 %). 1H NMR (D2O, pH = 2.17, 600 MHz): δH 2.62 
(3H, s, H12); 3.15 (2H, m, H4,5); 3.44 (2H, m, H4,5); 3.44  (2H, d, J 14, H2,7); 3.67 (3H, m, H4/5,10); 3.83 (3H, 
m, H4/5,8); 3.88 (2H, d, J 14, H2,7); 7.30 (1H, m, H4'); 7.35 (2H, m, H3'); 7.40 (2H, m, H2'). 13C NMR (D2O, 
pH = 2.17, 151 MHz): δc 32.60 (C
12); 51.89 (C4/5); 53.19 (C4/5); 58.73 (C10); 59.00 (C8); 63.00 (C2,7); 
71.85 (C1); 128.87 (C4'); 129.05 (C3'); 129.44 (C2'); 170.04 (C9); 172.80 (C11). HR MS ES+ (m/z): found 
380.1818 [M + H]+; C18H26N3O6 requires: 380.1822. Elemental analysis (%): found C (43.2) H (4.33) N 
(6.84); [C18H25N3O6].2CF3COOH requires C (43.5) H (4.48) N (6.92). 
 
Diethyl 2,2'-(6-nitro-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 30. 
 
 
Ethyl bromoacetate (0.061 g, 0.52 mmol) was added dropwise to a stirred solution of potassium 
carbonate (0.072 g, 0.52 mmol) and 22 (0.029 g, 0.13 mmol) in acetonitrile (10 mL). The reaction 
mixture was stirred at 308 K for 24 hours, and solvent removed under reduced pressure. The 
resulting oil was re-dissolved in chloroform (20 mL) and washed successively with aqueous 
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potassium carbonate solution (2 x 20 mL, 0.1 M) and water (20 mL), dried over MgSO4, filtered and 
solvent removed under reduced pressure. Purification by silica gel column chromatography (hexane 
 20 % ethyl acetate) yielded a yellow oil (0.034 g, 66%). Rf = 0.27 (hexane : ethyl acetate, 65 : 35). 
1H NMR (CDCl3, 700 MHz): δH 1.26 (6H, t, J 7, H
11); 2.96 (2H, m, H4,5); 3.04 (2H, m, H4,5); 3.49 (2H, d, J 
18, H8); 3.64 (2H, d, J 15, H2,7); 3.67 (2H, d, J 18, H8); 3.97 (2H, d, J 15, H2,7);  7.24 (2H, d, J 8, H2'); 7.32 
(2H, m, H3',4'). 13C NMR (CDCl3, 176 MHz): δC 14.26 (C
11); 55.85 (C4,5); 59.41 (C8); 60.40 (C10)62.70 
(C2,7); 97.76 (C1'); 124.63 (C2'); 128.62 (C4'); 128.84 (C3'); 138.41 (C1); 171.53 (C9). HR MS ES+ (m/z): 
found: 394.1968 [M + H]+; C19H28N3O6 requires 394.1978. 
 
Diethyl 2,2'-(6-amino-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 31. 
 
 
A water slurry of Raney nickel (0.010 g) was washed with methanol (3 x 25 mL) and ethanol added 
(10 mL). The suspension was transferred into a solution of 30 (0.050 g, 0.13 mmol) in ethanol (25 
mL). The flask was evacuated and back-filled with hydrogen gas using four vacuum-purge cycles, and 
the mixture stirred at 298 K under an atmosphere of hydrogen. The reaction was monitored by UV-
vis TLC for formation of the primary amine. Once complete (~ 3 h), the solution was decanted, and 
the solid washed with methanol (3 x 20 mL). The washings and decanted solution were combined, 
removed under reduced pressure and re-dissolved in methanol (25 mL). Remaining Raney nickel and 
insoluble by-products were removed by filtration through a base washed Celite® filter, and the 
solvent was removed under reduced pressure. The resulting oil was re-dissolved in chloroform : 
isopropyl alcohol (80 : 20, 20 mL) and washed successively with aqueous sodium hydroxide (2 x 20 
mL, 0.5 M) and water (15 mL), dried over MgSO4, filtered and the solvent removed under reduced 
pressure to yield a colourless oil (0.014 g, 30 %). 1H NMR (CDCl3, 700 MHz): δH 1.22 (6H, t+t, H
11); 
2.12 (2H, br. s, NH2); 2.63 (2H, d, J 14, H
2,7); 2.95 (4H, m, H4,5); 3.30 (2H, d, J 14, H2,7); 3.46 (4H, s, H8); 
4.10 (4H, q+q, J 7, H10) 7.25 (2H, t, J 7, H4'); 7.29 (1H, t, J 7, H3'); 7.59 (2H, d, J 7, H2'). 13C NMR (CDCl3, 
176 MHz): δC 14.25 (C
11); 56.90 (C4,5); 58.15 (C1); 60.28 (C10); 60.82 (C8); 69.25 (C2,7); 125.19 (C4'); 
128.11 (C3'); 128.44 (C2'); 146.62 (C1); 171.47 (C9). HR MS ES+ (m/z): found 364.2235 [M + H]+; 
C19H30N3O4 requires 364.2236. 
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Diethyl 2,2'-(6-(2-ethoxy-2-oxoethylamino)-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 32. 
 
 
Ethyl-bromoacetate (0.068 g, 0.41 mmol) was added to a solution of 31 (0.030 g, 0.083 mmol) and 
potassium carbonate (0.080 g, 0.58 mmol) in acetonitrile (20 mL), and the mixture stirred for 18 h at 
313 K under an atmosphere of argon.  The solvent was removed under reduced pressure and the 
resulting oil re-dissolved in chloroform (20 mL) and washed successively with aqueous potassium 
carbonate solution (2 x 15 mL, 0.1 M) and water (15 mL), dried over MgSO4, filtered and solvent 
removed under reduced pressure. Purification by silica gel column chromatography (hexane  15 % 
ethyl acetate) afforded the title compound as a yellow oil (0.016 g, 43 %). Rf = 0.35 (hexane : ethyl 
acetate; 65 : 35). 1H NMR (CDCl3, 700 MHz): δH 1.24 (9H, t, J 7, H
11,15); 1.69 (1H, br. s, NH); 2.89 (2H, 
d, J 14, H2,7); 2.94 (4H, s, H4,5); 3.18 (2H, s, H12); 3.34 (2H, d, J 14, H2,7); 3.49 (4H, s, H8); 4.13 (4H, q, J 7, 
H10); 4.17 (2H, q, J 7, H14)  7.19 (1H, t, J 8, H4'); 7.29 (2H, t, J 8,H3'); 7.50 (2H, d, J 8 , H2'). 13C NMR 
(CDCl3, 176 MHz): δC 14.16 (C
11/15); 14.27 (C11/15); 44.85 (C12); 55.23 (C1); 56.51 (C4,5); 60.39 (C10); 
60.57 (C12); 60.74 (C8); 65.51 (C2,7); 126.50 (C2'); 126.75 (C4'); 128.33 (C3'); 144.17 (C1'); 171.54 (C9); 
172.46 (C13). HR MS ES+ (m/z):  found: 450.2602 [M + H]+; C23H36N3O6 requires 450.2604; found: 
472.2423 [M + Na]+; C23H35N3NaO6 requires 472.2424. 
 
2,2'-(6-(Carboxymethylamino)-6-phenyl-1,4-diazepane-1,4-diyl)diacetic acid trisodium salt, Na3.L
6. 
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Sodium hydroxide (0.003 g, 0.069 mmol) dissolved in water (0.5 mL) was added to a solution of the 
triester 32 (0.010 g, 0.022 mmol) in THF (0.5 mL), and the mixture stirred at 298 K. The reaction was 
monitored using LC-ESI MS, to follow ester cleavage. Once complete, the solvent was removed by 
lyophilisation. Water (5 mL) was added and removed by lyophilisation, and the procedure repeated 
two more times. The resulting solid was washed with ice-cold dichloromethane (0.5 mL), and dried 
in vacuo, to afford the tetra-hydrated tri-sodium salt of the title compound as a white solid (0.010 g, 
85 %). 1H NMR (D2O, pD 11.78, 600 MHz, ppm): δH 2.61 (2H, m, H
4,5); 2.71 (3H, s, H10); 2.76 (2H, m, 
H4,5); 2.88 (2H, d, J 14, H2,7); 3.09 (2H, d, J 16, H8); 3.16 (4H, d+d, H2,7,8); 7.419 (1H, t, J 7, H4'); 7.29 
(2H, t, J 7, H3'); 7.34 (2H, d, J 7, H2'). 13C NMR (D2O, pD 11.78, 151 MHz, ppm): δC 46.32 (C
10); 56.72 
(C4,5); 61.99 (C1); 63.51 (C8); 65.09 (C2,7); 126.73 (C2'); 127.11 (C4'); 128.51 (C3'); 143.40 (C1'); 179.23 
(C11); 179.35 (C9). HR MS ES+ (m/z): found 366.1666 [M + H]+; C17H24N3O6 requires 366.1665. 
Elemental analysis (%): found C (40.7) H (5.73) N (8.27); Na3[C17H20N3O6].4H2O requires C (40.6) H 
(5.61) N (8.35). 
 
(2S,2'S)-Diethyl 2,2'-(6-nitro-6-phenyl-1,4-diazepane-1,4-diyl)dipropanoate, 34. 
 
 
Ethyl (2R)-2-{[(trifluoromethyl)sulfonyl]oxy}propanoate (0.20 g, 0.78 mmol) was added to a stirred 
solution of potassium carbonate (0.11 g, 0.78 mmol) and 22 (0.029 g, 0.13 mmol) in acetonitrile (15 
mL). The reaction mixture was stirred at 308 K for 24 h, and solvent removed under reduced 
pressure. The resulting oil was re-dissolved in chloroform (20 mL) and washed successively with 
aqueous potassium carbonate solution (2 x 20 mL, 0.1 M) and water (20 mL), dried over MgSO4, 
filtered and solvent removed under reduced pressure. Purification by silica gel column 
chromatography (hexane : ethyl acetate, 95 : 5) afforded the title compound as a colourless oil 
(0.042 g, 77 %). Rf = 0.54 (hexane : ethyl acetate; 65 : 35). 
1H NMR (CDCl3, 600 MHz, ppm): δ 1.15 
(3H, d, J 7, H9); 1.24 (6H, t+t, J 7, H12,17); 1.31 (3H, d, J 7, H14); 2.67 (2H, m, H4,5); 2.94  (1H, m, H5); 2.98  
(1H, m, H4); 3.48  (1H, q, J 7, H13); 3.51 (1H, d, J 15, H7); 3.59 (1H, q, J 7, H8); 3.70 (1H, d, J 15, H2); 3.89 
(1H, d, J 15, H2); 3.96 (1H, d, J 15, H7); 4.12 (4H, q, J 15, H11,16); 7.31 (5H, m, H2ˈ,3ˈ,4ˈ). 13C NMR (CDCl3, 
151 MHz, ppm): δ 14.38 (C12,17); 16.16 (C9); 16.34 (C14); 53.11 (C5); 55.24 (C4); 60.26 (C11/16); 60.38 
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(C11/16); 63.38 (C2); 63.48 (C8); 63.87 (C7); 63.93 (C13); 98.14 (C1ˈ); 124.79 (C2ˈ); 128.45 (C4ˈ); 128.71 
(C3ˈ); 139.39 (C1); 173.21 (C10,15); 173.56 (C10,15). HR MS ES+ (m/z): found: 422.2301 [M + H]+; 
C21H32N3O6 requires 422.2291. 
(2S,2'S)-Diethyl 2,2'-(6-amino-6-phenyl-1,4-diazepane-1,4-diyl)dipropanoate, 35. 
 
 
A water slurry of Raney nickel (0.010 g) was washed with methanol (3 x 25 mL) and ethanol added 
(10 mL). The suspension was transferred into a solution of 34 (0.050 g, 0.12 mmol) in ethanol (25 
mL). The flask was evacuated and back-filled with hydrogen gas using four vacuum-purge cycles, and 
the mixture stirred at 298 K under an atmosphere of hydrogen. The reaction was monitored by UV-
vis TLC for formation of the primary amine. Once complete (~ 3 h), the solution was decanted, and 
the solid washed with methanol (3 x 20 mL). The washings and decanted solution were combined, 
removed under reduced pressure and re-dissolved in methanol (25 mL). Remaining Raney nickel and 
insoluble by-products were removed by filtration through a base washed Celite® filter, and the 
solvent was removed under reduced pressure. The resulting oil was re-dissolved in chloroform : 
isopropyl alcohol (80 : 20, 20 mL) and washed successively with aqueous sodium hydroxide (2 x 20 
mL, 0.5 M) and water (15 mL), dried over MgSO4, filtered and the solvent removed under reduced 
pressure to yield a colourless oil (0.020 g, 44 %). 1H NMR (CDCl3, 600 MHz, ppm): δ 1.23 (9H, m, 
H12,17, 9/14); 1.29 (3H, d, J 7, H9/14); 2.13 (2H, br. s, NH2); 2.65 (1H, d, J 14, H
2); 2.74 (2H, d+m, H7 + 4/5); 
2.82 (1H, m, H4/5); 2.92 (1H, m, H4/5); 3.00 (1H, m, H4/5); 3.22 (2H, d+d, H2,7); 3.47 (2H, q+q, H8,13); 4.11 
(4H, q+q, H11,16); 7.22 (1H, t, J 7, H4ˈ); 7.31 (2H, t, J 7, H3ˈ); 7.60 (2H, d, J 7, H2ˈ). 13C NMR (CDCl3, 151 
MHz, ppm): δ 14.35 (C12,17); 14.38 (C12,17); 15.27 (C9); 16.37 (C14); 52.94 (C4); 55.31 (C5); 57.60 (C1); 
60.19 (C11/16); 60.23 (C11/16); 65.97 (C7); 63.48 (C13); 63.87 (C2); 63.93 (C8); 125.25 (C2ˈ); 126.51 (C4ˈ); 
128.15 (C3ˈ); 146.09 (C1ˈ); 173.59 (C10,15); 173.68 (C10,15). HR MS ES+ (m/z): found 392.2567 [M + H]+; 
C21H34N3O4 requires 392.2549. 
 
 
 
 
Chapter 6: Experimental 
 
 
 
Page 183 
 
  
 (2S,2'S)-Diethyl 2,2'-(6-((S)-1-ethoxy-1-oxopropan-2-ylamino)-6-phenyl-1,4-diazepane-1,4-
diyl)dipropanoate , 36. 
 
Ethyl (2R)-2-{[(trifluoromethyl)sulfonyl]oxy}propanoate (0.096 g, 0.38 mmol) was added to a solution 
of 35 (0.050 g, 0.13 mmol) and potassium carbonate (0.050 g, 0.38 mmol) in acetonitrile (15 mL), 
and the reaction mixture stirred at 308 K for 18 h. The solvent was removed under reduced pressure 
and the resulting oil re-dissolved in chloroform (20 mL) and washed successively with aqueous 
potassium carbonate solution (2 x 15 mL, 0.1 M) and water (15 mL), dried over MgSO4, filtered and 
solvent removed under reduced pressure. Purification by silica gel column chromatography (hexane : 
ethyl acetate, 95 : 5) afforded the title compound as a colourless oil (0.030 g, 47 %). Rf = 0.65 
(hexane : ethyl acetate; 65 : 35). 1H NMR (CDCl3, 600 MHz, ppm): δH 1.16 – 1.31 (19H, m, 
H9,14,19,12,17,22); 1.61 (1H, br. s, NH); 2.64 (1H, m, H5); 2.70 (1H, m, H4); 2.81 (1H, m, H4); 2.86 (1H, d, J 
13, H7); 2.90 (2H, m, H2,5); 3.05 (1H, d, J 13, H2); 3.13 (1H, q, J 7, H18); 3.27 (1H, d, J 13, H7); 3.39 (2H, 
q+q, H8,13); 4.01 (2H, q, J 7, H11/16/21); 4.09 (2H, q, J 7, H11/16/21); 4.14 (2H, q, J 7, H5); 7.18 (1H, t, J 8, 
H4ᶦ); 7.27 (2H, t, J 8, H3ᶦ); 7.56 (2H, d, J 8, H2ᶦ). 13C NMR (CDCl3, 151 MHz, ppm): δC 14.07 (C
9/12/14/17); 
14.37 (C9/12/14/17); 14.37 (C9/12/14/17); 14.42 (C9/12/14/17); 17.38 (C22); 21.78 (C19); 51.11 (C18); 52.83 (C5); 
55.01 (C4); 60.05 (C21); 60.09 (C11/16); 60.31 (C11/16); 62.28 (C1); 63.38 (C8/13); 63.51 (C2); 63.85 (C28/13); 
65.03 (C7); 126.49 (C4ᶦ); 127.19 (C2ᶦ); 127.84 (C3ᶦ); 145.61 (C1ᶦ); 173.64 (C10/15); 173.71 (C10/15); 177.13 
(C20). HR MS ES+ (m/z): found 492.3071 [M + H]+; C26H42N3O6 requires 492.3074. 
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(2S,2'S)-2,2'-(6-((S)-1-Carboxyethylamino)-6-phenyl-1,4-diazepane-1,4-diyl)dipropanoic acid 
trisodium salt, Na3.L
8. 
 
 
Sodium hydroxide (0.003 g, 0.063 mmol) dissolved in water (0.5 mL) was added to a solution of the 
triester 36 (0.010 g, 0.020 mmol) in THF (0.5 mL), and the mixture stirred at 298 K. The reaction was 
monitored using LC-ESI MS, to follow ester cleavage. Once complete, the solvent was removed by 
lyophilisation. Water (5 mL) was added and removed by lyophilisation, and the protocol repeated 
two more times. The resulting solid was washed with ice cold dichloromethane (0.5 mL), and dried in 
vacuo to afford the tri-sodium salt of the title compound as a white solid (0.091 g, 95 %). 1H NMR 
(D2O, pD 11.34, 600 MHz): δ 0.87 (3H, d, J 7, H
9); 0.90 (3H, d, J 7, H15); 1.09 (3H, d, J 7, H12); 2.49 (1H, 
m, H4/5); 2.60 (1H, m, H4/5); 2.67 (2H, q, J 9, H4,5); 2.73 (1H, q, J 7, H14); 2.83 (1H, d, J 14, H7); 2.96 (1H, 
q, J 7, H8); 2.99 (1H, d, J 14, H2); 3.10 (1H, d, J 14, H2); 3.21 (1H, q, 7, H11); 3.25 (1H, d, J 14, H7); 7.14 
(1H, t, J 8, H4ᶦ); 7.23 (2H, t, J 8, H3ᶦ); 7.37 (2H, d, J 8, H2ᶦ). 13C NMR (D2O, pD 11.34, 151 MHz): δ 14.87 
(C12); 15.70 (C9); 21.35 (C15); 53.50 (C14); 54.70 (C4/5); 56.07 (C4/5); 61.37 (C7); 62.08 (C1); 62.18 (C2); 
66.58 (C8); 67.07 (C11); 126.92 (C4ᶦ); 127.78 (C2ᶦ); 127.96 (C3ᶦ); 143.50 (C1ᶦ); 181.65 (C10/11); 181.94 
(C10/11); 183.84 (C16). HR MS ES+ (m/z): found 430.1972 [M + Na]+; C20H29N3NaO6 requires 430.1964. 
Elemental analysis (%): found C (45.4) H (6.33) N (7.77); Na3[C20H26N3O6].3H2O requires C (45.5) H 
(6.12) N (7.97). 
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1,4-Bis(2,4-dimethoxybenzyl)-6-phenyl-1,4-diazepan-6-ol, 38. 
 
 
The protected APPED scaffold, 22, (0.05 g, 0.10 mmol) was dissolved in ethanol (20 mL) and the 
solution refluxed. The solvolysis reaction was monitored using TLC (Hexane: Ethyl Acetate, 65 : 35). 
Once the nitro precursor (Rf = 0.55) had been consumed, solvent was removed under reduced 
pressure and the resulting oil re-dissolved in chloroform (50 mL) and washed successively with 
aqueous potassium carbonate solution (2 x 50 mL, 0.1 M) and water (50 mL), dried over MgSO4, 
filtered and solvent removed under reduced pressure. Purification by silica gel column 
chromatography (hexane  50 % ethyl acetate) yielded a yellow oil (0.017 g, 34 %). Rf = 0.45 
(hexane : ethyl acetate; 50 : 50). 1H NMR (CDCl3, 700 MHz): δH 2.53 (2H, m, H
4,5); 2.76 (2H, d, J 13, 
H2,7); 2.80 (2H, m, H4,5); 3.18 (2H, d, J 13, H2,7); 3.67 (2H, d, J 4, H8); 3.74 (2H, d, J 4, H8); 3.78 (6H, s, 
H16); 3.79 (6H, s, H15); 6.41 (2H, d, J 9, H11); 6.44 (2H, s, H13); 7.16 (2H, d, J 9, H10); 7.20 (1H, t , J 8, H4’); 
7.30 (2H, t, J 8, H3’); 7.48 (2H, d, J 8, H2’). 13C NMR (CDCl3, 176 MHz): δC 54.0 (C
4/5); 55.3 (C16); 55.3 
(C15); 56.8 (C8); 67.6 (C2,7); 74.7 (C1’); 98.5 (C13); 103.7 (C11); 120.0 (C9); 124.6 (C2’); 126.4 (C4’); 127.9 
(C3’); 131.0 (C10); 146.1 (C1); 158.8 (C12); 160.0 (C14). HR MS ES+ (m/z): found: 493.2724 [M + H]+; 
C29H37N2O5 requires 493.2702. 
 
6-Phenyl-1,4-diazepan-6-ol, 39. 
 
3,6-Bis(2,4-dimethoxybenzyl)-1-phenyl-3,6-diazepan-1-ol (0.100 g, 0.52 mmol) was dissolved in 
trifluoroacetic acid / dichloromethane (1:1, 2 mL) and left to stir for 2 days at room temperature. 
The solvent was removed under reduced pressure, the residue re-dissolved in dichloromethane and 
evaporated. This procedure was repeated twice. The residue was recrystallised from 
methanol/dichloromethane (1:1) to afford a white solid, (0.029 g, 76 %). 1H NMR (CD3OD, 700 MHz): 
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δH 2.83 (2H, d, J 14, H
2,7); 2.92 (2H, m, H4,5); 3.07 (2H, m, H4,5); 3.19 (2H, d, J 14, H2,7); 7.20 (1H, t, J 8 , 
H4’); 7.37 (2H, t, J 8 , H3’); 7.45 (2H, d, J 8 , H2’). 13C NMR (CD3OD, 176 MHz): δC 48.6 (C
4,5); 58.9 (C2,7); 
76.2 (C1); 124.3 (C2’); 126.6 (C4’); 127.8 (C3’); 145.4 (C1’). HR MS ES+ (m/z): found: 193.1271 [M + H]+;. 
Calculated for C11H17N2O: 193.1341. 
 
Tert-butyl 2,2'-(6-hydroxy-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 40. 
 
 
Tert-butyl-bromoacetate (0.20 g, 1.0 mmol) was added dropwise to a mixture of potassium 
carbonate (0.14 g, 1.0 mmol) and 39 (0.05 g, 0.26 mmol) in acetonitrile (15 mL), and the mixture 
stirred at 308 K for 18 h under an atmosphere of argon. The solvent was removed under reduced 
pressure and the resulting oil re-dissolved in chloroform (25 mL) and washed successively with 
aqueous potassium carbonate solution (2 x 25 mL, 0.1 M) and water (25 mL), dried over MgSO4, 
filtered and solvent removed under reduced pressure. Purification by silica gel column 
chromatography (hexane  20 % ethyl acetate) yielded white solid (0.084 g, 74 %). Rf = 0.15 (hexane 
: ethyl acetate, 65 : 35). m.p. 88 - 97 °C. Single crystals of 40 where grown by slow evaporation of 
saturated ethanol: dichloromethane solution. 1H NMR (CDCl3, 700 MHz): δH 1.43 (18H, s, H
11); 2.64 
(2H, d, J 14, H2,7); 2.94 (2H, m, H4,5); 3.01 (2H, m, H4,5); 3.38 (2H, d, J 14, H2,7); 3.40 (2H, s, H8); 5.02 
(1H, br. s, H12);  7.22 (1H, t, J 8, H4'); 7.31 (2H, t, J 8, H3'); 7.50 (2H, d, J 8, H2'). 13C NMR (CDCl3, 176 
MHz): δC 28.15 (C
11); 54.77 (C4,5); 60.67 (C8); 66.66 (C2,7); 73.78 (C1') 81.12 (C10); 124.57 (C2'); 126.70 
(C4'); 128.05 (C3'); 145.07 (C1); 170.87 (C9). HR MS ES+ (m/z): found: 421.2714 [M + H]+; C23H37N2O5 
requires 421.2702. The structure of BW-31 was confirmed by single crystal X-ray diffraction: 
C23H36N2O5, Mr = 420.54, triclinic (P-1); a = 5.7906(7) Å, b = 9.5843(11) Å, c = 20.978(2) Å, V = 
1145.6(2) Å3,α = 81.025(10)°, β = 87.158(10)°, γ = 85.460(10)°, Z = 2; μ = 0.085 mm-1, Dcalc. = 1.219 
mg.mm-3, T 120(2) K; 5749 independent reflections (Rint = 0.0595), R1 = 0.0563 , ωR2 = 0.1154 (I > 
2σ(I)).  
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2,2'-(6-Hydroxy-6-phenyl-1,4-diazepane-1,4-diyl)diacetic acid trifluoroacetate, 41.CF3COOH. 
 
 
The diester 40 (0.050 g, 0.12 mmol) was dissolved in trifluoroacetic acid / dichloromethane (1:1, 2 
mL) and left to stir for 2 days at room temperature. The solvent was removed under reduced 
pressure, the residue re-dissolved in dichloromethane and evaporated. This procedure was repeated 
twice, and also with methanol. The resulting solid was dissolved in water (15 mL) and washed with 
dichloromethane (15 mL). Removal of solvent under reduced pressure afforded the a white solid 
(0.026 g, 51 %). 1H NMR (D2O, pD 3.58, 700 MHz): δH 3.44 (2H, d, J 14, H
2,7); 3.72 (2H, m, H4,5); 3.84 
(2H, m, H4,5); 3.89 (4H, s, H8); 3.89 (2H, d, J 14, H2,7); 7.33 (1H, m, H4'); 7.34 (2H, br. s, H2',3'). 13C NMR 
(D2O, pD 3.58, 176 MHz): δC 51.78 (C
4,5); 58.75 (C8); 62.88 (C2,7); 71.75 (C1'); 124.09 (C2'); 128.92 (C4'); 
129.08 (C3'); 140.57 (C1); 169.54 (C9). HR MS ES+ (m/z): found: 309.1450 [M + H]+; C15H21N2O5 
requires 309.1450. Elemental analysis (%): found C (48.0) H (4.84) N (6.69); [C15H20N2O5].CF3COOH 
requires C (48.3) H (5.01) N (6.63).  
 
Tert-butyl 2,2'-(6-(2-tert-butoxy-2-oxoethoxy)-6-phenyl-1,4-diazepane-1,4-diyl)diacetate, 42. 
 
 
 
Tert-butyl-bromoacetate (0.10 g, 0.52 mmol) was added to a solution of 39 (0.02 g, 0.10 mmol) and 
caesium carbonate (0.10 g, 0.52 mmol) in acetonitrile (15 mL), and the mixture stirred for 18 h at 
363 K under an atmosphere of argon.  The solvent was removed under reduced pressure and the 
resulting oil re-dissolved in chloroform (15 mL) and washed successively with aqueous potassium 
carbonate solution (2 x 15 mL, 0.1 M) and water (10 mL), dried over MgSO4, filtered and solvent 
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removed under reduced pressure. Purification by silica gel column chromatography (hexane  20 % 
ethyl acetate) afforded a colourless oil (0.018 g, 33 %). Rf = 0.25 (hexane : ethyl acetate; 50 : 50). 
1H 
NMR (CDCl3, 700 MHz): δH 1.42 (18H, s, H
11/15); 1.43 (9H, s, H11/15); 1.46 (9H, s, H19); 1.48 (9H, s, H16); 
2.50 (1H, d, J 7, H8/12); 2.59 (1H, d, J 14, H2/7); 2.66 (1H, d, J 7, H8/12); 2.74 (1H, d, J 14, H2/7); 2.89 (1H, 
m, H4/5); 2.93 (1H, m, H4/5); 3.01 (2H, m, H4,5), 3.09 (1H, d, J 14, H2/7); 3.36 (3H, m, H2/7,8,12); 7.22 (1H, t, 
J 8, H4ᶦ); 7.31 (2H, t, J 8, H3ᶦ); 7.50 (1H, d, J 8, H2ᶦ). 13C NMR (CDCl3, 176 MHz): δC 28.08 (C
11/15/19); 28.14 
(C11/15/19); 28.20 (C11/15/19); 37.23 (C16); 55.18 (C4/5); 55.47 (C4/5); 60.70 (C8); 63.64 (C12); 64.19 (C2/7); 
66.37 (C2/7); 73.30 (C1); 80.78 (C10/14/18); 81.10 (C10/14/18); 81.46 (C10/14/18); 82.90 (C17); 124.56 (C2ᶦ); 
126.67 (C4ᶦ); 128.03 (C3ᶦ); 145.23 (C1ᶦ); 170.84 (C9/13); 170.91 (C9/13). HR MS ES+ (m/z): found: 
535.3362 [M + H]+; C29H47N2O7 requires 535.3383; found: 557.3192 [M + Na]
+; C29H46N2NaO7 requires 
557.3203. 
 
2,2'-(6-(Carboxymethoxy)-6-phenyl-1,4-diazepane-1,4-diyl)diacetic acid trifluoroacetate salt, 
L9.CF3COOH. 
 
 
The triester 5 (0.020 g, 0.037 mmol) was dissolved in trifluoroacetic acid : dichloromethane (1 : 1, 2 
mL) and left to stir for 2 days at room temperature. The solvent was removed under reduced 
pressure, the residue re-dissolved in dichloromethane : methanol (1 : 1, 2 mL) and evaporated. This 
procedure was repeated twice, and with methanol. The resulting solid was then dissolved in water 
(10 mL) and washed with dichloromethane (10 mL). Removal of the solvent under reduced pressure 
afforded, after drying in vacuo, a white solid (0.014 g, 81 %). 1H NMR (D2O, pD = 2.66, 700 MHz): δH  
2.70 (1H, m, H4/5); 2.79 (1H, m, H4/5); 2.98 (1H, m, H2/7); 3.25 (3H, m, H2,7,12); 3.36 (2H, m, H2/7, 4/5); 
3.52 (1H, m, H4/5); 3.81 (4H, m, H8,10); 4.01 (1H, d, J 12, H12); 7.30 – 7.33 (5H, m, Ph H). 13C NMR (D2O, 
pD = 2.66, 176 MHz): δC 34.18 (C
4/5); 49.87 (C2/7); 55.69 (C4/5); 59.38 (C8/10); 62.75 (C12); 63.38 (C2/7); 
72.90 (C1); 124.42 & 128.46 & 128.91 (C2’,3’,4’) 141.27 (C1’); 169.51 & 169.55 (C9/11); 175.20 (C13). MS 
ES+ (m/z): found 389.1337 [M+Na]+; C17H22N2NaO7 requires 389.1325. Elemental analysis (%): found 
C (47.8) H (4.97) N (5.71); [C17H22N2O7].CF3COOH requires C (47.5) H (4.83) N (5.83). 
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(E)-Tert-butyl 1,4-bis(2,4-dimethoxybenzyl)-6-phenyl-1,4-diazepan-6-ylcarbamate, 44*. 
 
 
Sodium borohydride (0.013 g, 0.58 mmol) was added portionwise to a solution of nickel(II)chloride 
hexahydrate (0.025 g, 0.11 mmol) in anhydrous methanol (20 mL) cooled in an ice-bath, and the 
mixture stirred for 30 min. The protected amine 22 (0.100 g, 0.19 mmol) dissolved in anhydrous 
methanol (2 mL) was added to the reaction mixture, followed by sodium borohydride (0.028 g, 0.74 
mmol) portionwise. The reaction mixture was allowed to warm to room temperature. The reaction 
was monitored using UV-vis TLC, to follow consumption of 22. Once complete the reaction mixture 
was filtered through Celite®, and the insoluble borate salts washed with ice-cold methanol. The 
filtrates were combined, and the solvent removed under reduced pressure. The resulting residue 
was re-dissolved in chloroform (40 mL) and washed successively with aqueous potassium carbonate 
solution (2 x 30 mL, 0.1 M) and water (30 mL), dried over MgSO4, filtered and the solvent removed 
under reduced pressure. Purification by silica gel column chromatography (hexane  20 % ethyl 
acetate) afforded a colourless oil (0.075 g, 78 %). Rf = 0.35 (hexane : ethyl acetate; 50 : 50). 
1H NMR 
(CDCl3, 500 MHz): δH 2.16 (3H, s, H
7); 2.66 (2H, m, H5); 2.74 (2H, m, H4); 3.46 (2H, s, H8); 3.67 (2H, s, 
H17); 3.75 (6H, s, H15/16,24/25); 3.79 (6H, s+s, H15/16,24/25); 3.86 (2H, s, H2); 6.41 (4H, m, H13,14,22,23); 7.08 
(1H, d, J 8, H20); 7.18 (1H, d, J 8, H11); 7.33 (3H, m, H3',4'); 7.59 (2H, m, H2'). 13C NMR (CDCl3, 125 MHz): 
δC 42.52 (C
7); 51.24 (C4); 53.23 (C17); 53.43 (C2); 54.34 (C5); 55.40 (C15/16,24/25); 55.50 (C15/16,24/25); 55.77 
(C8); 98.64 (C13/14/22/23); 98.71 (C13/14/22/23); 104.09 (C13/14/22/23); 104.28 (C13/14/22/23); 117.15 (C18); 119.16 
(C9); 126.31 (C2'); 128.52 (C3'/4'); 128.99 (C3'/4'); 131.82 (C11); 132.46 (C20); 136.52 (C1'); 154.26 (C1); 
159.03 (C10); 159.34 (C19); 160.24 (C12/21); 161.01 (C12/21). HR MS ES+ (m/z):  found 508.2818 [M + H]+; 
C29H38N3O5 requires 508.2811.*synthetic protocol adopted from
11. 
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(E)-2-((2,4-Dimethoxybenzyl)(2-((2,4-dimethoxybenzyl)(methyl)amino)ethyl)amino)-1-
phenylethanone oxime, 45. 
 
 
Synthesis of the NHBoc-protected primary amine, 45, was carried out in two steps. In the first step 
the primary amine 22ⱡ was formed by reduction of the nitro-functionality, followed by Boc-
protection of the resulting primary amine. 
 
A water slurry of Raney nickel (0.010 g) was washed with methanol (3 x 25 mL) and ethanol added 
(10 mL). The suspension was then transferred into a solution of 22 (0.050 g, 0.096 mmol) in ethanol 
(25 mL). The flask was evacuated and back-filled with hydrogen gas using four vacuum-purge cycles, 
and the mixture stirred at 298 K under an atmosphere of hydrogen. The reaction was monitored by 
UV-vis TLC for formation of the primary amine. Once complete (~ 3 h), the solution was decanted, 
and the solid washed with methanol (3 x 20 mL). The washings and decanted solution were 
combined, removed under reduced pressure and re-dissolved in methanol (25 mL). Remaining Raney 
nickel and insoluble by-products where removed by filtration through a base washed Celite® filter, 
and the solvent was then removed under reduced pressure. The resulting oil was re-dissolved in 
chloroform : isopropyl alcohol (80 : 20, 20 mL) and washed successively with aqueous sodium 
hydroxide (2 x 20 mL, 0.5 M) and water (15 mL), dried over MgSO4, filtered and the solvent removed 
under reduced pressure to yield a colourless oil. 
 
Di-tert-butyl dicarbonate (0.042 g , 0.19 mmol) was added gradually, to a solution of 22ⱡ (from the 
previous step) and triethylamine (0.029 g, 0.29 mmol) in chloroform (15 mL), and the mixture stirred 
at room temperature. The reaction was monitored by LS-ES MS, to follow consumption of 22ⱡ. Once 
complete the solvent was removed and the residue re-dissolved in chloroform (15 mL) and washed 
successively with aqueous sodium hydroxide (2 x 15 mL, 0.5 M) and water (3 x 10 mL), dried over 
MgSO4, filtered and the solvent removed under reduced pressure to yield a colourless oil. 
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Purification by silica gel column chromatography (hexane  60 % ethylacetate) afforded a colourless 
oil (0.005 g, 9 %). RF = 0.35 (hexane : ethylacetate, 50 : 50). 
1H NMR (CDCl3, 700 MHz): δH 1.36 (3H, s, 
H19); 2.48 (4H, s, H8); 2.72 (2H, m, H4,5); 3.35 (2H, m, H4,5); 3.46 (2H, d, J 13, H2,7); 3.59 (2H, d, J 13, 
H2,7); 3.73 (6H, s, H15/16); 3.78 (6H, s, H15/16); 6.37 (2H, d, J 8, H11); 6.41 (2H, s, H13); 7.14 (4H, m, 
H3ᶦ,4ᶦ,10); 7.35 (4H, m, H2ᶦ). 13C NMR (CDCl3, 176 MHz): δC 28.25 (C
19); 55.33 (C15/16); 55.53 (C15/16); 57.19 
(C8); 57.33 (C2/7); 57.84 (C1); 68.77 (C4/5); 78.61 (C18); 98.65 (C11); 103.73 (C13); 120.21 (C9); 125.17 
(C2ᶦ); 125.75 (C3ᶦ); 125.92 (C4ᶦ); 131.12 (C14); 146.19 (C17); 159.46 (C12); 159.76 (C10). HR MS ES+ (m/z): 
found 592.3406 [M + H]+; C34H46N3O6 requires 592.3387; found 614.3221 [M + Na]
+; C34H45N3NaO6 
requires 614.3206. 
 
6-phenyl-1,4-diazepan-6-amine, 46. 
 
 
Trifluoroacetic acid (1 mL) was added to a solution of the protected diamine/amido 45 (0.010 g, 
0.0.017 mmol) in dichloromethane (1 mL), and the mixture stirred at room temperature. The 
reaction was monitored using LC-ESI MS, to follow removal of the dimethoxy-benzyl substituents 
and deprotection of the primary amine. Once complete, the solvent was removed by lyophilisation. 
Excess trifluoroacetic acid was removed through repeated addition and removal of dichloromethane 
(3 x 2 mL) and subsequently methanol (3 x 2 mL), to afford a white solid (0.004 g*). 1H NMR (CD3OD, 
600 MHz): δH 3.37 (2H, m, H
4,5); 3.42 (2H, d, J 15, H2,7); 3.56 (2H, m, H4,5); 3.70 (2H, d, J 15, H2,7); 7.29 
(1H, t, J 8, H4ᶦ); 7.35 (2H, t, J 8, H3ᶦ); 7.38 (2H, d, J 8, H2ᶦ). 13C NMR (CD3OD, 151 MHz): δC 43.77 (C
4,5); 
53.13 (C2,7); 65.88 (C1); 124.76 (C2ᶦ); 125.00 (C4ᶦ); 129.48 (C3ᶦ). HR MS ES+ (m/z): found 192.1485 [M + 
H]+; C11H18N3 requires 192.1501. *Product isolated is of undetermined constitution. Presumed to be 
a trifluoroacetate salt. 
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4.3 Syntheses of ‘Cold’ Gallium(III) Complexes of Ln (n = 2, 3, 6, 8) 
 
[Ga.Ln]; n = 2, 3, 6, 8. 
 
The general procedure for the synthesis of cold gallium complexes is as follows. The ligand in 2 mL of 
a methanol : water (1 : 2) mixture and equilibrated at 333 K. Gallium nitrate hexahydrate (1 
equivalent) was added, and the pH adjusted to 4.5 using 0.10 M aqueous sodium hydroxide. The 
reaction mixture was stirred for 1 h, and allowed to cool slowly to room temperature. Single crystals 
of the complexes suitable for single crystal X-ray diffraction formed from solution upon standing 
over ~ 36 h. Crystalline material was isolated by filtration, and dried in vacuo. Yields and elemental 
constitution were not determined.  
 
In 1H NMR assignments Pureshift 1H NMR experiments were used to provide better signal resolution. 
Due to signal overlapping coupling constants are not provided in some cases. The superscript ‘*’ is 
used to denote proton resonances arising from protons attached to the same carbon atom, when 
the orientation (ax/eq) could not be assigned.  
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[Ga.L2]: 
1H NMR (D2O, pD 6.17, 600 MHz): δH 1.03 (3H, s, H
1ᶦ); 2.43 (3H, s, H14); 3.12 (1H, m, H4*/5*); 3.14 (1H, 
m, H5*/4*); 3.20 (1H, d, J 16, H2ax); 3.21 (1H, d, J 12, H12*); 3.28 (1H, d, J 16, H10*); 3.35 (1H, m, H4/5); 
3.41 (1H, m, H5/4); 3.46 (1H, d, J 16, H7eq); 3.57  (1H, d, J 16, H7ax); 3.59 (1H, d, J 16, H2eq); 3.71 (1H, d, J 
19, H8*); 3.77 (1H, d, J 16, H10); 3.89 (1H, d, J 12, H12); 3.91 (1H, d, J 19, H8). 13C NMR (D2O, pD 6.17, 
151 MHz): δC 12.10 (C
1ᶦ); 37.96 (C14); 53.01 (C14); 58.22 (C4/5); 59.80 (C1); 60.41 (C8); 61.31 (C10); 63.57 
(C7); 64.00 (C2); 174.10 & 174.67 & 174.82 (C9,11,13). HR MS ES+ (m/z): found 384.0677 [M + H]+; 
C13H21N3O6Ga requires 384.0686. The structure of [Ga.L
2] was confirmed by single crystal X-ray 
diffraction: C12H20N3O6.½H2O, Mr = 393.05, orthorhombic (Fdd2); a = 28.8536(7) Å, b = 27.2438(7) Å, 
c = 7.57981(19) Å, V = 5958.3(2) Å3,α = 90.00°, β = 90.00°, γ = 90.00°, Z = 16; μ = 1.888 mm-1, Dcalc. = 
1.753 mg.mm-3, T 120(2) K; 4319 independent reflections (Rint = 0.0417), R1 = 0.0307, ωR2 = 0.0657 (I 
> 2σ(I)). CCDC # 906036. 
 
[Ga.L3]: 
1H NMR (D2O, pD 6.13, 600 MHz): δH 1.13 (3H, d, J 7, H
10/13/16); 1.21 (3H, s, H1ᶦ); 1.36 (3H, d, J 7, 
H10/13/16); 1.46 (3H, d, J 7, H10/13/16); 2.83 (1H, d, J 15, H7ax); 2.85 (1H, m, H4*/5*); 3.07 (1H, m, H4/5); 3.21 
(1H, m, H5*/4*); 3.42 (2H, m, H5/4 & 7eq); 3.63 (1H, d, J 15, H2eq); 3.78 – 3.84 (3H, m, H8,11,14). 13C NMR 
(D2O,pD 6.13, 151 MHz): δC 10.49 & 14.23 & 17.36 (C
10,13,16); 17.95 (C1ᶦ); 41.15 (C4/5); 46.68 (C4/5); 
49.66 (C14); 56.94 (C7); 60.64 (C1); 64.77 (C2); 64.44 & 66.38 (C8,11); 176.96 & 178.42 & 179.07 (C9,12,15). 
HR MS ES+ (m/z): found 412.1018 [M + H]+; C15H25N3O6Ga requires 412.0999. The structure of [Ga.L
3] 
was confirmed by single crystal X-ray diffraction: C15H24N3O6.H2O, Mr = 430.11, monoclinic (P21); a = 
7.58267(20) Å, b = 12.6657(3) Å, c = 9.2185(2) Å, V = 869.85(4) Å3,α = 90.00°, β = 100.735(3)°, γ = 
90.00°, Z = 2; μ = 1.627 mm-1, Dcalc. = 1.642 mg.mm
-3, T 120(2) K; 4501 independent reflections (Rint = 
0.0433), R1 = 0.0322, ωR2 = 0.0670 (I > 2σ(I)). CCDC # 906037. 
 
[Ga.L6]: 
Insfficient amount of the complex was obtained to get a 1H and 13C NMR. Constitution has been 
confirmed by X-ray crystal structure analysis. HR MS ES+ (m/z): found 431.0599 [M + H]+; 
C17H21N3O6Ga requires 431.0608. The structure of [Ga.L
6] was confirmed by single crystal X-ray 
diffraction: C17H20N3O6, Mr = 432.08, triclinic (P-1); a = 10.6961(8) Å, b = 13.0778(12) Å, c = 
12.8414(12) Å, V = 1652.8(2) Å3,α = 116.076(9)°, β = 105.208(7)°, γ = 92.002(2)°, Z = 4; μ = 1.709 mm-
1, Dcalc. = 1.736 mg.mm
-3, T 120(2) K; 7571 independent reflections (Rint = 0.0881), R1 = 0.0699, ωR2 = 
0.1553 (I > 2σ(I)). CCDC # 906038. 
 
Chapter 6: Experimental 
 
 
 
Page 194 
 
  
[Ga.L8]: 
1H NMR (D2O, pD 6.02, 600 MHz): δH 0.86 & 1.25 & 1.42 (9H, d, J 7, H
10,13,16); 2.94 (1H, m, H4*/5*); 3.13 
(1H, m, H4*/5*); 3.33 (1H, m, H5*/4*); 3.53 (1H, q, H14); 3.56 (1H, m, H5/4); 3.65 (1H, d, J 14 H2*/7*); 3.75 
(2H, d+d, H7*/2* & 7/2); 3.97 (2H, m, H2/7 & 8*/11*); 4.17 (1H, d, J 16 H8/11); 7.42 (5H, m, H2ᶦ,3ᶦ,4ᶦ). 13C NMR 
(D2O, pD 6.02, 151 MHz): δC 10.69 & 14.38 & 16.29 (C
10,13,16); 46.67 (C4/5); 50.67 (C14); 55.58 (C2/7); 
58.92 (C1); 61.04 (C4/5); 64.34 (C2/7); 65.79 & 67.06 (C8,11); 77.73 (C1ᶦ); 126.47 & 129.32 & 129.96 
(C2ᶦ,3ᶦ,4ᶦ); 177.04 & 177.47 & 178.32 (C9,12,15). HR MS ES+ (m/z): found 474.1149 [M + H]+; 
C20H27N3O6Ga requires 474.1156.  
 
The structure of [Ga.L8] was confirmed by single crystal X-ray diffraction: C20H26N3O6, Mr = 474.16, 
orthorhombic (P212121); a = 7.3312(7) Å, b = 13.9288(12) Å, c = 19.6479(19) Å, V = 2006.3(3) Å
3,α = 
90°, β = 90°, γ = 90°, Z = 4; μ = 2.262 mm-1, Dcalc. = 1.570 mg.mm
-3, T 120(2) K; 2554 independent 
reflections (Rint = 0.0471), R1 = 0.0477, ωR2 = 0.1195 (I > 2σ(I)). Not yet submitted to CCDC. 
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